2015 program - Controlled Release Society

2015 program - Controlled Release Society

M A R G l O a R u P n on 5 n 1 A 0 i t S 2 i R s o C p d x 42n ng & E i t e Me CREATING VALUE THROUGH 2 Download the CRS Annual Meeting App ot ly J...

6MB Sizes 0 Downloads 18 Views

Recommend Documents

ROLLING OWNER CONTROLLED INSURANCE PROGRAM
Date 09/19/17 Rolling Owner Controlled Insurance Program Information / 00425B. Page 1 of 7. Bidding Requirements, Contra

2015 Program - Western Society of Naturalists
Steven Morgan. Eric Sanford ... Dr. Steve Gaines. “MOVING FROM ...... Steven D. Gaines, Bren School of Environmental S

Controlled Release, Biodegradable Cytokine Depots - Cancer Research
Dec 15, 1993 - An individu al's freshly excised tumor cells can potentially be irradiated and mixed .... Paul T. Golumbe

construction project controlled insurance program (cip) - Willis
every uncertainty, a controlled insurance program (CIP) can improve coverage ... contractors purchase guaranteed cost or

Safety Services for Owner Controlled Insurance Program
Mar 17, 2017 - RFP No.: 16-17/16, Safety Services for Owner Controlled Insurance Program. The Port of Oakland (the “Po

Controlled Substances Prescription Monitoring Program - Arizona
Oct 1, 2017 - the Controlled Substances Act must have a current CSPMP registration issued by the Board and be granted ac

California State University Owner-Controlled Insurance Program
California State University. Owner-Controlled Insurance Program. “Rolling OCIP”. Insurance Program Overview. January

UTAH'S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB)
Aug 19, 2016 - This bill amends the Controlled Substance Database Act. Specifically, this bill: • defines terms;. •

owner controlled insurance program - Griffin Construction
You are a participant in the Owner Controlled Insurance Program (“OCIP”), also ... The OCIP is a consolidated insura

1 OWNER-CONTROLLED INSURANCE PROGRAM PART 1
PART 1 GENERAL. 1.01 INTRODUCTION. A. The Water Authority has implemented an Owner-Controlled Insurance Program for its.

M A R G l O a R u P n on 5 n 1 A 0 i t S 2 i R s o C p d x 42n ng & E i t e Me CREATING VALUE THROUGH

2 Download the CRS Annual Meeting App

ot

ly Ju

6– 29

lan d

CUSTOMISED DELIVERY Sc , ,2 015 rgh  Edinbu

Access the Meeting Anytime, Anywhere 2015 CRS Annual Meeting App • Program Schedule • Abstracts • CRS Connect • Exhibit Listing • Personal Schedule & To-do List • Local Edinburgh Attractions, Restaurants & More!

Download Now. It’s Fast and Easy. Search “CRS Meeting” in your app store. Or access the desktop version: mobileapp.controlledrelease.org When accessing the app for the first time you will have the option to set a password. If you choose not to set a password, no password will be needed to access your app.

WiFi access in the conference centre: Username: delegate Password: exchange

Table of Contents General Meeting Information .................................... 2 Edinburgh International Conference Centre ............. 4 Schedule-at-a-Glance Saturday – Sunday ................................................. 8 Monday – Tuesday ................................................ 9 Tuesday – Wednesday ......................................... 10 Daily Schedule Saturday .............................................................. 11 Sunday ................................................................ 12 Technology Forums ........................................ 15 Soapbox Sessions ............................................ 17 Monday .............................................................. 18 Tuesday ............................................................... 24 Wednesday .......................................................... 33 Posters ...................................................................... 36 Exposition ................................................................ 48 Sponsors ................................................................... 53 Awards & Recognition ............................................. 56 Acknowledgements .................................................. 60 2015 CRS Presenting Author Index ......................... 62

2015 Annual Meeting Program Team

Chair Justin Hanes Johns Hopkins University, U.S.A.

Deputy Chair Kinam Park Purdue University, U.S.A.

Adah Almutairi University of California, U.S.A.

You Han Bae University of Utah, U.S.A.

Igor Bodnár Firmenich, Switzerland

David Brayden University College Dublin, Ireland

Doug Dale DuPont Industrial Biosciences, U.S.A.

Bill Lambert Omeros Corp., U.S.A.

Yvonne Perrie Aston University, United Kingdom

Suzie Pun University of Washington, U.S.A.

Ilva Rupenthal University of Auckland, New Zealand

Ron Smith Merck & Company, Inc., U.S.A.

Advertisers’ Index Capsugel Dosage Form Solutions............... Back Cover www.capsugel.com/DFS Drug Development & Delivery ................................ 14 drug-dev.com Controlled Release Society CRS and AAPS Workshop ........................................ 3 Publications ................................................................ 7 Abstracts .............................................................. 11, 33 CRS Volunteer Ad ................................................... 27 Springer .................................................................... 32 Member Benefits ...................................................... 59 2016 CRS Annual Meeting & Exposition .................................... Inside Back Cover

1

General Meeting Information Share Your Photos & Experiences

Exposition Hours and Location The Exposition is located in the Lennox Suite on Level –2. The scheduled Exposition activities are as follows:

#CRSMeeting

Registration The Registration Desk and self-serve kiosks are located in Strathblane Hall on Level 0. You can modify your registration and print your badges at the self-serve kiosks. Name badges can only be printed at the kiosk one time. CRS staff will be available at the Registration Desk. Registration Hours Saturday, July 25 Sunday, July 26 Monday, July 27 Tuesday, July 28 Wednesday, July 29

7:30 a.m. – 5:00 p.m. 7:30 a.m. – 7:30 p.m. 7:00 a.m. – 5:00 p.m. 7:00 a.m. – 5:00 p.m. 7:30 a.m. – 12:00 p.m.

*Your CRS name badge must be worn at all times in the conference centre.

Access the Abstracts CRS Annual Meeting abstracts can easily be accessed using the CRS Annual Meeting app and the CRS website. Within the app click on the Posters icon to begin viewing poster abstracts, and view podium abstracts directly from the schedule. Sign into the CRS website to view and search the abstracts, available to all registered attendees.

CRS Annual Meeting App View the program, read the abstracts, create your personal schedule and to-do lists, receive announcements, connect with fellow attendees using CRS Connect, and see what companies are in the Exhibit Hall. Download the CRS 2015 app by searching for “CRS Meeting” in the iTunes Store or Google Play. Reach the app from your BlackBerry or laptop via the app website: mobileapp.controlledrelease.org

CRS Connect CRS Connect allows you to network one-toone with colleagues while in Edinburgh. Select the CRS Connect icon in the meeting app and search through the database of meeting attendees. Click on an attendee’s name to either send them a private message or request an appointment. CRS Connect maintains your full privacy; personal contact information is never shared.

WiFi Access Wireless internet is available throughout the conference centre for the duration of the meeting. • Username: delegate • Password: Exchange 2

Set-Up Saturday, July 25 Sunday, July 26 8:00 a.m. – 5:00 p.m. 8:00 a.m. – 2:00 p.m. Exposition Open Sunday, July 26 5:30 – 7:30 p.m. Monday, July 27 9:30 – 10:30 a.m. 12:00 – 1:00 p.m. 4:30 – 5:30 p.m. Tuesday, July 28 9:30 – 10:30 a.m. 12:00 – 1:30 p.m.

Exposition Grand Opening & Welcome Reception Exposition Hall Open Exposition Hall Open (lunch available for purchase) Exposition Hall Happy Hour

3:00 – 4:30 p.m.

Exposition Hall Open Exposition Hall Open (lunch available for purchase) Exposition Hall Open

Take-Down Tuesday, July 28 4:30 – 6:30 p.m.

Exhibit Take-Down

Poster Sessions The posters are located in Cromdale Hall on Level –2. Posters will be on display during two poster sessions. Poster authors will be present during one of four time slots. All posters must be removed during Poster Take-Down or they will be removed and discarded. The poster viewing area will be secured overnight. Photographing posters is not permitted. 2015 Poster Schedule Poster Session I Sunday, July 26 1:00 – 4:00 p.m. Poster Session I Set-Up Monday, July 27 9:30 – 10:30 a.m.

Poster Session I Authors Present – Group A (odd-numbered poster boards) 9:30 a.m. – 6:00 p.m. Poster Session I Viewing Hours 5:00 – 6:00 p.m. Poster Session I Authors Present – Group B (even-numbered poster boards) 6:00 – 6:30 p.m. Poster Session I Take-Down Poster Session II Tuesday, July 28 7:00 – 8:00 a.m. 9:30 – 10:30 a.m.

Poster Session II Set-Up Poster Session II Authors Present – Group C (odd-numbered poster boards) 9:30 a.m. – 4:30 p.m. Poster Session II Viewing Hours 3:30 – 4:30 p.m. Poster Session II Authors Present – Group D (even-numbered poster boards) 4:30 – 5:00 p.m. Poster Session II Take-Down

Poster Snapshots

Exposition Hall Cash & Carry Lunch

Poster Snapshots are three-minute audio recordings that provide a summary preview of poster content. You can listen to a recording at any time, including prior to attending the poster sessions and even while standing in front of a poster. Poster Snapshots are submitted by poster presenters and are available through the CRS Annual Meeting app.

Network with exhibitors and colleagues during the noon-hour break. Lunch will be available for purchase on Monday from 12:00 – 1:00 p.m. and Tuesday from 12:00 – 1:30 p.m. outside of the Exposition Hall. Seating is available inside the hall.

Speaker Preparation Room Conference Organiser’s Room - Level –1 The Speaker Preparation Room is available for PowerPoint previewing and downloading presentation materials. Speakers are to upload presentations one day prior to their presentation date (e.g., if you speak on Monday, July 27, you will upload your presentation on Sunday, July 26). Presenters are not allowed to use their own laptops to give their presentations. The Speaker Preparation Room will be staffed and open as follows: Saturday, July 25 7:30 a.m. – 5:00 p.m. Sunday speakers upload presentations Sunday, July 26 7:30 a.m. – 5:00 p.m. Monday speakers upload presentations Monday, July 27 7:00 a.m. – 5:00 p.m. Tuesday speakers upload presentations Tuesday, July 28 7:00 a.m. – 5:00 p.m. Wednesday speakers upload presentations

Electronic Devices As a courtesy to other meeting attendees, please turn off or silence all electronic devices during all workshops, sessions, and presentations.

Photography Photography is not permitted in the session rooms, exhibit hall, or poster sessions.

Photo Release By virtue of your attendance, you agree to the Controlled Release Society’s use of your likeness in promotional media.

Children and the CRS Annual Meeting & Exposition The CRS Annual Meeting & Exposition is a professional, scientific meeting. CRS does not permit children under the age of 18 to attend the scientific sessions, poster sessions, exposition, and social events. For safety reasons, only registered exhibitors and poster presenters are permitted in the exposition/poster hall during set-up and take-down hours. Children 18+ must register and buy applicable individual tickets if not attending/registering as a student.

From the Controlled Release Society and the American Association of Pharmaceutical Scientists

Formulation, Processing, and Testing of Functionally Coated Multiparticulates Workshop October 24 • Orlando, Florida, U.S.A. Held immediately prior to the AAPS Annual Meeting and Exposition

R ISTE G E R NOW

This workshop will:

• Review the advantages of multiparticulate dosage forms in regard to dosing flexibility, i.e., targeted dosing and timed dosing. • Provide firsthand, practical knowledge about formulation and process development of multiparticulate dosage forms—including beads, pellets, and mini-tablets.

Workshop Organizers

©ajt / Shutterstock.com

Don Barbieri, Patheon, U.S.A. Lauren (Wood) Petraglia, LCI Corporation, U.S.A.

Register today! Visit controlledreleasesociety.org to register and view workshop details.

3

Edinburgh International Conference Centre

Level 3 PENTLAND

Sidlaw

Fintry

Level 1

GLADSMUIR ROOM DRESSING ROOMS

1 3

LLO LINKS TO GA

SU WAY

ITE

2

GALLOWAY SUITE

CAFÉ 3

1 2

r Ca

k

ric

3

4

1

2

Harris

1

2

il

ch

O

Level 0

SOUTRA

LOMOND FOYER

KS T O S TRATHBLANE HAL L

nt Ti

th

LOMOND SUITE

lsy

Ki

o

Moor foot

Business Centre

ATRIUM

L IN

STRATHBLANE HALL CRS REGISTRATION

Atrium Entrance

Strathblane Entranc e

Level -1 CEILIING VOID OVER CROMDALE HALL DRESSING ROOMS

4

5

CEILING VOID OVER LENNOX SUITE

Conference Organiser’s Room

Menteith Lowther

continued

5

Edinburgh International Conference Centre

DELIVERY BAYS A & B DELIVERY BAY C

POSTERS

Level -2

TURN TABLE ACCESS

CROMDALE HALL LENNOX SUITE

EICC KITCHEN

EXHIBITS

Bar Moffat

6

1 2

Lammermuir

Build your knowledge base with the CRS Advances in Delivery Science and Technology Book Series NEWEST TITLE

CRS books deliver essential knowledge on delivery science and technology, written and edited by scientific authorities and opinion leaders from around the globe. For a Stop by complete list of titles, visit Springer Booth 1002 to order. controlledreleasesociety.org.

CRS members qualify for a 25% discount on all

books in the Advances in Delivery Science and Technology series from CRS, along with all Springer book titles if you purchase through Springer’s online site and use the exclusive CRS member discount token when ordering. CRS members must sign in to the CRS site to gain access to the discount token before ordering at the Springer site.

#8822-4/2015

controlledreleasesociety.org

Schedule-at-a-Glance Saturday, July 25 7:30 a.m. – 5:00 p.m. CRS Registration Open 7:30 a.m. – 5:00 p.m. Speaker Preparation Room Open 8:00 a.m. – 5:00 p.m. Exhibit Set-Up 8:00 a.m. – 5:00 p.m. Premeeting Workshop: Ocular Drug Delivery – Challenges of Matching New Technologies with Drug Pharmacokinetics* 8:00 a.m. – 5:00 p.m. Young Scientist Workshop: The Rise, and Rise, of Precision Medicine

Strathblane Hall Conference Organiser’s Room Lennox Suite Moorfoot Sidlaw

Sunday, July 26 7:30 a.m. – 5:00 p.m. Speaker Preparation Room Open 7:30 a.m. – 7:30 p.m. CRS Registration Open 8:00 a.m. – 12:00 p.m. Young Scientist Workshop: Finding Your Career Edge 8:00 a.m. – 12:10 p.m. Premeeting Workshop: Delivery of Therapeutic Bioconjugates: From Polymer Conjugates to Antibody-Drug Conjugates* 8:00 a.m. – 2:00 p.m. Exhibit Set-Up 9:00 – 10:00 a.m. Technology Forum: Evonik Industries AG 9:00 – 10:00 a.m. Technology Forum: Lucideon Limited 9:00 – 10:00 a.m. Technology Forum: MedImmune 9:00 – 10:00 a.m. Technology Forum: Wyatt Technology Corporation 10:15 – 11:15 a.m. Technology Forum: Agilent Technologies 10:15 – 11:15 a.m. Technology Forum: Evonik Industries AG 10:15 – 11:15 a.m. Technology Forum: MedPharm 11:30 a.m. – 12:30 p.m. Technology Forum: Catalent Pharma Solutions & BASF Corp. 11:30 a.m. – 12:30 p.m. Technology Forum: Corbion Purac Biomaterials & Medincell 11:30 a.m. – 12:30 p.m. Technology Forum: Powder Systems Limited 12:00 – 2:00 p.m. Leadership Forum (by invitation) 12:30 – 2:00 p.m. Young Scientist Roundtable: Drug Delivery Technology and Clinical Development 1:00 – 2:40 p.m. Soapbox Sessions 1:00 – 4:00 p.m. Poster Session I Set-Up 2:00 – 3:00 p.m. First Timers’ Meeting 3:00 – 3:50 p.m. Plenary Session: Vincent H. L. Lee 4:00 – 5:30 p.m. Industry Roundtable – Drugs, Delivery, and Patients – How Will We Bring It All Together in the New World? 4:30 – 5:30 p.m. Speed Mentoring Event 5:30 – 7:30 p.m. Exposition Grand Opening and Welcome Reception

*Additional registration, payment, and ticket required. 8

Conference Organiser’s Room Strathblane Hall Sidlaw Menteith Lennox Suite Carrick Harris 2 Harris 1 Ochil Ochil Carrick Harris 1 Carrick Harris 1 Ochil Sheraton, Edinburgh Suite 2 (offsite) Sidlaw Lomond Suite Cromdale Hall Lowther Pentland Lomond Suite Lammermuir Lennox Suite

Monday, July 27 7:00 – 8:00 a.m. 7:00 a.m. – 5:00 p.m. 7:00 a.m. – 5:00 p.m. 8:00 – 9:30 a.m. 9:30 – 10:30 a.m. 9:30 – 10:30 a.m. 9:30 a.m. – 6:00 p.m. 10:30 a.m. – 12:00 p.m. 10:30 a.m. – 12:00 p.m. 12:00 – 1:00 p.m. 1:00 – 2:45 p.m. 3:00 – 4:30 p.m. 3:00 – 4:30 p.m. 4:30 – 5:30 p.m. 5:00 – 6:00 p.m. 5:30 – 6:30 p.m. 6:00 – 6:30 p.m. 9:00 – 10:30 p.m.

Get Up! Get Educated! Choosing the Best Animal Model for Your Drug Delivery Studies Speaker Preparation Room Open CRS Registration Open CRS Opening Session Poster Session I Authors Present – Group A Exposition Hall Open Poster Session I Viewing Hours Mini-Symposium: Modeling and Simulation of Oral Absorption – A Progress Report from the EU/IMI Project OrBiTo Scientific Sessions • Drug Delivery to the Brain • Encapsulation for Industrial Applications • Modulated and Responsive Delivery Systems • Transdermal Delivery Exposition Hall Open (lunch available for purchase) Plenary & Special Session: Cameron Alexander and Nicholas A. Peppas Mini-Symposium: Therapeutic Cancer Nanomedicines Scientific Sessions • Delivery of Vaccines • Manufacture, Characterization, Measurement, and Stability • Oral Delivery for Food • Respiratory Drug Delivery Exposition Hall Happy Hour Poster Session I Authors Present – Group B PSAH Networking Event* Poster Session I Take-Down Young Scientist Networking Event*

Moorfoot

Get Up! Get Educated! Trends in Protein Delivery Poster Session II Set-Up Speaker Preparation Room Open CRS Registration Open Plenary Session: María José Alonso Exposition Hall Open Poster Session II Authors Present – Group C Poster Session II Viewing Hours Chapter Chair Networking Break (by invitation) Mini-Symposium: Next-Generation Vaccine Development and Delivery Technologies Scientific Sessions • In Vivo Nucleic Acid Delivery • Nano-Sized Carriers for Small Molecule Oncology Drugs • Ocular Drug Delivery • Oral Drug Delivery Lunch with the Luminaries* Exposition Hall Open (lunch available for purchase) C&DP Luncheon* Mini-Symposium: European Technology Platform on Nanomedicine: Translation of Nanomedicines

Moorfoot Cromdale Hall Conference Organiser’s Room Strathblane Hall Pentland Lennox Suite Cromdale Hall Cromdale Hall Atrium Café Moorfoot

Conference Organiser’s Room Strathblane Hall Pentland Cromdale Hall Lennox Suite Cromdale Hall Pentland Sidlaw Tinto Fintry Moorfoot Lennox Suite Pentland Pentland Sidlaw Tinto Fintry Moorfoot Lennox Suite Cromdale Hall Shakespeare (offsite) Cromdale Hall The Scotch Whisky Experience (offsite)

Tuesday, July 28 7:00 – 8:00 a.m. 7:00 – 8:00 a.m. 7:00 a.m. – 5:00 p.m. 7:00 a.m. – 5:00 p.m. 8:00 – 9:30 a.m. 9:30 – 10:30 a.m. 9:30 – 10:30 a.m. 9:30 a.m. – 4:30 p.m. 10:30 – 11:30 a.m. 10:30 a.m. – 12:00 p.m. 10:30 a.m. – 12:00 p.m. 12:00 – 1:00 p.m. 12:00 – 1:30 p.m. 12:00 – 1:30 p.m. 1:30 – 3:00 p.m.

Tinto Sidlaw Fintry Pentland Carrick Lennox Suite Sheraton, Stirling Suite (offsite) Moorfoot

continued

9

Schedule-at-a-Glance Tuesday, July 28 (continued) 1:30 – 3:00 p.m.

3:00 – 4:30 p.m. 3:30 – 4:30 p.m. 4:00 – 5:30 p.m. 4:30 – 5:00 p.m. 4:30 – 6:30 p.m. 5:00 – 6:30 p.m. 7:30 – 10:00 p.m.

Scientific Sessions: • Delivery of Peptides and Proteins • Delivery Science in Cosmetics, Personal Care, and Household Products • Parenteral Delivery Technologies • siRNA and mRNA Delivery Exposition Hall Open Poster Session II Authors Present – Group D College of Fellows Panel: How Can We Make Nanomedicine Work? Poster Session II Take-Down Exhibit Take-Down Women in Science Networking Event* CRS Closing Reception

Pentland Tinto Sidlaw Fintry Lennox Suite Cromdale Hall Pentland Cromdale Hall Lennox Suite Moorfoot The Assembly Rooms (offsite)

Wednesday, July 29 7:30 a.m. – 12:00 p.m. 8:00 – 9:30 a.m. 8:00 – 9:30 a.m.

9:45 – 11:00 a.m.

CRS Registration Open Mini-Symposium: Cost-Effective Encapsulation for Industrial Applications: Limitations and Solutions Scientific Sessions • Drug Delivery in Tissue Engineering • Formulating Oral Solid Dosage Forms to Enhance Drug Delivery • Nanocarriers for Combined Delivery • Nanosystems for Non-Oncology Drug Delivery Plenary Session: Renata Pasqualini

*Additional registration, payment, and ticket required.

10

Strathblane Hall Moorfoot Sidlaw Tinto Pentland Fintry Pentland

Daily Schedule Saturday, July 25 Strathblane Hall Conference Organiser’s Room Lennox Suite Moorfoot Sidlaw

Saturday

7:30 a.m. – 5:00 p.m. CRS Registration Open 7:30 a.m. – 5:00 p.m. Speaker Preparation Room Open 8:00 a.m. – 5:00 p.m. Exhibit Set-Up 8:00 a.m. – 5:00 p.m. Premeeting Workshop: Ocular Drug Delivery – Challenges of Matching New Technologies with Drug Pharmacokinetics* 8:00 a.m. – 5:00 p.m. Young Scientist Workshop: The Rise, and Rise, of Precision Medicine

Saturday Program Highlights Premeeting Workshop* Ocular Drug Delivery – Challenges of Matching New Technologies with Drug Pharmacokinetics*

interested conference attendees.

Looking for the Abstracts?

Cosponsored by Envisia Therapeutics, GrayBug, Novaliq GmbH, Ora, Phoenix Research Labs, and pSivida Corp. 8:00 a.m. – 5:00 p.m. • Moorfoot Organizers: Ilva Rupenthal, University of Auckland, New Zealand; and Michael O’Rourke, Scotia Vision Consultants, U.S.A.

Young Scientist Workshop The Rise, and Rise, of Precision Medicine 8:00 a.m. – 5:00 p.m. • Sidlaw Chairs: Patrick Baumhof, CureVac GmbH, Germany; Yewande Oni, University of Nottingham, United Kingdom; and Jennifer Wong, University of Sydney, Australia Panelists: Simon Gaisford, University College London, United Kingdom; Carlos Garcia-Echeverria, Sanofi, France; and Heinrich Haas, BioNTech RNA Pharmaceuticals GmbH, Germany; and Devendra Pade, SimCyp Limited, United Kingdom The era of precision medicine has emerged since the human genome sequence was completed in 2001. Advancements involving the use of marker-assisted diagnosis and targeted therapies derived from an individual’s genetic makeup will impact the way drugs are developed. This workshop will provide an overview of precision medicine to understand the opportunities in drug delivery that can be leveraged. This session features invited speakers to provide in-depth insights, practical case studies, and lively scientific debate.

CRS MEETING APP Download the app to your mobile device, or use the desktop app website: mobileapp.controlledrelease.org. Abstracts are available in the Posters and the Program Guide session details. CRS WEBSITE The abstracts are available within the CRS meeting website and can be accessed using your CRS username and password.

Complimentary event open to all young scientists and other

*Additional registration, payment, and ticket required. 11

Daily Schedule Sunday, July 26

Sunday

7:30 a.m. – 5:00 p.m. Speaker Preparation Room Open CRS Registration Open 7:30 a.m. – 7:30 p.m. Young Scientist Workshop: Finding Your Career Edge 8:00 a.m. – 12:00 p.m. 8:00 a.m. – 12:10 p.m. Premeeting Workshop: Delivery of Therapeutic Bioconjugates: From Polymer Conjugates to Antibody-Drug Conjugates* Exhibit Set-Up 8:00 a.m. – 2:00 p.m. Technology Forum: Evonik Industries AG 9:00 – 10:00 a.m. Technology Forum: Lucideon Limited 9:00 – 10:00 a.m. Technology Forum: MedImmune 9:00 – 10:00 a.m. 9:00 – 10:00 a.m. Technology Forum: Wyatt Technology Corporation Technology Forum: Agilent Technologies 10:15 – 11:15 a.m. 10:15 – 11:15 a.m. Technology Forum: Evonik Industries AG 10:15 – 11:15 a.m. Technology Forum: MedPharm 11:30 a.m. – 12:30 p.m. Technology Forum: Catalent Pharma Solutions & BASF Corp. 11:30 a.m. – 12:30 p.m. Technology Forum: Corbion Purac Biomaterials & Medincell 11:30 a.m. – 12:30 p.m. Technology Forum: Powder Systems Limited Leadership Forum (by invitation) 12:00 – 2:00 p.m. Young Scientist Roundtable: Drug Delivery Technology 12:30 – 2:00 p.m. and Clinical Development 1:00 – 2:40 p.m. Soapbox Sessions Poster Session I Set-Up 1:00 – 4:00 p.m. 2:00 – 3:00 p.m. First Timers’ Meeting Plenary Session: Vincent H. L. Lee 3:00 – 3:50 p.m. Industry Roundtable – Drugs, Delivery, and Patients – How Will 4:00 – 5:30 p.m. We Bring It All Together in the New World? 4:30 – 5:30 p.m. Speed Mentoring Event Exposition Grand Opening and Welcome Reception 5:30 – 7:30 p.m. *Additional registration, payment, and ticket required.

12

Conference Organiser’s Room Strathblane Hall Sidlaw Menteith Lennox Suite Carrick Harris 2 Harris 1 Ochil Ochil Carrick Harris 1 Carrick Harris 1 Ochil Sheraton, Edinburgh Suite 2 (offsite) Sidlaw Lomond Suite Cromdale Hall Lowther Pentland Lomond Suite Lammermuir Lennox Suite

CRS Innovation Sunday

Young Scientist Workshop

Cosponsored by Pfizer

Finding Your Career Edge

Delivery Science Meets Business Opportunities

8:00 a.m. – 12:00 p.m. • Sidlaw

CRS Innovation Sunday is all about the business of delivery science, taking innovative ideas and technologies into the commercial sector. All of these sessions give you important new information on companies and technologies as well as great opportunities for networking face-to-face. This is the start of the CRS Annual Meeting program—don’t miss it!

Industry Roundtable Drugs, Delivery, and Patients – How Will We Bring It All Together In the New World? 4:00 – 5:30 p.m. • Lomond Suite There is a new world of patient centric care coming, and it is both exciting and complex. As pharma and biotech companies position to expand the boundaries of self- and home-care via increased connectivity, it is clear that controlled release and combination drugs are central to their plans. We will discuss the facts and predictions surrounding this field of study. How do innovators of delivery technology take advantage? How do patients want their drugs delivered? What do patients want from their providers? Much of this is still unknown, but much of it has been discovered and is playing out in real time as seen in recent M&A activity and strategic partnerships. The panel of experts with deep industry knowledge from both the small innovative and large pharmaceutical company perspectives will discuss this industry shift that will impact each of our professional and personal lives. Speaker and Moderator: Debra Bingham, CRS PresidentElect, Partner, Valeo Partners, U.S.A. Panelists: Barbara Lead, CEO of Oval Medical Begoña Carreño, Novartis Pharmaceuticals, Switzerland Caroline Feeley, New Products Director, Respiratory Devices & Telehealth

Premeeting Workshop* Cosponsored by Caisson Biotech LLC

Delivery of Therapeutic Bioconjugates: From Polymer Conjugates to Antibody-Drug Conjugates 8:00 a.m. – 12:10 p.m. • Menteith Organizer: Roger Pak, Pfizer Inc., U.S.A.

Organizers: Shiow Fern Ng, National University of Malaysia, Malaysia; Yewande Oni, University of Nottingham, United Kingdom; and Jennifer Wong, University of Sydney, Australia Speaker: Teresa Virgallito, Microtek Laboratories, U.S.A. Panelists: Patrick Baumhof, CureVac GmbH, Germany; and Joshua Reineke, Wayne State University, U.S.A. Additional panelists TBD. Gain an edge in today’s job market through this workshop that aims to help young scientists launch successful careers in academia, industry, and government. This workshop will encompass career planning, job application and interview tips, and a discussion panel who will reflect on their career progression. Complimentary event open to all young scientists and other interested conference attendees.

Young Scientist Roundtable Drug Delivery Technology and Clinical Development 12:30 – 2:00 p.m. • Sidlaw Moderators: Ron Ortiz, Upsher-Smith Laboratories, U.S.A.; and Joshua Reineke, Wayne State University, U.S.A. Panelists: Richard Korsmeyer, Pfizer Inc, U.S.A.; Christopher Rhodes, Drug Delivery Experts, U.S.A.; and Mark Tracy, Tracy BioConsulting, LLC, U.S.A. Clinical trials are arguably the most complex and expensive part of the drug development process. Learn about what is required to advance a drug delivery technology from discovery to commercial development. This roundtable will discuss the challenges and lessons learned in developing drug delivery technology through the clinical trials process and to commercial marketing. The panel of speakers will cover a series of case studies featuring a variety of delivery systems and technologies.

Speed Mentoring Event 4:30 – 5:30 p.m. • Lammermuir Organizers: The Young Scientist Committee Through a series of quick exchanges with multiple contacts, students and young professionals will have the opportunity to seek career and research guidance, hear about the experiences of others, and potentially find a long-term mentor/protégé match. Bring plenty of business cards and plan on starting connections that could last a lifetime. Please be advised this event is open only to individuals who have preregistered. Thank you for your cooperation!

*Additional registration, payment, and ticket required.

continued

13

Sunday

Sunday Program Highlights

Sunday Program Highlights (continued) Plenary 3:00 – 3:50 p.m. • Pentland/Fintry Moderator: Justin Hanes, Johns Hopkins University, U.S.A. Customized Drug Delivery: A Personal Odyssey

Sunday

Vincent H. L. Lee, School of Pharmacy, Faculty of Medicine, Chinese University of Hong Kong, China Dr. Lee will share how his personal struggle with Parkinson’s Disease and his tenure at ALZA and subsequently at the FDA have sharpened his appreciation for the sea change in the culture of drug delivery science and regulation that must take place in order for society to benefit from the promise of customized drug delivery in a timely manner.

First Timers’ Meeting 2:00 – 3:00 p.m. • Lowther If this is your first CRS Annual Meeting, or even if you have attended for many years, learn how to get the most from the annual meeting program by attending this welcome and question-and-answer session.

Exposition Grand Opening and Welcome Reception Cosponsored by LACTEL Absorbable Polymers 5:30 – 7:30 p.m. • Lennox Suite Innovation Sunday concludes with the official opening of the exhibit hall in a quintessentially Scottish fashion—with a strolling Scottish bagpiper! Enjoy a beverage and snack as you follow the bagpiper and move through the exhibit hall to find new products and services. Connect with some of the leading suppliers in delivery science, meet with exhibitors, and visit with colleagues.

14

Technology Forums These forums are open to all registered attendees on a complimentary basis, offering in-depth coverage of controlled release technologies and services, hosted by the following companies.

9:00 – 10:00 a.m.

Strategies for Modified Release Alcohol Resistant Formulations Carrick Presenter: Dr. Firouz Asgarzadeh Presentation Areas: Formulation This presentation provides insights into effective formulation strategies meeting physiological/regulatory challenges when developing alcohol resistant products. The relevance of hydroalcoholic in vitro dissolution media selection on formulation development is discussed. Several formulation concepts with EUDRAGIT® enabling development of robust modified release formulations for both matrix and coated multiparticulates are presented. Company website: www.evonik.com/eudragit ________________________________________________________

The Light Scattering Toolkit for Characterization and Formulation of Drug Delivery Nanoparticles Ochil Presenter: Daniel Some Presentation Areas: Characterization, Formulation Light scattering addresses many key analytical challenges in drug nanoparticle R&D, including accurate size distributions, conformation, payload, and formulation. We review light scattering fundamentals and then present examples illustrating how Wyatt’s unique light scattering instrumentation facilitates rapid and effective development of controlled release vehicles including liposomes, VLPs, polymer-encapsulated nanoparticles, and nanogels. Company website: www.wyatt.com

10:15 – 11:15 a.m. Inorganic Materials for Controlled Release – The Much-Needed Alternative to Polymers? Harris 2 Presenter: Dr. Mark Cresswell Presentation Areas: Formulation Inorganic materials offer enhanced versatility for delivery of actives, through understanding and control of the process and chemistry. We will highlight the benefits of using inorganic controlled release technologies (iCRT) for sustained/immediate release of organic actives/inorganic ions for applications including oral drug formulations, abuse deterrence, antimicrobial activity, remineralization of teeth, and fertilizers. Company website: www.lucideon.com/crt ________________________________________________________

Can Formulation Science Improve Your Delivery Strategy for Emerging Antibody Formats? Harris 1 Presenter: Dr. Chris van der Walle Presentation Areas: Formulation To explore what lies “beyond injections” for monoclonal antibody formats an understanding of their formulation needs is essential. For example, translating sophisticated delivery systems into development may require consideration of protein (cargo) behavior at high concentration. The presentation will address potential gaps in knowledge and invite discussion from the audience. Company website: www.medimmune.com

Extreme Dissolution – Techniques for Testing Novel Delivery Systems Ochil Presenter: Terry Way Presentation Areas: Formulation, Quality & Analytical, Processing The dissolution test has evolved to become a definitive tool used to evaluate the rate of drug release and thereby define the performance characteristics of many types of pharmaceutical dosage forms. The variety of dosage forms today includes orally ingested products such as tablets, capsules, and suspensions, as well as powders, ointments, creams, gels, osmotic pumps, transdermal patches, implants, medicated contact lenses, stents, coated beads, wound care products, bone cement, powders for inhalation, chewing gums, nanoparticulate injections, and so on…. Over the last 50 years, dissolution apparatus has therefore required continuous improvement and modification to provide suitable conditions for appropriate performance testing of these products. This forum session will review the range of techniques used to evaluate the more recent formulation technologies requiring specialized apparatus using volumes of media from 5 to 5,000 mL over time intervals from 7 minutes to 7 days, illustrated with specific case studies. Company website: www.agilent.com

continued

15

Case Study Developing Complex, ExtendedRelease Products from Feasibility to Production Carrick Presenter: Dr. Thomas R. Tice Presentation Areas: Formulation The interplay between drug properties, polymer properties, process parameters, and aspects such as meeting regulatory requirements make complex parenteral formulations challenging to develop. The presentation shows Evonik’s experiences addressing these challenges and highlights key topics such as product design, technology selection, feasibility studies, process scale-up, manufacturing, and product release testing. Company website: www.evonik.com/resomer ________________________________________________________

PLGA in Controlled Release Gel Systems, from Polymer to Product Harris 1 Presenter: Wim Hennink Presentation Areas: Formulation Prof. Wim Hennink will give an introduction to gel-based controlled drug delivery systems. Dr. Mart Eenink will present PURASORB PLGAs as resorbable polymers for use in parenteral drug delivery systems. Dr. Georges Gaudriault will introduce the Bepo™ technology platform for a new generation controlled release, localized, and sustained drug delivery. Company website: www.corbion.com/biomaterials ________________________________________________________

Drug Permeation Enhancement Across Skin Using Novel Components from Natural Moisturising Factor (NMF) Harris 1 Presenter: Prof. Marc Brown Presentation Areas: Formulation MedPharm has developed a series of patented novel hydrotropes (AquaRMed™) that increase hydration of the skin. These compounds are derived from natural moisturising factor (NMF), a series of compounds that aid water retention within the skin. NMF is a breakdown product of filagrin. Company website: www.medpharm.co.uk

11:30 a.m. – 12:30 p.m.

Formulation Solutions Using Hot Melt Extrusion for Poorly Soluble Drugs Carrick Presenter: Sampada B. Upadhye, and BASF presenter Presentation Areas: Formulation, Processing This forum will discuss development of hot melt extruded oral solid dosage forms leveraging the OptiMelt™ HME platform. Expert speakers will provide guidance on selection and screening of polymers/excipients for optimal development and scale-up of hot melt extruded products, followed by a Q&A session hosted by BASF and Catalent Pharma. Company website: www.catalent.com

16

A Refined Solution for Microsphere Formulation Ochil Presenter: Sylvain Querol Presentation Areas: Formulation, Processing Parenteral microsphere drug production is experiencing a fastgrowing demand, and drug manufacturers are facing new challenges during process scale-up from R&D to commercial formulation. Microspheres obtained from encapsulation processes require aseptic filtration and drying methods to recover the final product. PSL will present their innovative solution, the Microsphere Refiner. Company website: www.powdersystems.com

Soapbox Sessions Cosponsored by Catalent Pharma Solutions 1:00 – 2:40 p.m. • Lomond Suite

1:00 – 1:05 p.m. Introduction and Welcome Moderator: Michael J. Valazza, Catalent Pharma Solutions

1:50 – 1:55 p.m. V-Smart™ Nanomedicines for Neurology Susan Rosenbaum, Lauren Sciences LLC, U.S.A.

Session I

1:55 – 2:00 p.m. Modular. Scalable. Future-proof. The New Xtend™ Dissolution Testing Concept Michel Magnier, Sotax, Switzerland

1:05 – 1:10 p.m. Molded Polymer Dosage Forms – Current and Future Applications in Women’s Health James Arps, ProMed Pharma, U.S.A. 1:10 – 1:15 p.m. Shaping of Polymers for Drug Delivery Applications Anthony Listro, Foster Delivery Science, U.S.A. 1:15 – 1:20 p.m. Don’t Fry Your API! Try Low Temperature Extrusion with Lipids Sophie Hughes, Gattefosse, France 1:20 – 1:25 p.m. SmartPearls - Dermal Delivery System for Amorphous Poorly Soluble Drugs Rainer H. Müller, Grace, Germany 1:25 – 1:30 p.m. Foamed Polymer Excipients: Novel Way to Deliver Stem Cells, Growth Factors and Biologics For Controlled Release Applications Christian Schneider, Celanese, U.S.A. 1:30 – 1:40 p.m. Networking Break

Session II 1:40 – 1:45 p.m. Microjet Reactor Technology for Continuous Nanoparticle Production under Controlled Conditions Nazende Günday Türeli, MJR PharmJet, Germany

Sunday

What’s new in delivery science? Come to the program where presenters “get up on their soapbox” to give you a quick glimpse of some of the most innovative technologies and products in development today. Session breaks allow time to network with presenters at their designated tables during beverage breaks, hosted by our sponsor.

2:00 – 2:05 p.m. Innovative Dissolution For a Better Formulation Understanding Samir Haddouchi, SPS Pharma Services, France 2:05 – 2:15 p.m. Networking Break

Session III 2:15 – 2:20 p.m. Novel Direct Injectable and Biodegradable DDS for Parenteral Controlled Release Karsten Maeder, Institute of Pharmacy, Martin Luther University Halle, Germany 2:20 – 2:25 p.m. Functionalized Calcium Carbonate (FCC): Newly Developed Structured Minerals as Multifunctional Excipients Carolina Diaz Quijano, Omya, Switzerland 2:25 – 2:30 p.m. Consumer Buying Behavior Michael Osafo Yeboah, MacDove Ventures, Ghana 2:30 – 2:40 p.m. Networking Break

1:45 – 1:50 p.m. Injectable Hydrogels to Treat Low Back Pain via Controlled Release of Celecoxib or siRNA Transfection Nicole Papen-Botterhuis, TNO, The Netherlands

17

Daily Schedule Monday, July 27

Monday

7:00 – 8:00 a.m. 7:00 a.m. – 5:00 p.m. 7:00 a.m. – 5:00 p.m. 8:00 – 9:30 a.m. 9:30 – 10:30 a.m. 9:30 – 10:30 a.m. 9:30 a.m. – 6:00 p.m. 10:30 a.m. – 12:00 p.m. 10:30 a.m. – 12:00 p.m. 12:00 – 1:00 p.m. 1:00 – 2:45 p.m. 3:00 – 4:30 p.m. 3:00 – 4:30 p.m. 4:30 – 5:30 p.m. 5:00 – 6:00 p.m. 5:30 – 6:30 p.m. 6:00 – 6:30 p.m. 9:00 – 10:30 p.m.

Get Up! Get Educated! Choosing the Best Animal Model for Your Drug Delivery Studies CRS Registration Open Speaker Preparation Room Open CRS Opening Session Poster Session I Authors Present – Group A (odd-numbered) Exposition Hall Open Poster Session I Viewing Hours Mini-Symposium: Modeling and Simulation of Oral Absorption – A Progress Report from the EU/IMI Project OrBiTo Scientific Sessions • Drug Delivery to the Brain • Encapsulation for Industrial Applications • Modulated and Responsive Delivery Systems • Transdermal Delivery Exposition Hall Open (lunch available for purchase) Plenary & Special Session: Cameron Alexander and Nicholas A. Peppas Mini-Symposium: Therapeutic Cancer Nanomedicines Scientific Sessions • Delivery of Vaccines • Manufacture, Characterization, Measurement, and Stability • Oral Delivery for Food • Respiratory Drug Delivery Exposition Hall Happy Hour Poster Session I Authors Present – Group B (even-numbered) PSAH Networking Event* Poster Session I Take-Down Young Scientist Networking Event*

Moorfoot Strathblane Hall Conference Organiser’s Room Pentland Cromdale Hall Lennox Suite Cromdale Hall Pentland Sidlaw Tinto Fintry Moorfoot Lennox Suite Pentland Pentland Sidlaw Tinto Fintry Moorfoot Lennox Suite Cromdale Hall Shakespeare (offsite) Cromdale Hall The Scotch Whisky Experience (offsite)

*Additional registration, payment, and ticket required.

Monday Program Highlights Get Up! Get Educated!

Opening Session

Choosing the Best Animal Model for Your Drug Delivery Studies

8:00 – 9:30 a.m. • Pentland

7:00 – 8:00 a.m. • Moorfoot

Co-organized by the Young Scientist Committee and Preclinical Sciences & Animal Health Division

Chair: Raquel De Souza, University of Toronto, Canada Speakers: Marcel B. Bally, Centre for Drug Research and Development (CDRD), Canada; Tamara Minko, Rutgers, The State University of New Jersey, U.S.A.

Significant preclinical efforts exist in developing nano drug delivery systems. Unfortunately, few undergo successful clinical development due in part to evaluation in inadequate animal models, hindering clinical translation of findings. In this workshop, attendees will acquire insightful perspectives on selecting appropriate animal models for nanodelivery research. An overview of important considerations and introduction to various classes of animal models will be followed by discussions on specific applications, including oncology. 18

The Opening Session will feature a welcome by President Art Tipton, who will provide a brief update on what your association is doing to further delivery science and technology during the annual business meeting portion of the meeting. This session will also be a time to honor the 2015 CRS Distinguished Service awardee, Kinam Park, outstanding Pharmaceutical Paper awardee, Jason Li, along with talks from our Founders Award winner, Gary Cleary, and CRS T. Nagai Postdoctoral Research Achievement Award winner, Gaurav Sahay. Five new members of the College of Fellows will also be inducted.

Monday Program Highlights (continued)

Posters are an important element of the CRS Annual Meeting—attendees share groundbreaking scientific achievements and learn about the latest technologies in delivery science.   Posters are displayed on Monday or Tuesday, and authors will be present during the dedicated sessions to discuss their research and answer questions. Monday’s poster topics include: • Delivery of Proteins, Peptides, and Vaccines • Manufacture, Characterization, Measurement, and Stability • Oral Delivery for Food and Pharma • Parenteral Controlled Release • Regional Delivery  9:30 – 10:30 a.m. Poster Session I Authors Present – Group A (odd-numbered poster boards) 5:00 – 6:00 p.m. Poster Session I Authors Present – Group B (even-numbered poster boards)

Intelligent Polymer Hydrogels: From Obscure Molecular Structures to Useful Multifunctional Systems for Drug and Protein Delivery, Targeting and Molecular Sensing Nicholas A. Peppas, University of Texas at Austin, U.S.A. Cross-linked polymeric networks with diverse characteristics and properties have been in the center of development of drug delivery systems over the past 40 years. Understanding of the structural characteristics of such systems provides for accurate design on new delivery systems with targeting and recognition characteristics. This lecture offers a brief history of such hydrogels and discusses present and future applications.

Plenary Lecture and Special Session

Prior to the plenary, the CRS Foundation’s 2014 Alexander “Sandy” Florence Postdoctoral Fellowship recipient, Christopher Nelson, will present research from his fellowship year. The 2015 Nicholas A. Peppas Student Travel Grant awardees will also be recognized.

1:00 – 2:45 p.m. • Pentland

PSAH Networking Event*

Moderators: David Brayden, University College Dublin, Ireland; and Randy Mrsny, University of Bath, United Kingdom

5:30 – 6:30 p.m. • Shakespeare (offsite)

Polymers and Nanomedicines – The Promises and Pitfalls of New Materials Cameron Alexander, School of Pharmacy, University of Nottingham, United Kingdom There are many challenges in the development of new drugs, not least of which are the issues relating to controlled release and targeting. Current therapies are suboptimal for diseases ranging from viral and bacterial infection to cancers, and existing carrier materials have not been able to completely address the delivery problems. New materials offer much promise for controlled release, with many spectacular examples of efficacy in laboratory-scale experiments. However, very few proof-of-concept studies have progressed beyond these stages. Dr. Alexander’s plenary presentation will deliver examples of recent scientific advances and consider the hurdles to translating these toward the clinic.

This hour-long networking event is hosted by the Preclinical Sciences & Animal Health (PSAH) Division and will be held at a local Edinburgh pub. All attendees interested in the use of animal models in preclinical studies, interspecies differences in drug absorption, pharmacokinetics, and target site drug delivery, and all matters relating to the animal health industry are invited to attend.

Young Scientist Networking Event* Cosponsored by Diurnal Limited and Upsher-Smith Laboratories, Inc. 9:00 – 10:30 p.m. • The Scotch Whisky Experience (offsite) Reunite with familiar faces and make new connections when you attend this popular networking event, organized by the Young Scientist Committee. The event will be held at the Scotch Whisky Experience, where attendees will experience a whisky tasting featuring the four primary regions of Scotch whisky.

*Additional registration, payment, and ticket required. 19

Monday

Poster Sessions

Podium • Monday Morning Sidlaw

Tinto

Drug Delivery to the Brain Moderator: Kannan Rangaramanujam Session Chairs: Mariarosa Mazza, Anthony Kim

Fintry

Encapsulation for Industrial Applications Moderator: Ruth Schmid Session Chairs: Chris McDaniel, Teresa Virgallito

Modulated and Responsive Delivery Systems Moderator: Christine Allen Session Chairs: Darren Svirskis, Qin He

INVITED SPEAKERS

Monday

10:30

1

Invited Speaker: Polymer Nanoparticles Delivered by Convection-Enhanced Delivery For Treatment of Brain Tumors W Saltzman Yale Univ, U.S.A.

3

Invited Speaker: Does size matter? Navigating the path from milli through micro to nano in the packaging of bioactives. R J Neufeld Queen’s Univ, Canada

5

Invited Speaker: Photo, pH, and Reduction-Responsive Drug Release Nanosystems: Which is the Best for Targeted Cancer Chemotherapy? Z Zhong Soochow Univ, China

10:50

2

Invited Speaker: Targeted CNS delivery of cGMP analogue preventing inherited retinal degeneration P J Gaillard, H Genieser, M Valeria, P Ekström, F Paquet- Durand 2-bbb medicines BV, Netherlands

4

Invited Speaker: R Kent AnaBio Technologies Ltd., Ireland

6

Invited Speaker: Nanoscale Stimuli Responsive Systems for Targeted Delivery of Drugs and Nucleotides J Kost Ben-Gurion Univ of the Negev, Israel

RESEARCH HIGHLIGHT TALKS AND MODERATED DISCUSSION 11:10

439

Delivery of Brain-Penetrating Nanoparticles Across the Blood-Brain Barrier with Focused Ultrasound: Brain Tumor and Neurodegenerative Disease Applications B Mead, K Timbie, W Miller, P Mastorakos, C Zhang, J Suk, J Song, J Hanes, R Price University of Virginia, U.S.A.

519

Dry Polymer Coating for Improving Physical Stability of Amorphous Drug Formulations M Capece, R Dave New Jersey Instiute of Technology, U.S.A.

674

Hybrid Bioactive Nanoparticles Modulate Tumor Microenvironment and Enhance Radiation Therapy M Amini, A Z Abbasi, C R Gordijo, A Maeda, R S DaCosta, A M Rautth, X Wu Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

11:15

489

Selective Accumulation of PEGliposomes in Brain after Traumatic Brain Injury B J Boyd, A Galle, J Rosenfeld, R Medcalf Monash Institute of Pharmaceutical Sciences, Australia

530

Stimuli-responsive organo-silica/ polyurea composite microcapsules J Yang, M Pilz, C Simon SINTEF Materials and Chemistry, Norway

753

pH-sensitive liposomes for the delivery of therapeutic proteins: potential application for the treatment of bladder cancer M Vila-Caballer, G Codolo, F Munari, S Bersani, M Fassan, M Rugge, P Caliceti, M de Bernard, S Salmaso Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy

11:20

157

Targeted Delivery of GDNF to Brain by Novel V-SmartTM Nanovesicles and its Efficacy in Parkinson’s Disease Animal Model S Rosenbaum, M Popov, C Linder, E Shaubi, V Kas’yanov, I Hollander, S Grinberg, E Heldman Lauren Sciences LLC, U.S.A.

531

Taste Masking Active Pharmaceutical Ingedients Using a Novel Acoustic Mixing Process R T McLaughlin, A P Parker, S A Howes, C Smith, T Brown Catalent Pharma Solutions, United Kingdom

725

Multistage Stimuli-responsive and Sequential Size-alterable Nanovehicle for Systemic Nuclear-targeted Drug Delivery L Li, Y Huang Sichuan University, China

11:25

459

Image-guided Drug Delivery across the Blood-Brain Barrier using Theranostic Microbubbles T Lammers, P Koczera, F Kiessling RWTH Aachen University, Germany

249

Scaling up a high shear granulation process to gain granules suitable to formulate orally disintegrating tablets S Fros, T Agnese, A Zakhvatayeva, F Cembali, G Mondelli, T Cech, C Funaro BASF SE, Germany

806

Targeted Imaging of Cyclooxygenase-2 in Inflammation and Cancer by Fluorocoxib A-Loaded ROS-Responsive Nanoparticles T Werfel, M Uddin, B Crews, M Gupta, L Marnett, C Duvall Vanderbilt University, U.S.A.

11:30

692

Lactoferrin-bearing Polypropylenimine Dendrimer for Targeted Gene Delivery to the Brain S Somani, G Robb, B Pickard, C Dufès University of Strathclyde, United Kingdom

522

Enzymatically Triggered Release from Zein Particles for Antimicrobial Coatings and Plasters M Nieuwland, N E Papen-Botterhuis, W C Drost, T M Slaghek, J Eversdijk, B Erich TNO Materials Solutions, Netherlands

784

Site-Specific Time and Sequential Nanoparticle Delivery of Chemotherapeutics for Synergy Enhancement V Segura-Ibarra, S Wu, F E Cara, F Meric-Bernstam, M Ferrari, E Blanco Houston Methodist Research Institute, U.S.A.

20

Mini-Symposia • Monday Morning Moorfoot

Pentland

Transdermal Delivery Moderator: Mark Prausnitz Session Chairs: Nicole Brogden, Samir Mitragotri

7

Invited Speaker: V Preat

10:50

8

Invited Speaker: Expanding Transdermal Delivery to Biologics B Singh Corium Intl Inc., U.S.A.

11:10

947

In vivo Monitoring of Compound Permeation and Age Related Effects in Human Stratum Corneum N J Starr, J Wibawa, I Marlow, M Bell, D A Barrett, D J Scurr University of Nottingham, United Kingdom

11:15

927

Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-dose Combination of Cardiovascular Drugs H L Quinn, L Bonham, R F Donnelly Queen’s University Belfast, United Kingdom

11:20

976

Targeting of skin resident dendritic cells via laser microporation Y J Machado, M Mayr, T Thalhamer, V Höpflinger, M Schmid, U Ritter, S Gordon, C Lehr, S Scheiblhofer, J Thalhamer, R Weiss University of Salzburg - Department of Molecular Biology, Austria

11:25

920

Allergen-coated microneedles as a novel way for asthma preventive immunotherapy A K Shakya, C H Lee, H S Gill Texas Tech University, U.S.A.

11:30

956

Micropore Closure Kinetics are Delayed Following Microneedle Insertion in Elderly Subjects C C Converse, M N Kelchen, M J Farley, G O Holdren, N K Brogden University of Iowa, U.S.A.

Invited Speaker: P Langguth Johannes Gutenberg-University, Germany

10:30

9

11:00

10

Invited Speaker: Enhanced in vitro inputs for in silico prediction of oral absorption – progress within the Innovative Medicines Initiative OrBiTo project M McAllister, R Holm, A Müllertz, J Butler, P Augustijns, B Abrahamsson, H Lennernäs Pfizer Inc, United Kingdom

11:30

11

Invited Speaker: X Pepin Sanofi, France

Monday

10:30

Modeling and Simulation of Oral Absorption - A Progess Report from the EU/IMI Project OrBiTo Moderators: Peter Langguth, Clive Wilson

21

Podium • Monday Afternoon Sidlaw

Tinto

Delivery of Vaccines Moderator: Derek O’Hagan Session Chairs: Hideyoshi Harashima, Camilla Foged

Fintry

Manufacture, Characterization, Measurement, and Stability Moderator: Martyn Davies Session Chairs: Jaime Oxley, Jean-Antoine Meiners

Oral Delivery for Food Moderator: Iain Beck Session Chairs: Joeska Husny, Hans Tromp

INVITED SPEAKERS

Monday

3:00

12

Invited Speaker: Mucosal delivery of particulate vaccines E C Lavelle School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland

14

Invited Speaker: A Florence University of Strathclyde, United Kingdom

16

Invited Speaker: Assembly of Karifin Nanoparticles-Based Pickering Emulsions for Nutraceutical Delivery Q Huang Rutgers Univ, U.S.A.

3:20

13

Invited Speaker: Vaccine delivery – depot or not? D Christensen Statens Serum Inst, Denmark

15

Invited Speaker: Assessing how excipients properties as well as the manufacturing process would influence solid oral dosage form performance and overall cost of manufacturing. A Faham Dow Chemical, Switzerland

17

Invited Speaker: D O’Riordan Food for Health, University College Dublin, Ireland

RESEARCH HIGHLIGHT TALKS AND MODERATED DISCUSSION 3:40

126

Needle-Free Transdermal Vaccine Delivery Systems Using HyaluronateVaccine Conjugates S Hahn, H Kim, K Kim, S Yun POSTECH, South Korea

256

Structural analysis of nanosystems: Solid Span Nanoparticles (SSN) as a case study A Pensado, I Fernández Piñeiro, M Martín Pastor, A Sánchez, B Seijo University of Santiago de Compostela, Spain

375

Silica Encapsulated Lipid Based Drug Delivery Systems for Reducing the Food Effect of Ziprasidone T J Dening, S Rao, N Thomas, A Tan, C A Prestidge Ian Wark Research Institute, University of South Australia, Australia

3:45

120

Liposome-based vaccines for lung cancer treatment C Loira Pastoriza, C Herin, M Machado, K Vanvarenberg, R Vanbever Université catholique de Louvain, Belgium

210

Infacort® - Manufacturing Process Scale Up and Characterisation of a Taste Masked Multiparticulate Oral Hydrocortisone Formulation for Paediatric Use G Neal, M J Whitaker, A Grave, A Foerg, N Poellinger, D N Margetson Diurnal Ltd, United Kingdom

277

ß-Casein Based Nano-vehicles for Oral Delivery of Chemotherapeutic Combinations Overcoming Multidrug Resistance in Human Gastric Cancer M Bar-Zeev, Y G Assaraf, Y D Livney Technion - Israel Institute of Technology, Israel

3:50

145

Rabies vaccination in dogs using a dissolving microneedle patch J Arya, K Dewitt, M Scott-Garrard, Y Chiang, M R Prausnitz Georgia Institute of Technology, U.S.A.

212

Injection Moulding of Controlled Release Solid Dispersions A L Kelly, S Deshmukh, A Paradkar, S Abrahmsén Alami, J Booth Centre for Pharmaceutical Engineering Science, University of Bradford, United Kingdom

273

Application of sodium alginate for enteric coated lactoferrin tablets C Takahashi, Y Obayashi, A Uchiyama, S Tanaka, H Iwasaki Lion Corporation, Japan

3:55

73

Biomimetically Engineered Demi-bacteria Potentiate Vaccination Against Cancer W Wei, D Ni, H Yue, G Ma National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences. Beijing, China

250

Simultaneous Enhancement of Dissolution and Tribo-electrification of Solid Dispersions K Asare-Addo, A Nokhodchi, E Supuk, B Conway University of Huddersfield, United Kingdom

340

Intestinal permeation enhancers improve flux of food-derived tripeptides across rat intestinal mucosae in vitro J P Gleeson, S M Ryan, D J Brayden University College Dublin, Ireland

4:00

161

Therapeutic Tumor Lysate Vaccine for B cell lymphoma: Efficacy and Mechanistic properties of Soluble vs Particulate Tumor Lysate Formulations K Roy, J Leleux, J Liu, P Pradhan Professor, U.S.A.

221

Microfluidics liposome formulation and investigation of liposome-cell interactions by Atomic Force Microscopy (AFM) O Kemp, D Lamprou, H M Grant University of Strathclyde, United Kingdom

360

Optimization of the Microencapsulation of Anthocyanins from Haskap Berries (Lonicera caerulea L.) in Ca-Alginate Beads for Oral Delivery G B Celli, A Ghanem, M S Brooks Dalhousie University, Canada

22

Mini-Symposia • Monday Afternoon Moorfoot

Pentland

 Respiratory Drug Delivery Moderator: Claus-Michael Lehr Session Chairs: Sara Barthold, Joshuar Reineke

18

Invited Speaker: Technological and pharmacological rationale for regional drug delivery S Senel Hacettepe Univ, Turkey

3:20

19

Invited Speaker: Extended Release in the Lungs: Challenges and Opportunities R Niven Novartis, U.S.A.

3:40

500

The Development of All-Trans Retinoic AcidLoaded Collagen-Hyaluronic Acid Films for Respiratory Tissue Regeneration C O’Leary, F J O’Brien, S Cryan Royal College of Surgeons in Ireland, Ireland

3:45

535

A comparison of the pharmacokinetics of an inhaled PEGylated dendrimer between rats and sheep and the role of the pulmonary lymphatic system in absorption from sheep lungs. L M Kaminskas, G M Ryan, C J Porter, D J Owen Monash Institute of Pharmaceutical Sciences, Australia

3:50

820

Transport Properties of Liposomes for Pulmonary Drug Delivery depend on the Surface Characteristics of  the Liposomes and the Atomization Technique used for Nebulization B Lehofer, P P Jain, F Bloder, R Leber, G Leitinger, L M Marsh, H Olschewski, A Olschewski, R Prassl Institute of Biophysics, Medical University of Graz, Austria

3:55

465

Inhalable nano-embedded microparticles for sustained delivery of cationic antimicrobial peptides: overcoming lung barriers I d’Angelo, B Casciaro, M Mangoni, A Miro, F Quaglia, F Ungaro DISTABIF, Second University of Naples, Italy

4:00

469

Layered Nanoemulsion-based Mucoadhesive Buccal Systems for Controlled Delivery of Oral Cancer Therapeutics A Gavin, N Kim, D Wang, B Brownlow, T A Elbayoumi Midwestern University-Glendale, AZ, U.S.A.

3:00

20

Invited Speaker: Development of Fixed-Ratio Anticancer Drug Combination Nanomedicines That Markedly Improve Clinical Efficacy and Survival Outcomes L Mayer Celator Pharmaceuticals Inc., U.S.A. and Canada

3:30

21

Invited Speaker: Clinical Experience Combining CRLX101, an Investigational Nanoparticle-Drug Conjugate, With Other Agents: A Translational Research Program S Eliasof Cerulean Pharma, U.S.A.

4:00

22

Invited Speaker: Clinical Fact Sheet of Cancer Nanomedicine and Revisiting its Working Mechanisms Y Bae University of Utah, U.S.A.

Monday

3:00

Therapeutic Cancer Nanomedicines Moderators: Lawrence Mayer, You Han Bae

23

Daily Schedule Tuesday, July 28

Tuesday

7:00 – 8:00 a.m. Get Up! Get Educated! Trends in Protein Delivery Moorfoot 7:00 – 8:00 a.m. Poster Session II Set-Up Cromdale Hall Speaker Preparation Room Open Conference Organiser’s Room 7:00 a.m. – 5:00 p.m. 7:00 a.m. – 5:00 p.m. CRS Registration Open Strathblane Hall Plenary Session: María José Alonso Pentland 8:00 – 9:30 a.m. 9:30 – 10:30 a.m. Exposition Hall Open Lennox Suite 9:30 – 10:30 a.m. Poster Session II Authors Present – Group C (odd numbered) Cromdale Hall 9:30 a.m. – 4:30 p.m. Poster Session II Viewing Hours Cromdale Hall Chapter Chair Networking Break (by invitation) Atrium Café 10:30 – 11:30 a.m. 10:30 a.m. – 12:00 p.m. Mini-Symposium: Next-Generation Vaccine Development Moorfoot and Delivery Technologies 10:30 a.m. – 12:00 p.m. Scientific Sessions Tinto • In Vivo Nucleic Acid Delivery • Nano-Sized Carriers for Small Molecule Oncology Drugs Sidlaw Fintry • Ocular Drug Delivery • Oral Drug Delivery Pentland 12:00 – 1:00 p.m. Lunch with the Luminaries* Carrick 12:00 – 1:30 p.m. Exposition Hall Open (lunch available for purchase) Lennox Suite 12:00 – 1:30 p.m. C&DP Luncheon* Sheraton, Stirling Suite (offsite) 1:30 – 3:00 p.m. Mini-Symposium: European Technology Platform on Moorfoot Nanomedicine: Translation of Nanomedicines 1:30 – 3:00 p.m. Scientific Sessions: • Delivery of Peptides and Proteins Pentland Tinto • Delivery Science in Cosmetics, Personal Care, and Household Products • Parenteral Delivery Technologies Sidlaw • siRNA and mRNA Delivery Fintry 3:00 – 4:30 p.m. Exposition Hall Open Lennox Suite 3:30 – 4:30 p.m. Poster Session II Authors Present – Group D (even numbered) Cromdale Hall 4:00 – 5:30 p.m. College of Fellows Panel: How Can We Make Pentland Nanomedicine Work? 4:00 – 6:00 p.m. Exhibit Take-Down Lennox Suite 4:30 – 5:00 p.m. Poster Session II Take-Down Cromdale Hall Women in Science Networking Event* Moorfoot 5:00 – 6:30 p.m. CRS Closing Reception The Assembly Rooms (offsite) 7:30 – 10:00 p.m. *Additional registration, payment, and ticket required.

24

Tuesday Program Highlights Get Up! Get Educated!

Poster Sessions

Trends in Protein Delivery

Posters are an important element of the CRS Annual Meeting—attendees share groundbreaking scientific achievements and learn about the latest technologies in delivery science.   Posters are displayed on Monday or Tuesday, and authors will be present during the dedicated sessions to discuss their research and answer questions.

Chair: Shiow Fern Ng, National University of Malaysia, Malaysia Speakers: Edith Mathiowitz, Brown University, U.S.A.; and Ulrik Lytt Rahbek, Novo Nordisk, Denmark With biologics and vaccines making up a growing share of pharmaceutical pipelines, drug delivery plays an increasingly important role in driving safety, efficacy, and product differentiation. This session will present an introduction to growing opportunities and emerging trends in the delivery of proteins, peptides, and vaccines.

Plenary Speaker 8:00 – 9:30 a.m. • Pentland Moderator: Andy Lewis, Ipsen, France Global Efforts and Successes in Needle-Free Peptide Delivery María José Alonso, University of Santiago de Compostela, Spain, and coordinator of the TRANS-INT European consortium Peptide molecules, including drugs and antigens, are gaining increasing space in the pharmaceutical industry pipelines. Despite their high potential, difficulties in crossing epithelial barriers have greatly limited their appropriate exploitation. Globally, there have been significant efforts to overcome these limitations through the design of transmucosal delivery strategies, many relying on the use of nanotechnology. In this plenary presentation, María José Alonso will discuss the results of global, cooperative efforts to accelerate progress on the rational design of peptide nanomedicines: the TRANS-INT European consortium, exploring the potential of nanotechnology for oral peptide delivery; and a Grand Challenges in Global Health Consortium that has resulted in the development of needle-free nanovaccine technologies. Awards presented prior to the plenary will include the CRS Jorge Heller Journal of Controlled Release Outstanding Paper Award to Richard Price, University of Virginia, U.S.A., and the Drug Delivery and Translational Research Outstanding Paper Award to Kanjiro Miyata, University of Tokyo, Japan.

Tuesday’s poster topics include: • Delivery Science Cosmetics, Personal Care, and Household Products • Encapsulation for Industrial Applications • Micro- and Nanoparticle Delivery • RNA and DNA Delivery • Topical and Transdermal Delivery 9:30 – 10:30 a.m. Poster Session II Authors Present – Group C (odd-numbered poster boards) 3:30 – 4:30 p.m. Poster Session II Authors Present – Group D (even-numbered poster boards)

Lunch with the Luminaries* 12:00 – 1:00 p.m. • Carrick CRS has a long tradition of esteemed leaders in the delivery science community who are active members in our society. CRS has invited two distinguished luminaries to participate in this exciting new event. Space is limited, so register early and join in the lively conversation over the lunch hour. 

Vincent H. L. Lee, School of Pharmacy, Faculty of Medicine, Chinese University of Hong Kong, China

Nicholas A. Peppas, University of Texas at Austin, U.S.A.

C&DP Luncheon* Cosponsored by Coating Place, Inc., The Dow Chemical Company, Microtek Laboratories, Inc., and Ronald T. Dodge Co. 12:00 – 1:30 p.m. • Sheraton, Stirling Suite (offsite) Join your colleagues for lunch at this annual event hosted by the Consumer & Diversified Products (C&DP) Division. This event connects attendees interested in encapsulation and controlled release research for food, nutraceuticals, personal care, cosmetics, home care, agriculture, textiles, and coatings. All attendees interested in C&DP are welcome to attend! continued

25

Tuesday

7:00 – 8:00 a.m. • Moorfoot

Tuesday Program Highlights (continued) College of Fellows Panel

Women in Science Networking Event*

4:00 – 5:30 p.m. • Pentland

5:00 – 6:30 p.m. • Moorfoot

How Can We Make Nanomedicine Work?

Speaker: Begoña Carreño, Novartis Pharmaceuticals, Switzerland

This special panel discussion is presented by the CRS College of Fellows. The panel this year features College of Fellows members who have direct experience in nanomedicines. Despite three decades of pursuit, there has been little progress. Do we need to help develop standards, so that studies can be rigorously compared? Can we identify disease and patient characteristics that are more amenable to nanotreatment than others? How should nanodrugs be regulated?

Tuesday

Panel Moderator: Susan Cady, Merial Ltd., U.S.A.

There Is Light on the Dark Side: A Journey Through Big Pharma Don’t miss this popular event, which provides an insightful and informational presentation along with ample time for networking. Join your fellow attendees for wine and hors d’oeuvres and a presentation from Begoña Carreño, Global Head of Search and Evaluation (S&E) in respiratory as well as the venture capital liaison, Novartis Pharmaceuticals.

NEW EVENT – CRS Closing Reception** 7:30 – 10:00 p.m. • The Assembly Rooms (offsite)

Panelists:

Nicholas A. Peppas University of Texas at Austin, U.S.A.

Edith Mathiowitz Brown University, U.S.A.

Samir Mitragotri University of California, Santa Barbara, U.S.A.

The Closing Reception will be held at the Assembly Rooms in Edinburgh, a UNESCO World Heritage site, home of grand assemblies, balls, and musical performances since 1787. Follow the piper into the Music Hall as we kick off our party with the Address to a Haggis. Experience tastes of fine whisky from Ian Macleod Distillers, one of the most respected, independent family-owned distillers in Scotland. You will become acquainted with local craft beer during a tasting with Harviestoun Breweries, founded in Central Scotland in 1984. The evening would not be complete without a traditional social dance or ceilidh. Enjoy Scotland’s best loved electric ceilidh band, The Sensational Jimi Shandrix Experience. When Scots think of a ceilidh they think of great music, fun dancing and good company.  Drinks, Scottish canapés and fork food will be served. ** The closing reception is included in the registration fee with regular, student, and postdoc registration. A limited number of tickets are available for other registration types. Early purchase is encouraged.

*Additional registration, payment, and ticket required. 26

GET MORE OUT OF CRS! Volunteer for a Committee Join a Chapter

Publish with CRS Contribute to the CRS Newsletter Organize a Workshop

Present at the Annual Meeting

Interested? See controlledreleasesociety.org

Podium • Tuesday Morning Tinto In Vivo Nucleic Acid Delivery Moderator: Ernst Wagner Session Chairs: Ronit Satchi-Fainaro, Koen Raemdonck

Sidlaw

Fintry

Nano-Sized Carriers for Small Molecule Oncology Drugs Moderator: Mark Tracy Session Chairs: Scott Eliasof, Khaled Greish

Ocular Drug Delivery Moderator: Vince Lee Session Chairs: Todd Hoare, Rocio Herrero-Vanrell

INVITED SPEAKERS 23

Invited Speaker: U Griesenbach

25

Invited Speaker: Nanotechnology Approaches for Personalized Treatment of Cancer T Minko, A Kuzmov, J Sapiezynski, O Taratula, V Shah, M Zhang, O B Garbuzenko, S R Pine, L RodriguezRodriguez Rutgers Univ, U.S.A.

27

Invited Speaker: Non-viral gene therapy for eye diseases:  Which perspectives? How to translate to the clinic? F F Behar-Cohen Hospital Ophtalmique Jules-Gonin, France

10:50

24

Invited Speaker: Genome Editing with Zinc Finger Nucleases M C Holmes Sangamo BioSciences, U.S.A.

26

Invited Speaker: A Lieber

28

Invited Speaker: Development of Drug Delivery Systems for the Eye: Focus and Team E de Juan ForSight Labs, U.S.A.

Tuesday

10:30

RESEARCH HIGHLIGHT TALKS AND MODERATED DISCUSSION 11:10

915

Ultrasound-mediated gene transfer to the brain J Y Tan, D Sellers, H Wei, N Coulsen, D O Maris, P Mourad, P J Horner, S H Pun University of Washington, U.S.A.

651

Extracellular vesicles as smart carriers for small molecule drugs G Fuhrmann, A Serio, M M Stevens Imperial College, Department of Materials, Department of Bioengineering, United Kingdom

434

Clinical and Preclinical Demonstration of Continuous and Adjustable Methotrexate Delivery from a Novel Refillable “Port Delivery System” Implant S R Erickson, R Campbell, K Farinas, J Horvath, J M Stewart ForSight Vision4, U.S.A.

11:15

881

Gene Delivery to the Brain Using Brain Penetrating DNA Nanoparticles P Mastorakos, C Zhang, E Song, S Berry, J Suk, J Hanes Johns Hopkins University Medical School, U.S.A.

541

A novel antitumour strategy using bidirectional autophagic vesicles accumulation via combined  treatment with TAT-Beclin 1 and liposomal hydroxychloroquine Y Wang, Y Liu, Q He Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, China

431

Antioxidant Activity and Real-Time Imaging of HPMC–coated Cerium Oxide Nanoparticles: New Modality for AgeRelated Cataract A A Al-kinani, S Patel, A Vangala, G Calabrese, B Pierscionek, D Naughton, R G Alany School of Pharmacy and Chemistry, Kingston University London, United Kingdom

11:20

853

Cell Derived Nano-Ghosts: A Novel Targeted Gene Delivery System For Cancer Therapy L Kaneti, M Machluf Technion, Israeli Institute of Technology, Israel

815

Theranostic Barcoded Nanoparticles for Personalized Cancer Medicine Z Yaari Israel Institute of Technology, Israel

437

Corneal ulcer amelioration in response to in situ gelling naltrexone hydrochloride (NTX) films: pharmaceutical formulation and clinical evaluation H Abdelkader, B Pierscionek, H Mohharam, R Abdelkader Kingston University London, United Kingdom

11:25

856

Chitosan coated PLGA Nanoparticles for Pulmonary Delivery of mRNA encoding a Zinc Finger Nuclease: An in-vivo proof of concept study for somatic genome editing B Loretz, E Malaeksefat, A J Mahiny, A Dewerth, L E Mays, M Alkhaled, B Mothes, J Rottenberger, D M Brosch, P Reautschnig, P Surapolchai, F Zeyer, A Schams, M Carevic, M Bakele, M Griese, M Schwab, B Nürnberg, S Beer-Hammer, R Handgretinger, D Hartl, M S Kormann, C Lehr Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Germany

823

Tumor Targeting Efficiency of Hyaluronic acid Based Micelle Containing Paclitaxel F Dorkoosh, E Saadat, M GholamiTehran University of Medical Sciences, Iran

425

A Physically-Associative, Shear-Responsive Ophthalmic Hydrogel for Anterior and Posterior Segment Drug Delivery P Sheikholeslami, B Muirhead, D Baek, H Wang, X Zhao, D Sivakumaran, S Boyd, H Sheardown, T Hoare McMaster University, Canada

11:30

891

Mannosylated Polyion Complexes for In Vivo Gene Delivery into CD11c+ Dendritic Cells  L Raviv, M Jaron-Mendelson, M Golan, A David Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel

546

A novel vincristine submicron emulsion system with enhanced antitumor effect T Zhang, T Gong, Z Zhang West China School of Pharmacy, Sichuan University, China

478

Patterned Nanoporous Polypyrrole for Tunable Ocular Drug Delivery A Seyfoddin, H Zhang, S Moulton, M Higgins, I D Rupenthal, G I Waterhouse School of Pharmacy, University of Auckland, New Zealand

28

Mini-Symposia • Tuesday Morning Pentland

Moorfoot

Oral Drug Delivery Moderator: Randy Mrsny Session Chairs: Rod Walker, Daniel Kirby

29

Invited Speaker: S Gaisford

10:50

30

Invited Speaker: Oral Fixed Dose Combination Products D Desai Bristol-Myers Squibb Inc., U.S.A.

11:10

341

Investigating the barrier properties of an intestinal co-culture model of CCD-18co intestinal sub-epithelial myofibroblasts and Caco-2 intestinal epithelial cells J D Patient University of Nottingham, United Kingdom

11:15

345

Lipid co-administration that promotes incorporation into intestinal lipoproteins is critical for efficient lymphatic transport of a bio-mimetic triglyceride prodrug S Han, L Hu, T Quach, J S Simpson, N L Trevaskis, C J Porter Monash University, Australia

11:20

328

Gastroretentive Dosage Form for Once Daily (QD) Dosing of a Compound with a Narrow Absorption Window P Gupta, S Patel, W Lin, L C-Lens, M Rizk, J McDermott, A Connor, R Krishna, R L Smith Merck and Co., U.S.A.

11:25

366

Polymeric microcontainers improve oral bioavailability of a poorly soluble drug L Hagner Nielsen, A Melero, S Sylvest Keller, T Rades, A Müllertz, A BoisenDepartment of Micro- and Nanotechnology, Technical University of Denmark, Denmark

11:30

267

A Case Study - Formulation Development for Carcinogenicity Study Z Nazir, K Hill, S Horner AstraZeneca, United Kingdom

10:30

31

Invited Speaker: Enhancing Vaccine Efficacy Through Novel Vaccines and Delivery Technology L Babiuk University of Alberta, Canada

11:00

32

Invited Speaker: The Next Generation of Vaccine Adjuvants D O’Hagan Novartis Vaccines, U.S.A.

11:30

33

Invited Speaker: P Marsh PHE Porton, United Kingdom

Tuesday

10:30

Next-Generation Vaccine Development and Delivery Technologies Moderators: Sevda Senel, David Brayden

29

Podium • Tuesday Afternoon Pentland Delivery of Peptides and Proteins Moderator: Alexander Florence Session Chairs: Richard Gemeinhart

Tinto

Sidlaw

Delivery Science in Cosmetics, Personal Care, and Household Products Moderator: John Brahms Session Chairs: Nicole Papen-Botterhuis, Zhibing Zhang

Parenteral Delivery Technologies Moderator: Wim Hennink Session Chairs: Bill Lambert, Diane Burgess

INVITED SPEAKERS

Tuesday

1:30

34

Invited Speaker: Cell-Penetrating Peptides for Oral Delivery of Peptide and Protein Drugs N Kamei, M Takeda-Morishita Kobe Gakuin University, Japan

36

Invited Speaker: Encapsulation of oil in Ca-alginate microcapsules by inverse gelation technique D Poncelet GEPEA, France

38

Invited Speaker: Controlled Release of an Old Chemotherapeutic Using a Low-Temperature Thermal Sensitive Liposome:  A New Paradigm for Drug Release in the Blood Stream of Warmed Tumors D Needham Duke University and University Southern Denmark, U.S.A.

1:50

35

Invited Speaker: Advances in Oral GLP1 Delivery U L Rahbek Novo Nordisk A/S, Denmark

37

Invited Speaker: Engineering Controlled Fragrance Release Systems for Superior Performance Y Lei, L Xu, M Popplewell, J Brahmas International Flavors and Fragrance, U.S.A.

39

Invited Speaker: Titania Nanoporous Membranes: Enabling Extended, Constant Delivery from a Rice-GrainSized Device A D Mendelsohn, K E Fischer Nano Precision Medical, Inc., U.S.A.

RESEARCH HIGHLIGHT TALKS AND MODERATED DISCUSSION 2:10

61

A New Structural Design of a ClosedLoop Insulin Delivery Implant Extends the Duration of Insulin Efficacy in a Type 1 Diabetic Rat Model by Impeding Immune Cell Infiltration J Li, M K Chu, C R Gordijo, A Giacca, M Lohn, O Plettenburg, X Wu Leslie L. Dan Faculty of Pharmacy, University of Toronto, Canada

508

Controlled Release of Encapsulated Bioactive Volatiles by Rupture of the Capsule Wall through the LightInduced Generation of a Gas D L Berthier, N Paret, A Herrmann, A Trachsel Firmenich SA, Switzerland

392

An injectable liquid crystal system for sustained delivery of entecavir M Joo, M Ki, J Lim, S An, E Park CKD Research Institute, South Korea

2:15

131

Parkinsonian monkeys showed brain structural and functional recovery following local delivery of microencapsulated GDNF E Garbayo, H Lana, G D´Addario, M Carmona, I Marcilla, J Lanciego, M Luquin, M Blanco-Prieto Pharmacy and Pharmaceutical Technology Department, University of Navarra, Spain

507

Coffee silverskin as new cosmetic ingredient: in vitro and in vivo evaluation F Rodrigues, C Pereira, F B Pimentel, R C Alves, M Ferreira, B Sarmento, M Amaral, M Oliveira Requimte, Faculty of Pharmacy, University of Porto, Portugal

411

Novel Methods for the Evaluation of Drug Release from Drug Eluting Beads T S Swaine, P Garcia, Y Tang University of Huddersfield, Biocompatibles UK Ltd, United Kingdom

2:20

144

Pseudomonas Exotoxin A as a drug carrier for oral protein delivery F Laurent, J Mackay, R Mrsny Univ of Bath, United Kingdom

515

Visualization and Quantification of Delivery in Hair Care Products D J Scurr, M R Alexander, M C Davies University of Nottingham, United Kingdom

397

Development of an Extended-Release Leuprolide Formulation using the FormEZE Technology W Deng, B Perkins, B Hudson, C Davis, K Burton

2:25

160

The Use of Inkjet Printing for Dosing Biomacromolecular Actives in Drug Delivery Systems M Montenegro-Nicolini University of Chile, Chile

517

Controlled Release of Menthol from Polycaprolactone C M Baker, N Jain, K Munoz, E Atherton, E Mathiowitz Brown University, U.S.A.

391

A Novel Fluorescent Assay to Determine the Influence of Oil Type and Surface Composition on Lipid Emulsion Lipoprotein Lipase Mediated Metabolism P W Dougall University of Nottingham, United Kingdom

2:30

81

Creation of human TNFR1-selective antagonistic TNF mutants using phage display to develop novel antiinflammatory biodrugs D Ando, H Kamada, M Inoue, K Nagano, Y Mukai, Y Tsutsumi, S Tsunoda National Institute of Biomedical Innovation, Japan

509

Criopass Laser Efficiency as an Enhancer of Caffeine and Caffeisilane C permeation: 3D Human Skin Equivalent as a Model Barrier P S Lopes, D P Luco, P G Oliveira, I M Rufino, E B Herbst, G Grecco, M B Mathor, H D Silva, M A Andreo, V R Leite-Silva Federal University of São Paulo, Brazil

418

Questioning the rate-limiting drug release and absorption mechanisms from an intramuscular sustainedrelease nano-/microsuspension: the effect of local macrophage depletion N Darville, M van Heerden, D Mariën, M De Meulder, S Rossenu, A Vermeulen, P Sterkens, S De Jonghe, P Annaert, g Van den Mooter Drug Delivery and Disposition - KU Leuven, Belgium

30

Mini-Symposia • Tuesday Afternoon Fintry

Moorfoot

1:30

40

Invited Speaker: Delivery of siRNA with nanoparticles based on PEG-PLA block copolymer for cancer therapy J Wang, C Xu, A Liu, C Sun, X Yang Univ of Science and Technology, China

1:50

41

Invited Speaker: Advances in Polymer Conjugates Designed for siRNA Delivery S E Barrett, R S Burke, R M Garbaccio, E N Guidry, B J Howell, E A Kemp, A H Latham, A M Leone, S L Colletti Merck & Co., Inc, U.S.A.

2:10

893

Peptide Nanofiber Vectors of siRNA for Glioblastoma Treatment M Mazza, L O’Donnell, K Kostarelos University of Manchester, United Kingdom

2:15

899

Reciprocal dormancy-promoting nanomedicine altering EGFR and TSP-1 for the management of glioblastoma S Ferber, G Tiram, E Yavin, N Almog, J Henkin, M Calderon, R Haag, R Satchi-Fainaro Tel Aviv University, Israel

2:20

845

anti-IL8 siRNA Nanoparticles Induce Knockdown in Epithelial Cells-in vitro and in vivo J Ramsey, A Hibbitts, R MacLoughlin, J Barlow, S Cryan School of Pharmacy, Ireland

2:25

875

Efficient Expression of mRNA PEG-Peptide Polyplexes in Liver K Rice Department of Pharmaceutical Science, College of Pharmacy, University of Iowa, U.S.A.

2:30

911

Targeted mitochondrial delivery of functional nucleic acids using MITO-Porter E Kawamura, Y Yamada, H Harashima Faculty of Pharmaceutical Sciences, Hokkaido University, Japan

1:30

42

Invited Speaker: L Good Tecrea Ltd, United Kingdom

2:00

43

Invited Speaker: D Palmer Midatech Pharma, United Kingdom

2:30

44

Invited Speaker: Nanomedicine in Ophthalmology: Myriocin loaded Lipid Nanoparticles for therapy in Retinitis Pigmentosa P Gasco Nanovector, Italy

Tuesday

European Technology Platform on Nanomedicine: Translation of Nanomedicines Moderators: Patrick Boisseau, Ruth Schmid

 siRNA and mRNA Delivery Moderator: Jeff Cleland Session Chairs: Kathryn Whitehead, Harry Parekh

31

32

Daily Schedule Wednesday, July 29 7:30 a.m. – 12:00 p.m. CRS Registration Open Mini-Symposium: Cost-Effective Encapsulation for Industrial 8:00 – 9:30 a.m. Applications: Limitations and Solutions Scientific Sessions 8:00 – 9:30 a.m. • Drug Delivery in Tissue Engineering • Formulating Oral Solid Dosage Forms to Enhance Drug Delivery • Nanocarriers for Combined Delivery • Nanosystems for Non-Oncology Drug Delivery 9:45 – 11:00 a.m. Plenary Session: Renata Pasqualini

Strathblane Hall Moorfoot Sidlaw Tinto Pentland Fintry Pentland

*Additional registration, payment, and ticket required.

Wednesday Program Highlights 9:45 – 11:00 a.m. • Pentland Moderator: Yvonne Perrie, Aston University, United Kingdom

Wednesday

Plenary

Looking for the Abstracts?

Ligand-Directed Therapy and Molecular Imaging Based on In Vivo Phage Display Technology Renata Pasqualini, University of New Mexico Cancer Center, U.S.A. In this plenary presentation, Dr. Pasqualini will discuss the development of in vivo phage display, a functional peptide screening established in animal models and later in patients. She will present research on how isolation of homing peptides enables subsequent identification of tissue-specific receptors and how systematic implementation of this strategy will lead to the construction of a comprehensive map of vascular markers in each organ, tissue, or disease. Long term, the broader vision of her research is a large-scale mapping of receptors in human vasculature toward a new ligand-directed pharmacology. Prior to the plenary, outgoing CRS Board members will be recognized.

CRS MEETING APP Download the app to your mobile device, or use the desktop app website: mobileapp.controlledrelease.org. Abstracts are available in the Posters and the Program Guide session details. CRS WEBSITE The abstracts are available within the CRS meeting website and can be accessed using your CRS username and password.

33

Podium • Wednesday Morning Sidlaw Drug Delivery in Tissue Engineering Moderator: Richard Gemeinhart Session Chairs: Michael Doschak, Hyunjoon Kong

Tinto Formulating Oral Solid Dosage Forms to Enhance Oral Drug Delivery Moderator: Gavin Andrews Session Chairs: Mark McAllister, Ben Boyd

Fintry Nano-Systems for Non-Oncology Drug Delivery Moderator: Hamid Ghandehari Session Chairs: Andrew Parker, Yoon Yeo

INVITED SPEAKERS

Wednesday

8:00

45

Invited Speaker: Designer Nanoneedles for Regenerative Medicine and Biosensing M Stevens Imperial College, United Kingdom

47

Invited Speaker: Modifying the solid state of drugs to enhance oral drug delivery T Rades, H Grohganz, P Priemel, A Mullertz, K Loebmann Univ of Copenhagen, Denmark

51

Invited Speaker: Macromolecular Dexamethasone Prodrug Prevents And Resolves Lupus Nephritis With Reduced Systemic Toxicities D Wang University of Nebraska Medical Center, U.S.A.

8:20

46

Invited Speaker: Collagen-Based Scaffolds For Therapeutic Delivery To Enhance Tissue Regeneration F J O’Brien Royal College of Surgeons in Ireland, Ireland

48

Invited Speaker: The effect of plasticizer used in hot melt extrusion on drug product intermediate properties S Page F. Hoffmann-La Roche Ltd, Switzerland

52

Invited Speaker: Liposomal drug delivery to atherosclerotic lesions in cardiovascular patients G Storm, J M Metselaar, M E Lobatto, Z Y Fayad, E S Stroes, W J Mulder Utrecht University and University of Twente, Netherlands

RESEARCH HIGHLIGHT TALKS AND MODERATED DISCUSSION 8:40

96

Engineering a Bioartifical Pancreas: Tuning Device Geometry Prevents Foreign Body Immune Responses and Fibrosis to Enable Prolonged Efficacy in Diabetic Rodents O Veiseh, R Langer, D Anderson David H. Koch Institute for Integrative Cancer Research at MIT, U.S.A.

297

Design of Modified Release MultiParticulate Floating Drug Delivery System for Levodopa and Carbidopa Combination Based on a Multilayer Structure S Y Charde, P P Rraut Birla Inst of Technology and Science Pilani, India

772

Raltegravir Prodrugs for Improved Nanoparticle Delivery I T Suydam, M E Ebner, A M Bever, Y Jiang, K A Woodrow Seattle University, U.S.A.

8:45

129

Novel Bone Targeting Parathyroid Hormone Analogues Impart Significantly Improved Peptide Hormone Delivery and Efficacy upon Osteoporotic Bone Surfaces Y Yang, A Panahifar, K Tang, F Wuest, M R Doschak Pharmaceutical Orthopaedic Research Lab, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada

339

Infacort® - Development and Clinical Evaluation of a Taste Masked Multiparticulate Oral Hydrocortisone Formulation for Paediatric Use D N Margetson, G Neal, R Ross, H Huatan, D Eckland, D Digweed, A Grave, A Foerg, N Poellinger, M J Whitaker Diurnal Ltd, United Kingdom

589

Comparative study of curcumin-loaded lipid-based nanocarriers for inflammatory bowel disease treatment A Beloqui, P B Memvanga, R Coco, S Reimondez-Troitino, M Alhouayek, A Staub, G G Muccioli, M J Alonso, N Csaba, M de la Fuente, V Preat Universite Catholique de Louvain, Belgium

8:50

857

Chitosan-pDNA Nanoparticles Facilitate Controlled Gene Delivery on Collagen Scaffolds for Orthopaedic Tissue Engineering Applications R M Raftery, C M Curtin, S Cryan, F J O’Brien Tissue Engineering Research Group, Royal College of Surgeons, Ireland,

333

Impact of monoacyl phosphatidylcholine on the nanoemulsification capacity of selfnanoemulsifying drug delivery systems T Tran, X Xi, T Rades, A Mullertz University of Copenhagen, Denmark

703

Macromolecular Prodrugs of AZT and Ribavirin - Towards a Treatment of Infection with HIV and HCV. K Zuwala, A A S. Smith, B M Wohl, M B L. Kryger, P Ruiz-Sanchis, C Guerrero-Sanchez, A Postma, M Tolstrup, A N Zelikin Department of Infectious Diseases, Aarhus University Hospital, Denmark

8:55

137

Polymeric electrospun scaffolds: Neuregulin encapsulation and biocompatibility studies in a rat model of myocardial ischemia T Simon-Yarza, A Rossi, K Heffels, E Garbayo, F Prosper, J Groll, M J Blanco-Prieto University of Navarra, Spain

299

Development of local controlledrelease fenretinide as a chemopreventive therapy for oral squamous cell carcinoma (OSCC) K J Nieto, S Schwendeman, S Mallery University of Michigan, U.S.A.

704

Macrophages targeting with low molecular weight heparin-loaded eudragit nanoparticles for the treatment of ulcerative colitis T Yazeji University of Bonn, Germany

9:00

105

Identification of a Lung Carcinomaspecific Peptide for in vivo Targeting J Yu, M Oh, M Yang, Y Nam KAIST, South Korea

383

The synergistic effect of silica and polymer in establishing improved lipidbased solid dosage forms for poorly water soluble drugs C A Prestidge University of South Australia, Australia

795

Suppression of Inflammatory Cytokines with “Eat-me” Signal Bearing Particles Y Katayama, P Kumar, M Hosain, D Funamoto, A Kishimura, T Mori Kyushu University, Japan

34

Pentland

Moorfoot

Nanocarriers for Combined Delivery Moderator: Ronit Satchi-Fainaro Session Chairs: Rohit Kolhatkar, Sei-Kwang Hahn

Cost-Effective Encapsulation for Industrial Applications: Limitations and Solutions Moderators: Igor Bodnar, Doug Dale

8:00

49

Invited Speaker: Dermatan Sulfate, a Silent Actor of a Ternary Gene Delivery System Y Yeo, B Kim, S Kim, I Kwon Purdue University, U.S.A.

8:20

50

Invited Speaker: An Injectable 3-drug Nanotherapeutic for Disseminated Angiosarcoma G S Kwon University of Wisconsin, U.S.A.

8:40

680

In vivo evaluation of a novel chemoimmunotherapeutic strategy to treat glioblastoma: paclitaxel and CpG loaded lipid nanocapsules G Lollo, M Vincent, G Ullio Gamboa, L Lemaire, F Franconi, D Couez, J Benoit LUNAM University— Micro et Nanomédecines Biomimétiques, France

8:45

713

Microfluidic Fabrication of a Stimulus Responsive Hybrid Nanocomposite for Antitumoral Applications B Herranz Blanco, D Liu, E Mäkila, M Shahbazi, E Ginestar Nadal, H Zhang, V Aseyev, V Balasubramanian, J Salonen, J hirvonen, H A Santosv University of Helsinki, Finland

8:50

588

Combined treatment with CXCR4 antagonist and liposomal doxorubicin for enhancing antitumor and anti-metastasis efficiency L Mei, Y Liu, Q He Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, China

8:55

742

Paclitaxel-Lapatinib loaded F127 Pluronic micelles; an in vitro- in vivo evaluation P Dehghankelishadi, F Dorkoosh, E Saadat, F Ravar Department of Pharmaceutics, Tehran University of Medical Science, Iran

9:00

539

A Lipid Nanoemulsion System for Concurrent Delivery of Chemotherapeutics and Bromotetrandrine (W198) to Overcome Multidrug Resistance in Breast Cancer Therapy X Cao, T Gong, Z Zhang, Y Fu Sichuan University, China

8:00

53

Invited Speaker: Improved Formulation for Cellular Uptake of Peptides in the Skin F Suter, D Schmid, F Zuelli Mibelle Biochemistry, Switzerland

8:30

54

Invited Speaker: Cost effective encapsulation of flavors J Weissbrodt, I Reiss Symrise AG, Germany

9:00

55

Invited Speaker: Cost effective encapsulation of active ingredients in the agricultural chemical and microbial control industries I A Tomlinson, L Liu, M Zhao, R E Boucher, F Zeng, T Ghosh Dow Advanced Materials, U.S.A.

Wednesday

Mini-Symposia • Wednesday Morning

35

2015 CRS Posters Scientific posters are an essential element of the CRS Annual Meeting & Exposition. The display of posters allows annual meeting attendees an excellent opportunity to share with one another important scientific achievements and learn the newest technologies in delivery science on a personal basis. Each submitted poster abstract is peer reviewed and chosen based upon predetermined selection criteria. Posters will be on display in Cromdale Hall during two poster sessions and authors will be present during one of four time slots. Photographing posters is not permitted.

Poster Sessions (authors present) Poster Session I – Group A Poster Session I – Group B Poster Session II – Group C Poster Session II – Group D

Monday, July 27 Monday, July 27 Tuesday, July 28 Tuesday, July 28

9:30 – 10:30 a.m. 5:00 – 6:00 p.m. 9:30 – 10:30 a.m. 3:30 – 4:30 p.m.

Delivery of Proteins, Peptides, and Vaccines 57

59 60 61 64 67 68 69 70 72 73 74 75 77 78 79 81 82 83 86 87 88 89 90

36

A liquid-in-liquid multi-compartmental system for the oral delivery of subunit vaccines to treat colorectal cancer; J Liau; Session 1, Group A A microscopic-enabled microfluidic device for transport of nanoparticles in intestinal mucus; S Bhattacharjee; Session 1, Group A A Multisystem to Orally Co-deliver Glucagon-like Peptide-1 and Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes Mellitus Therapy; F Araújo; Session 1, Group B A New Structural Design of a Closed-Loop Insulin Delivery Implant Extends the Duration of Insulin Efficacy in a Type 1 Diabetic Rat Model by Impeding Immune Cell Infiltration; J Li; Session 1, Group A A Supramolecular Carrier for Regulating Oral Absorption Profile of Insulin; K Kawakami; Session 1, Group B Active transport and lysosome-evading dual functional nanocomplexes for oral insulin delivery; W Fan; Session 1, Group A Alteration of carbon nanotube’s length and surface charge affects antigen uptake and immune response induced by dendritic cell in vitro; H Hassan; Session 1, Group B Aqueous Remote Loading of Cationic Peptides in PLGA microspheres; M Giles; Session 1, Group A BBB-shuttle peptides for CNS drug delivery; M Teixido; Session 1, Group B Bioactivity of Liposomal Antimicrobial Peptides in Herpes Virus In Vitro Models; G Golomb; Session 1, Group B Biomimetically Engineered Demi-bacteria Potentiate Vaccination Against cancer ; W Wei; Session 1, Group A Brain Delivery of Peptide Drugs via Intranasal Administration for Alzheimer’s Disease Treatment; N Kamei; Session 1, Group B Comparative in vitro and in vivo analysis of nanovaccine - immune cell interactions; N Csaba; Session 1, Group A Comparison the Pharmacokinetic Profiles between Monomeric and Oligomeric Transferrin; H Wang; Session 1, Group A Controlled Release of biologicals from Microspheres Using Layer-byLayer (LbL) Technology; O Sakr; Session 1, Group B Controlled Release of Biologics from Core-Sheath Electrospun Fibers with High Loading; Q Pham; Session 1, Group A Creation of human TNFR1-selective antagonistic TNF mutants using phage display to develop novel anti-inflammatory biodrugs; D Ando; Session 1, Group A Dendritic cell subsets interact with pathogen mimicking particles in a size dependent manner; K Roy; Session 1, Group B Developing recombinant single-chain Fc dimer fusion proteins for protein drug delivery; L Zhou; Session 1, Group A Development and characterization of aqueous core nanocapsules designed for protein oral delivery; H Malhaire; Session 1, Group B Development and evaluation of a monoclonal antibody against Eph receptor A10 for novel molecularly targeted therapy of breast cancer; K Nagano; Session 1, Group A Development of a novel enzymatic nano-reactor for the application of biodetoxification; H Tang; Session 1, Group B Development of a personalized treatment vaccination for melanoma; B DSouza; Session 1, Group A Development of Alendronate and Heparin Incorporated Atelocollagen Matrices for Controlling BMP-2 Release and Osteogenic Differentiation; S Park; Session 1, Group B

91 93 94 96 97 98 100 101 102 103 104 105 106 107 108 110 112 114 115 116 118 119 120

Development of Novel Immunoliposome for the Enhancement of Antibody-Based Therapy; T Niwa; Session 1, Group A Dual functional Collagen Nerve Conduits, Endowed with Collagen Binding Neurotrophic Factor and Guidance Fibers, Trigger Axonal Outgrowth; B Gander; Session 1, Group A Electrosprayed pp65489-503 peptide-loaded PLGA-nanoparticles enhance proliferation of antigen-specific cytotoxic T cells as compared to non-encapsulated peptide; B Kandil; Session 1, Group B Engineering a Bioartifical Pancreas: Tuning Device Geometry Prevents Foreign Body Immune Responses and Fibrosis to Enable Prolonged Efficacy in Diabetic Rodents; O Veiseh; Session 1, Group B Enhanced Paracellular Transport of Insulin Can Be Achieved Via Transient Induction of Myosin Light Chain Phosphorylation; A Taverner; Session 1, Group A Enhanced uptake and transports of bovine lactoferrin in human intestinal Caco-2 cells by pectin and chitosan modified solid lipid particles; J Wen; Session 1, Group B Enzymatic Bio-surgery: replacing surgical blades with tissue-cleaving enzymes; A Zinger; Session 1, Group B Fabrication of Double-wall Microparticles with Protein Loaded in the Hydrophilic Gel Core Using Coaxial Electrohydrodynamic Atomization; C Wang; Session 1, Group A Formulation and Characterization of Microemulsion System for Oral Peptidal Delivery; S SHARMA; Session 1, Group B HER2-Targeted Hepatitis B Virus Core Particle as Nanocarriers to Treat Cancer; K Al-Jamal; Session 1, Group A Highly Efficient Delivery of Functional Cargoes by the Synergistic  Effect of GAG Binding Motifs and Cell-Penetrating Peptides; J Dixon; Session 1, Group B Identification of a Lung Carcinoma-specific Peptide for in vivo Targeting; J Yu; Session 1, Group A Identification of Potential Binding Partners for the N-Terminal Domain of Occludin; T Ikem; Session 1, Group B Immobilized transglutaminase for enzymatic protein PEGylation.; A Grigoletto; Session 1, Group A Impact of Freeze-drying and Cryoprotectant Loading on the Stability of Insulin Loaded into PLGA Nanoparticles; P Fonte; Session 1, Group B In vivo evidence of nasal vaccination with novel poly (β-amino ester)-poly (lactic-co-glycolic acid) nanoparticles; H. Alpar; Session 1, Group B Injectable PLGA Implants for Controlled Release of Bevacizumab; R Chang; Session 1, Group B Internalization of radical-scavenging metallothionein for cytoprotection of transplanted pancreatic islets from xenogeneic immune reactions; M Kim; Session 1, Group B Intestinal regional localisation of coated SmPill® beads in rats: proof of principle using X-ray imaging; T Aguirre; Session 1, Group A Intranasal Delivery of mRNA Vaccine Using Cyclodextrin-PEI As A Carrier Elicits Both Systemic and Mucosal Immunity; M Li; Session 1, Group B Investigating of Protein-Coated Nanoparticles for Controlled Release Films; J McConville; Session 1, Group B Investigation of the effect of thermal and shear stress on the stability of the monoclonal antibody Infliximab; J Alsaddique; Session 1, Group A Liposome-based vaccines for lung cancer treatment; C Loira Pastoriza; Session 1, Group B

121 Local Delivery of Brain-Derived Neurotrophic Factor to the Brain For Functional Recovery Following Stroke; J Obermeyer; Session 1, Group A 122 Measles and Rubella Vaccination Using a Microneedle Patch; J Joyce; Session 1, Group B 123 Nanoencapsulation of an hTS inhibitor octapeptide against ovarian cancer in solid lipid matrix; V Iannuccelli; Session 1, Group A 124 Nano-polyplex MK2 Inhibitory Peptide Delivery Inhibits Vascular Graft Intimal Hyperplasia by Blocking Inflammation and Maintaining the Contractile VSMC Phenotype; T Werfel; Session 1, Group B 125 Nanosized Phytosomes for Ocular Delivery of the Histidine Dipeptide Drug L-Carnosine; H Abdelkader; Session 1, Group A 126 Needle-Free Transdermal Vaccine Delivery Systems Using Hyaluronate-Vaccine Conjugates; S Hahn; Session 1, Group B 127 New Intrinsically Enteric Two-Piece Capsule Drug Delivery System A Sivert; Session 1, Group A 128 Novel approach to enhance the oral absorption of peptide and protein drugs through an endogenous pathway; K Almansour; Session 1, Group B 129 Novel Bone Targeting Parathyroid Hormone Analogues Impart Significantly Improved Peptide Hormone Delivery and Efficacy upon Osteoporotic Bone Surfaces; Y Yang; Session 1, Group A 130 Novel in vitro instrument for estimating formulation performance of subcutaneously administered therapeutics; K Box; Session 1, Group B 131 Parkinsonian monkeys showed brain structural and functional recovery following local delivery of microencapsulated GDNF; E Garbayo; Session 1, Group A 133 PEGylated interferon shows differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice; L Kaminskas; Session 1, Group A 134 PEGylated TRAIL as an efficient biotherapeutics on rheumatoid arthritis model; S Lim; Session 1, Group B 135 Peptide Post Encapsulation onto Porous Polymeric and Inorganic Microparticles; s eilleia; Session 1, Group A 136 Photocrosslinked microgels for oral delivery of macromolecular based-therapeutics; P Marizza; Session 1, Group B 137 Polymeric electrospun scaffolds: Neuregulin encapsulation and biocompatibility studies in a rat model of myocardial ischemia; M Blanco-Prieto; Session 1, Group A 138 Polymeric nanocarries delivery of protein through epithelial cells; R Li; Session 1, Group B 139 Polymeric, Cytokine-Aided Cell Recruitment & Histological Analysis; V Léandre; Session 1, Group A 140 PolySTAT: A peptide-based, synthetic injectable hemostat that reduces bleeding in trauma models; S Pun; Session 1, Group B 141 Porous silicon microparticle potentiates anti-tumor immunity by enhancing antigen cross-presentation and inducing type I interferon response; H Shen; Session 1, Group A 142 Preparation, Characterization, and In Vitro Release Study of Stromal Cell-Derived Factor-1-Loaded Chitosan Membrane; K Chen; Session 1, Group B 144 Pseudomonas Exotoxin A as a drug carrier for oral protein delivery; F Laurent; Session 1, Group B 145 Rabies vaccination in dogs using a dissolving microneedle patch; J Arya; Session 1, Group A 146 Redox-Sensitive Dextran Nanogels aimed for Intracellular Delivery of Antigens; D Li; Session 1, Group B 147 Self-Assembled Excipient-Free Enzyme Formulations For Oral Administration; M Mateescu; Session 1, Group A 148 Self-assembled nanoparticles of a peptide-drug conjugate for targeted cancer therapy; H Kim; Session 1, Group B 149 Self-Assembling MMP-2 Cleavable Hydrogel for On-demand Peptide Delivery; K Koss; Session 1, Group A 151 Simultaneous Delivery System of Antigenic Protein and Cytokine Gene Based on pH-Sensitive Polymer-Modified Liposomes for Induction of Antigen-Specific Immune Responses; E Yuba; Session 1, Group A 152 Size effects of gold nanoparticles on induction of cellular immune response toward cancer immunotherapy; S Kang; Session 1, Group B 154 Surface charge of adjuvant-modified PLGA microspheres can differently skew the immune response; M Igartua; Session 1, Group B 155 Sustained Gelatin Release from Injectable Polymer Hydrogel System for Human Mesenchymal Stem Cells Delivery with Improved Survival Rate; B Seo; Session 1, Group A 156 Sustained release formulations of biologics composed of cross-linked HA hydrogels; O Dall; Session 1, Group B

157 158 160 161 162 165 855

Targeted Delivery of GDNF to Brain by Novel V-SmartTM Nanovesicles and its Efficacy in Parkinson’s Disease Animal Model; S Rosenbaum; Session 1, Group A Targeting Skin Immune Cell Subsets for Intradermal Immunisation Against Influenza; M Ivory; Session 1, Group B The Use of Inkjet Printing for Dosing Biomacromolecular Actives in Drug Delivery Systems; M MONTENEGRO-NICOLINI; Session 1, Group B Therapeutic Tumor Lysate Vaccine for B cell lymphoma: Efficacy and Mechanistic properties of Soluble vs Particulate Tumor Lysate Formulations; K Roy; Session 1, Group A Thermoresponsive Nano/Micro-Particles Based on PEGylated a-elastin for Protein Delivery; Y Jung; Session 1, Group B Tuning Physical Properties of Sustained BMP-2 Releasing Hydrogel:  Head-to-Head Study for Effective Bone Regeneration; B Seo; Session 1, Group A Characterization of DNA complexes with cyclodextrin and polyethylene gycol bisphenol A as potential formulations for gene therapy; Y Rosales Morgan; Session 1, Group A

Delivery Science in Cosmetics, Personal Care, and Household Products 506 Cell Toxicity and Ocular Tolerability of Chitosan Nanoparticles Loaded with OTZ; A Al-kinani; Session 2, Group D 507 Coffee silverskin as new cosmetic ingredient: in vitro and in vivo evaluation; F Rodrigues; Session 2, Group C 508 Controlled Release of Encapsulated Bioactive Volatiles by Rupture of the Capsule Wall through the Light-Induced Generation of a Gas; D Berthier; Session 2, Group D 509 Criopass Laser Efficiency as an Enhancer of Caffeine and Caffeisilane C permeation: 3D Human Skin Equivalent as a Model Barrier; P Lopes; Session 2, Group C 510 Hyalgel(R): A novel hybrid system for dermo-cosmetic applications; D Morelló-Bolumar; Session 2, Group D 511 In Vitro Skin Permeation of Octyl Methoxycinnamate Encapsulated in a New Gelatin Capsule System; V Leite-Silva; Session 2, Group C 512 Morphological Changes in Polycaprolactone/Oil Systems; C Baker; Session 2, Group D 514 The effect of a damaged skin barrier on percutaneous absorption of SDS and skin hydration investigated by confocal Raman spectroscopy; M Hoppel; Session 2, Group D 515 Visualization and Quantification of Delivery in Hair Care Products; D Scurr; Session 2, Group C

Encapsulation for Industrial Applications 516 Antibacterial coating of catheters with solid lipid nanoparticles using physical plasma sources; G Lukowski; Session 2, Group D 517 Controlled Release of Menthol from Polycaprolactone; C Baker; Session 2, Group C 518 Development of Stable Polymersomes Encapsulating Bacteria for Release of Metabolites; J Barlow; Session 2, Group D 519 Dry Polymer Coating for Improving Physical Stability of Amorphous Drug Formulations; R Dave; Session 2, Group C 522 Enzymatically Triggered Release from Zein Particles for Antimicrobial Coatings and Plasters; N Papen-Botterhuis; Session 2, Group D 523 Hydrogels-Based Systems for Controlled Release in Agricultural Applications; A Dalmoro; Session 2, Group C 524 Multidrug Encapsulation Using PDMS Microfluidic Devices for Pulmonary Drug Delivery; H A. Santos; Session 2, Group D 525 Novel Encapsulation System for Water Soluble Powder; F Tchuenbou-Magaia; Session 2, Group C 526 Observation of Phase Separation in Polyacrylamide Hydrogels with Variation in Cross-Linker Concentration: A Rheological Study; S JENA; Session 2, Group D 527 Optimization of dry coating formulation for improvement of acidresistance and stability of probiotics by 3-factor, 3-level Box-Behnken Design; H Park; Session 2, Group C 529 Preparation of poly(e-caprolactone) microcapsules containing thyme oil; Y Kim; Session 2, Group C 530 Stimuli-responsive organo-silica/polyurea composite microcapsules; J Yang; Session 2, Group D 531 Taste Masking Active Pharmaceutical Ingredients using a Novel Acoustic Mixing Process; R T McLaughlin; Session 2, Group C

continued

37

continued

Manufacture, Characterization, Measurement, and Stability 167 A combined spectroscopic and thermal methods for ketoprofen inclusion in cyclodextrins in solid state and analysis of the profile dissolution; M Vueba; Session 1, Group A 168 A Mathematical Approach for Assessing Release Kinetics of Nanosized Formulations by Application of a Novel Dialysis Apparatus; L Xie; Session 1, Group B 169 A New Solvent System for Electrospinning Polycaprolactone; A McLaughlin; Session 1, Group A 170 A Systematic Investigation of Surface Properties and Compression Profiles of Milled D-Mannitol; J Koner; Session 1, Group B 171 Amorphous Solid Dispersions: A Comparison Between Hot Melt Extrusion and Supercritical Fluid Impregnation; A Madi; Session 1, Group A 172 Analyzing lipid nanoparticles by Solid Phase Extraction; A Guillot; Session 1, Group B 173 Application of Polymer Coating on Size M “Mouse” Capsules Containing Immediate and Delayed Release Formulations; I McIntosh; Session 1, Group A 174 Aqueous Based Enteric Coating Formulation Containing Hypromellose Acetate Succinate (HPMCAS); A Quadir; Session 1, Group B 175 Aqueous Ethyl Cellulose Coatings for Pharmaceutical Dosage Forms; J Kazlauske; Session 1, Group A 176 Assessing PLGA microsphere porosity by means of fluid imaging microscopy techniques; A Sediq; Session 1, Group B 177 Biomimetic Barrier PermeapadTM: an innovative tool for passive drug permeabilities investigation; M di Cagno; Session 1, Group A 178 Cell cytotoxic effects of clioquinol  and prepare of a gellam gum/ glucosamine hydrogel carrier for oral cancer therapy; M Lee; Session 1, Group B 179 Cell Sheet Engineering for Primary Rabbit Corneal Epithelial Cell under Serum-free Culture Condition; H TSENG; Session 1, Group A 180 Characterisation of polymeric films with thermal methods: measurement of critical humidity and glass transition temperature; A Buanz; Session 1, Group B 181 Characterization of Self-Assembling PEG-PLGA Nanoparticles Encapsulating Semiconducting Conjugated Polymers; T Abelha; Session 1, Group A 182 Computer-Assisted Drug Formulation: Computational tools for dosage form design; R Hathout; Session 1, Group B 184 Controlling Polymeric Particle Size and Distribution by Adjusting the Applied Mechanical Force; A Azagury; Session 1, Group B 185 Deconstructing the tumor microenvironment - The role of fibronectin; F Vanterpool; Session 1, Group A 186 Designing a Permeation Model of the Gram Negative Bacterial Cell Envelope; F Gräf; Session 1, Group B 188 Determination of the Crystalline State of Ritonavir in Medium Chain Triglyceride Softgel Fill Formulations by X-ray Powder Diffraction; N Mahajan; Session 1, Group B 189 Development and Application of a Stability Indicating HPLC Method for the Estimation of Lidocaine Release from Poly Ethylene co-Vinyl Acetate (EVA) Melt Extrudates; P Bhusal; Session 1, Group A 192 Docetaxel Nanosuspension: Preparation and optimization using Quality by design approach; K Singh; Session 1, Group B 194 Effect of polyethyleneglycol bisphenol A epichlorohydrin copolymer and gluconolactone on trypsin biological activity; A Salem; Session 1, Group B 195 Effect of Processing Methods on Physical Stabilities of Amorphous Solid Dispersions Consisting of Naproxen and Povidone; T Listro; Session 1, Group A 196 Encapsulation of antifungal agents into solid lipid nanoparticles: Physicochemical characterization and biocompatibility studies; R Shah; Session 1, Group B 197 Evaluation of a Co-processed Excipient for Orally Disintegrating Tablets; S Obara; Session 1, Group A 198 Evaluation of Swelling and Erosion of HPMC Based Captopril Tablets; R Walker; Session 1, Group B 199 Evaluation the palatability of ebastine orally disintegrating tablets using OD-mate; as new apparatus of detecting disintegration time and electronic tongue system; T Uchida; Session 1, Group A 200 Fabrication of Nanoparticles By A Versatile And Robust Microfluidic Platform For Drug Delivery; D Liu; Session 1, Group B 201 Formation of Lipid and Polymer Based Gold Nanohybrids for Intracellular Trafficking; D Witzigmann; Session 1, Group A

38

202 Formulation and Characterization of Lipid Particles with Nephroprotective Properties; R Donaghey; Session 1, Group B 207 Impact of cationic polymer coatings on PLGA nanoparticle characteristics and immunogenicity; N Kunschke; Session 1, Group A 209 Importance of Osmotic Effects for the Control of Drug Release from Kollicoat SR Coated Pellets; J Fahier; Session 1, Group A 210 Infacort® - Manufacturing Process Scale Up and Characterisation of a Taste Masked Multiparticulate Oral Hydrocortisone Formulation for Paediatric Use; G Neal; Session 1, Group B 211 Influence of CO2 Laser Irradiation on the Physical, Mechanical and Contact Angle Properties of Treated Enteric Coating Films; V Titapiwatanakun; Session 1, Group A 212 Injection Moulding of Controlled Release Solid Dispersions; A Kelly; Session 1, Group B 214 International Acceptability Study of Orally Disintegrating Tablets (ODTs) in Children and Yong Adults; H Alyami; Session 1, Group B 215 Investigation of the stabilizer elimination during the washing step of charged PLGA microparticles utilizing a novel HPLC-UV-ELSD method; M Riehl; Session 1, Group A 216 Key Parameters and Limits for Quantification in Optical Imaging; J Stelzner; Session 1, Group B 220 Mechanical activation – milling induced solid state interaction as a mechanism to mitigate process induced amorphisation; K Gallagher; Session 1, Group B 221 Microfluidics liposome formulation and investigation of liposome-cell interactions by Atomic Force Microscopy (AFM); O Kemp; Session 1, Group A 222 Microfluidics-Controlled Manufacturing of Drug-loaded Nanoparticles in a Scalable and High-throughput Setup; E Kastner; Session 1, Group B 223 Microwave-Assisted Process For The Preparation of Microneedle Arrays; E Larrañeta; Session 1, Group A 224 Modeling in vitro Microsphere Settling Through Mucin; V Léandre; Session 1, Group B 225 Modelling Physical Stability of Amorphous Systems; D Serrano; Session 1, Group A 227 Monitoring the dissolution mechanisms of amorphous solid dispersions by real time Raman mapping and on-line UV-vis; F Tres; Session 1, Group A 228 Mucoadhesive characterization and in vitro antifungal activity of liquid crystal systems for buccal release of curcumin; G Calixto; Session 1, Group B 230 Nanogram scale High Throughput Characterization of Pharmaceutical Materials; M Algahtani; Session 1, Group B 231 Nanotoxicity Testing UsingThe Zebrafish Embryo Assay; S Golombek; Session 1, Group A 233 Non-steroidal anti-inflammatory drugs encapsulated into solid lipid nanoparticles: Characterization, cytotoxic and anti-inflammatory studies; R Shah; Session 1, Group A 234 Optimelt™ Technology: Unique Approach To Development & Scale-up Of Melt Extruded Oral Dosage Forms; N Mahajan; Session 1, Group B 235 Optimizing the Loading of Diagnostic and Therapeutic Agents into the Shell of PBCA-Based Microbubbles for Image-Guided Drug Delivery; L Appold; Session 1, Group A 236 Pellet Distribution Analysis by UV Imaging and HPLC: A Comparative Study; A Novikova; Session 1, Group B 237 Physicochemical Characterization of Liposome-Peptides Complexes; P Iavicoli; Session 1, Group A 239 Polyethyleneimine-based liquid crystal precursor vehicle with in situ gelling for buccal administration: development and characterization; G Calixto; Session 1, Group A 240 Predicting in-vitro cumulative 28-day dapivirine release from a cured disc by modeling: A novel critical quality attribute; L Kanu; Session 1, Group B 241 Preparation and Evaluation of Chrysosplenol C-loaded Solid Dispersion with Hydrophilic Carriers; C Ng; Session 1, Group A 244 Protein-polyelectrolyte complexation kinetics monitored by nanoparticle tracking analysis and flow imaging microscopy; A Sediq; Session 1, Group B 245 Quality by Design Approach to Formulation of Rebamipide Gastroretentive Tablet; K Hwang; Session 1, Group A 246 Quality evaluation of ibuprofen and quinine sulphate formulations sold on the market in Angola, using differential scanning calorimetry technique; M Vueba; Session 1, Group B 249 Scaling up a high shear granulation process to gain granules suitable to formulate orally disintegrating tablets; A Zakhvatayeva; Session 1, Group A

250 Simultaneous Enhancement of Dissolution and Tribo-electrification of Solid Dispersions; K Asare-Addo; Session 1, Group B 251 Softgel Capsules Low Batch Size Optimization on Industrial Equipment; V Plassat; Session 1, Group A 252 Sol-gel Transition Study of Thermosensitive Chitosan Hydrogels Using Low-field NMR; R Yu; Session 1, Group B 254 Solubility Improvement of Novel Antimicrobial Compounds, NCL812 and NCL099; Y Song; Session 1, Group B 255 Stabilization of Influenza Vaccine in Microneedle Patches for RoomTemperature Storage; M Mistilis; Session 1, Group A 256 Structural analysis of nanosystems: Solid Span Nanoparticles (SSN) as a case study; I Fernández Piñeiro; Session 1, Group B 257 Surface Characterisation of Composite Particles Produced using a Novel Isothermal Particle Coater; E Dahmash; Session 1, Group A 258 Swellable/erodible capsular devices for oral pulsatile release prepared by 3D printing; A Melocchi; Session 1, Group B 260 The Development of hot melt-injection moulding technique buccal patches for enhanced delivery of felodipine; M Alhijjaj; Session 1, Group B 261 The Effect of Surfactants and Polymers on the Dissolution of Amorphous Indomethacin; T Laaksonen; Session 1, Group A 262 The NanoAssemblr™ Platform for the Scalable, Microfluidics-based Manufacture of Lipid-Based Nanoparticles for the Controlled Release of Therapeutics; C Walsh; Session 1, Group B 263 Tight Junctions as a Barrier in the Hair Follicle - Relevance for Drug Delivery; C Mathes; Session 1, Group A 264 Utilization of SoluPath Flex™ to Provide Data-Driven Choices in Preclinical Formulation Development; P Sabo; Session 1, Group B 265 UV Imaging of the Dissolution Mechanism of HPMC Extended Release Tablets; K Box; Session 1, Group A

Micro- and Nanoparticle Delivery 532 3D alginate micro-scaffolding for cumulus-oocyte complex in vitro culture: formulation and stability evaluation; B Conti; Session 2, Group D 533 5-fluorouracil liposomes targeted with cetuximab for skin squamous cell carcinoma: characterization studies; R Petrilli; Session 2, Group C 534 A biodistribution study of albumin-lyophilisomes; R Raavé; Session 2, Group D 535 A comparison of the pharmacokinetics of an inhaled PEGylated dendrimer between rats and sheep and the role of the pulmonary lymphatic system in absorption from sheep lungs.; L Kaminskas; Session 2, Group C 537 A Doxorubicin Nano Drug Delivery System for Postoperative Treatment of Ovarian Cancer Residual Disease; R De Souza; Session 2, Group C 539 A Lipid Nanoemulsion System for Concurrent Delivery of Chemotherapeutics and Bromotetrandrine (W198) to Overcome Multidrug Resistance in Breast Cancer Therapy; Y Fu; Session 2, Group C 540 A New Precipitation/Self-Assembly Method to Fabricate Monodisperse and Biodegradable Smart Microgels for Drug Delivery; T Hoare; Session 2, Group D 541 A novel antitumour strategy using bidirectional autophagic vesicles accumulation via combined  treatment with TAT-Beclin 1 and liposomal hydroxychloroquine; Q He; Session 2, Group C 543 A Novel BBB-Penetrating Peptide Improves pBAE-Mediated Gene Delivery into Brain Endothelial Cells; A Cascante; Session 2, Group C 544 A Novel Oxalipatin Derivative Showed Enhanced Efficacy in a Xenograft Model of Pancreatic Cancer; A Abu Ammar; Session 2, Group D 546 A novel vincristine submicron emulsion system with enhanced antitumor effect; T Zhang; Session 2, Group D 547 A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus; Q Zhang; Session 2, Group C 548 A Simple and Effective Numerical Method for Quantifying Real-Time Drug Release from Nano-/microparticles inside Dialysis Tubing; X Wu; Session 2, Group D 551 Active Macropinocytosis Induction Potentiates Exosome-mediated Intracellular Delivery; I Nakase; Session 2, Group C 552 Active Targeting of Hepatocytes via Asialoglycoprotein-Receptor – Evaluation of Expression Level; D Witzigmann; Session 2, Group D 553 Adipose-Derived Stem Cells Adhered To PLGA Microparticles Containing Neuregulin-1 Improved Heart Tissue Regeneration In A Rat Model; P Díaz-Herráez; Session 2, Group C

554 Advantages of fluorescent nanoprobes for tumor imaging and photodynamic therapy (PDT) and pitfalls of PDT in earlier studies; H Maeda; Session 2, Group D 555 Aerosol Nanocomposites Microparticles Capable of Penetrating Pulmonary Physiological Barriers; S Meenach; Session 2, Group C 557 An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agentfor tumor-specific chemotherapy that overcomes multidrug resistance; H Sung; Session 2, Group C 558 Antibody-mediated targeting of nanoparticles to human endothelium; the importance of physiologic shear for assessing targeting specificity.; G Tietjen; Session 2, Group D 560 Anti-inflammatory Mechanism of Liposomal Bisphosphonates: The Effect on CD11b++ Monocytes; G Golomb; Session 2, Group D 562 Application of Nanoparticles for Oral Delivery of Acid Labile Lansoprazole: In Vitro and In Vivo; W Lin; Session 2, Group D 563 Axitinib-loaded Nanohybrid Liposomal Nanoparticles for Hypoxic Tumor; J Kim; Session 2, Group C 564 Bacteriophage loaded liposomes for controlling Salmonella colonization in broilers; M Cano-Sarabia; Session 2, Group D 565 Barley Protein based Nanoparticles for Vitamin B12 Delivery; G Liu; Session 2, Group C 567 Biodegradable Theranostic Agent of Melanoidin for Non-Invasive Photoacoustic Imaging and Photothermal Therapy; H Jung; Session 2, Group C 569 Biodistribution Study of Cationic Polymeric Biodegradable Nanoparticles by Optoacoustic Imaging; M Igartua; Session 2, Group C 570 Bio-inspired silica nanoparticles as drug delivery vehicles; S Davidson; Session 2, Group D 571 Bioreducible Shell-Cross-Linked Hyaluronic Acid Nanoparticles for Efficient Intracellular Drug Delivery; H Han; Session 2, Group C 572 Brain Tumor Targeting of Nano Curcumin via LDLr-mediated Pathway; M Das; Session 2, Group D 573 Buprenorphine Nanoparticles for Long Term Pain Relief and the Treatment of Addiction; Y Lin; Session 2, Group C 574 Carbon nanotubes uptake in brain after intravenous injection in mice; K Al-Jamal; Session 2, Group D 575 Carbon onion as a porous carrier for amorphous drug delivery; N Miriyala; Session 2, Group C 576 Carboxymethyl dextran-based self-assembled nanoparticles for hypoxia-triggered drug delivery; S Son; Session 2, Group D 577 Cationic Lipid-Free Cationic Nanoemulsions with Dexamethasone Acetate and Poylmyxin B Sulfate; C Keck; Session 2, Group C 578 Cationic nanosystems enhance melatonin ocular delivery: insights from a human corneal epithelial cell line model; J Lovric; Session 2, Group D 580 Characterisation and comparison of DOPE:DOTAP and DOPE:DCChol liposomes produced using microfluidics; F Crofts; Session 2, Group D 581 Characterisation of Biofilm Conditions Towards the Prevention of Urinary Catheter Biofouling; N Irwin; Session 2, Group C 582 Chitosan and its derivatives as appropriate nanocarriers for ocular release; D Bikiaris; Session 2, Group D 583 Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration; R Hernandez; Session 2, Group C 584 Chitosan lipid nanocapsules as tunable systems for antigen delivery; J Crecente-Campo; Session 2, Group D 585 Co-Delivery of Curcumin Analog and Paclitaxel with Reduction Sensitive Micelles to Treat Drug Resistant Cancer; J Reineke; Session 2, Group C 586 Co-Delivery of Curcumin and Doxorubicin by Temperature Responsive Hollow Microspheres; Y Su; Session 2, Group D 587 Combined effects of PLGA and vascular endothelial growth factor promote healing in non-diabetic and diabetic wounds; K Chereddy; Session 2, Group C 588 Combined treatment with CXCR4 antagonist and liposomal doxorubicin for enhancing antitumor and anti-metastasis efficiency; Q He; Session 2, Group D 589 Comparative study of curcumin-loaded lipid-based nanocarriers for inflammatory bowel disease treatment; A Beloqui; Session 2, Group C 590 Comparative Study of Folate Receptor-Targeted Delivery Systems: Dosing Regimens and Therapeutic Index; A Scomparin; Session 2, Group D 594 Curcumin-loaded Nanoparticles made of Comb-like PEG-PLA Copolymers as a Potential Drug Delivery System for Neurodegenerative Diseases; J Faivre; Session 2, Group D 596 Customizable Protein Microparticles as Carriers for Controlled Drug Delivery; K Lai; Session 2, Group D continued

39

Micro- and Nanoparticle Delivery continued 598 Cytotoxic T cells as transport vehicles for targeted nanoparticle delivery to the tumor; K Raemdonck; Session 2, Group D 600 Delayed-Release Silica-Coated Nanocapsules; T Haber; Session 2, Group D 601 Delivery Enhancement of Cisplatin Using Non-Ionic Surfactant Vesicles; M Alsaadi; Session 2, Group C 602 Delivery of Indocyanine Green to Cancer Cells by Chitosan-Based Nanocarriers; F Mi; Session 2, Group D 603 Design and Evaluation of Lipid-Polyethylene Glycol-Polymer Hybrid Nanoparticles for Intranasal Delivery of Farnesylthiosalicylic Acid Against Glioblastoma; E Sekerdag; Session 2, Group C 605 Design of Fiber-Shaped Nanovectors for Neurosurgically-Precise Gene Knockdown: The Case of Peptide Nanofiber-siRNA mediated Gene Silencing in the Brain; M Mazza; Session 2, Group C 609 Developing and assessing a combinatorial dietary phytochemical based polymeric micellar drug delivery system as a chemotherapeutic strategy; D Rao; Session 2, Group C 610 Development of a multimodal fluorescence probe for easy diagnosis of diseases; Y Narita; Session 2, Group D 611 Development of a Resveratrol Solid Dispersion with Soluplus; B Sarmento; Session 2, Group C 612 Development of Aspherical Nanoparticles Functionalised with Invasion Moieties for Studying the Influence of Particle Shape on Cellular Uptake; A Castoldi; Session 2, Group D 613 Development of Bauhinia purprea agglutinin-modified liposomes for treatment of prostate cancer; K Shimizu; Session 2, Group C 614 Development of Liposomal Delivery Systems that Target the Lymphatics; S Khadke; Session 2, Group D 615 Development Of Multifunctional Gold Nanostructures For Cancer Phototherapy; C Silva; Session 2, Group C 616 Development of Nanobody Targeted-Liposomes Directed Against Tumors for Image-Guided Drug Delivery; M Bolkestein; Session 2, Group D 617 Development of peptide based imaging probe for drug efficacy monitoring.; D Kim; Session 2, Group C 618 Development of pH-dependent Endosome-Destabilizing High-Density Lipoprotein Nanoparticles; H Kim; Session 2, Group D 620 Development of sustained release systems with alendronate based on mesoporous silica MCM41; L Ochiuz; Session 2, Group D 622 Development of untoxic cyclic ester/polyester solution-based biodegradable microspheres; D Grizic; Session 2, Group D 623 Development, Optimization and In-vitro Characterization of Lazaroid Nano-structured Lipid Carriers; P Gadgil; Session 2, Group C 624 Development, physicochemical characterization and cytotoxicity evaluation of bone-targeted pH-sensitive liposome based formulation containing doxorubicin; D Ferreira; Session 2, Group D 625 Dexamethasone Releasing Novel Three-Layered Monolithic Scaffold; D Algul; Session 2, Group C 629 Dose- and surface protein dependency of extracellular vesiclemediated drug delivery; H Saari; Session 2, Group C 630 Droplet Based Microfluidics for Drug Delivery Applications; H Zhang; Session 2, Group D 631 Drying of b-galactosidase by Electrospinning Followed by Tableting and Scaling-up Experiments.; G Verreck; Session 2, Group C 632 Dual pH-sensitive liposomes for enhanced liposomal membrane stability and potential tumor targeted drug delivery; Z Wu; Session 2, Group D 633 Dual receptor recognizing cell penetrating peptide modified liposomes for anti-glioma therapy; Q He; Session 2, Group C 634 Dual Stimuli-Responsive Charge-Convertible Nanoparticles for Intracellular Delivery of Doxorubicin; H Ko; Session 2, Group D 635 Dual Stimuli-Responsive Nanogel Assemblies for Intracellular Drug Delivery; W Huang; Session 2, Group C 636 Effect of Methyl Substitution on the Redox Response and Biological Impact of Aniline Based Nanostructures Used for Cancer Therapy; M Shahbazi; Session 2, Group D 638 Efficient Delivery of Neuregulin Into Infarcted Hearts Usign Polymeric Microparticles; S Pascual-Gil; Session 2, Group D 639 Electrostatic interaction and reversibility of adsorption on the loading of therapeutic peptide GLP-1 into porous silicon nanoparticles; M Kaasalainen; Session 2, Group C 640 Embedding of gefitinib eluting microspheres in polyurethane stent coatings; W Chen; Session 2, Group D 641 Encapsulation of Didanosine within Polymeric Particles for Enhanced Oral Bioavailability in HIV: Spray-drying versus Coaxial Electrohydrodynamic Atomization; A Sosnik; Session 2, Group C

40

643 Enhanced solubility and dissolution rate of gatifloxacin by solid dispersion technique; R Al-Kassas; Session 2, Group C 644 Enhanced water solubility and tumor selectivity for polymeric photosensitizers in cancer treatment; S Jeong; Session 2, Group D 645 Enteric shell-core microparticles production by coupling ultrasonic atomization and polyelectrolytes complexation; A Dalmoro; Session 2, Group C 647 Evaluation of a nanotechnological approach for treatment of neurological diseases; S Caban; Session 2, Group C 648 Ex Vivo Diffusion Model of Microparticles Crossing Intestinal Mucosa and Epithelium; S Rege; Session 2, Group D 649 Exploring computational approach for optimizing polymeric nanoparticles for biomedical applications; A Dey; Session 2, Group C 650 External Manipulation of Nanostructure in Photoresponsive Lipid Depot Matrix to Control Drug Release In Vivo; W Fong; Session 2, Group D 651 Extracellular vesicles as smart carriers for small molecule drugs; G Fuhrmann; Session 2, Group C 654 Fibrillar pH-responsive micelles loading succinobucol suppresses lung metastasis of breast cancer; Z Zhang; Session 2, Group D 655 First In Vitro Characterization of Novel Nucleic Acid-Based Nanocomplexes for the Treatment of Antibiotic Resistant Pathogens; A Hibbitts; Session 2, Group C 656 Fluconazole-loaded chitosan nanoparticles is an effective alternative to topical treatment of vaginal candidiasis; G Gelfuso; Session 2, Group D 657 Fluorescent Stability and Imaging of Liposomal Quantum-Dots in Carotid-Injured Rats; G Golomb; Session 2, Group C 658 Folate-conjugated Reducible Polyethylenimine Passivated Carbon dots Complexation with siRNA as Theranostic Nanoagent for Lung Cancer Therapy; T Wang; Session 2, Group D 660 Folate-Targeted Liposomes for Co-delivery of Paclitaxel and Imatinib: Combined Antitumoral Properties on Cytotoxicity and VEGF Expression; E Lima; Session 2, Group D 661 Folic acid-Polyethylene glycol-Photosensitizer for Photodynamic Tumor Theragnosis; J Kim; Session 2, Group C 662 Formulation and In vitro Cytotoxicity of pH-sensitive Liposomes for a Novel Hypoxia-activated Prodrug; M Yang; Session 2, Group D 664 Gelatin/Aminolyzed PDLLA Nanoparticles for Delivery of Hydrophobic Drugs; T Chung; Session 2, Group D 665 Gelatinized core liposomes: Towards an advanced carrier for hydrophilic drugs formulation; R Hathout; Session 2, Group C 668 Herceptin Conjugated Liposome Encapsulating Metformin for Targeting Breast Cancer Stem Cell; J Lee; Session 2, Group D 669 High Shear mixing : An alternative approach for the size reduction of liposomes; P Stone; Session 2, Group C 670 High Throughput Approach to the Elucidation of the Role of Lipid Geometry in the Design and Development of Liposomal Drug Delivery Systems; E Suleiman; Session 2, Group D 672 Hyaluronan-immobilized Magnetic Bioceramic Nanocrystals for Active Targeting and Intracellular Hyperthermia; H Wu; Session 2, Group D 673 Hyaluronic acid nanogel systems for poorly water-soluble drugs; T Nakai; Session 2, Group C 674 Hybrid Bioactive Nanoparticles Modulate Tumor Microenvironment and Enhance Radiation Therapy; M Amini; Session 2, Group D 675 Improved Circulation Time of Imageable Mesoporous Silicon Nanocarrier; V Lehto; Session 2, Group C 676 Improved Tumor Specific Drug Accumulation by Polymer Therapeutics with pH-sensitive Drug Release overcomes Chemotherapy Resistance; A Heinrich; Session 2, Group D 677 In vitro characterization and real-time label-free monitoring of cell interactions of pH responsive gold nanoparticles; T Viitala; Session 2, Group C 678 In vitro digestion of cetyl palmitate SLN monitored with two different readouts: Are the pH-stat and HPTLC results equivalent?; M Heider; Session 2, Group D 680 In vivo evaluation of a novel chemo-immunotherapeutic strategy to treat glioblastoma: paclitaxel and CpG loaded lipid nanocapsules; G Lollo; Session 2, Group D 681 In vivo Evaluation of Etoposide Polymeric Nanoparticles for Brain Delivery by Nasal Route; N Udupa; Session 2, Group C 682 In vivo mitochondrial delivery of coenzyme Q10 via MITO-Porter prevents ischemic reperfusion injury in the liver; Y Yamada; Session 2, Group D 683 Inhalable Microparticles Encapsulating the Immunomodulator, All-trans-Retinoic Acid, for the Treatment of Mycobacterium tuberculosis (Mtb) Infection.; G O’Connor; Session 2, Group C

684 Injectable doxorubicin thermosensitive hydrogels incorporated with docetaxel mixed micelles for localized cancer therapy; C Su; Session 2, Group D 685 Injectable Microspheres for non-invasive in vivo Oximetry using Electron Paramagnetic Resonance (EPR); J Frank; Session 2, Group C 687 Integrin-nanoparticles regenerate collapsed alveoli; M Horiguchi; Session 2, Group C 690 Invasin-functionalized Liposomes for Intracellular Delivery of Antiinfectives; S Gordon; Session 2, Group D 691 Investigating the performance and interactions of conjugated polymer nanoparticles with primary human blood cells; R Ahmad Khanbeigi; Session 2, Group C 692 Lactoferrin-bearing Polypropylenimine Dendrimer for Targeted Gene Delivery to the Brain; S Somani; Session 2, Group D 693 Layer-by-Layer Nanoparticles with PEGylated Polyelectrolytes for Systemic Delivery of Multiple Anticancer Drugs; J Kim; Session 2, Group C 694 LbL-Microcarriers for the Treatment of Chronic Inflammation: Interaction, Uptake and Viability Studies of LbL-Drug Delivery Systems; M Fichtner; Session 2, Group D 696 Light-triggered internalization of nanocomplex for effective gene delivery to hMSCs; J Han; Session 2, Group D 697 Lipid based Nanocarriers for Carbamazepine; S Kumar; Session 2, Group C 698 Lipid Platforms For Gene Therapy: The Bridge Between siRNA Silencing Efficiency and Intracellular Delivery; M Videira; Session 2, Group D 699 Lipid-Based Nanoparticulate Formulation of CopperDiethyldithiocarbamate: The Active Agent When Using Disulfiram for Treating Cancer; M Wehbe; Session 2, Group C 701 Looking into Blood Trash: Searching for Low Molecular Weight Biomarkers using Polyacrylic Acid Coated Gold Nanoparticles; L Khoury; Session 2, Group C 702 LyP1-decorated hyaluronan nanocapsules for an improved interaction with tumor cells in a 3D co-culture model; M de la Fuente; Session 2, Group D 703 Macromolecular Prodrugs of AZT and Ribavirin - Towards a Treatment of Infection with HIV and HCV.; K Zuwala; Session 2, Group C 704 Macrophages targeting with low molecular weight heparin-loaded eudragit nanoparticles for the treatment of ulcerative colitis; T Yazeji; Session 2, Group D 705 Magnetic-Guiding pH-responsive Co-delivery Nanomedicine System to Enhance Cancer Therapy; S Chen; Session 2, Group C 706 Melatonin-loaded chitosan/Pluronic® F127 microspheres as in situ forming hydrogel: an innovative approach toward improved wound healing; A Hafner; Session 2, Group D 707 Mesoporous Phospholipid Particles: A Novel Drug Delivery Platform; K Kawakami; Session 2, Group C 709 Micellar formulation of crizotinib and dasatinib for the treatment of glioblastoma multiforme; H Nehoff; Session 2, Group C 710 Micellar Raloxifene improves its pharmacokinetics and cellular uptake with enhanced activity for the treatment of castrate-resistant Prostate cancer; K Greish; Session 2, Group D 713 Microfluidic Fabrication of a Stimulus Responsive Hybrid Nanocomposite for Antitumoral Applications; B Herranz Blanco; Session 2, Group C 714 Microfluidics-formulated Drug Nanocrystals for Pulmonary Delivery; M Pereira; Session 2, Group D 715 Microgels for Hydrophilic Drug Delivery to the Brain; T Hoare; Session 2, Group C 716 Micro-scale liposome formulation via dual centrifugation; T Fritz; Session 2, Group D 717 MIL100 nanoparticles as a Busulfan delivery system; T Simon-Yarza; Session 2, Group C 718 Mitigating Tacrolimus Nephrotoxicity By PLGA Nanoparticles: A Comparative In Vivo Study With Prograf®; A Alshamsan; Session 2, Group D 719 MMP-sensitive size-shrinkable “raspberry-type” nanoparticles for tumor microenvironment-response penetration and pH triggered doxorubicin release in breast cancer; Q He; Session 2, Group C 721 Molecular dynamics simulation as a tool in drug delivery liposome development; A Bunker; Session 2, Group C 722 MP-SPR New Characterization Method for Targeted Drug Delivery Systems and Controlled Release; A Jokinen; Session 2, Group D 723 Multimodal imaging of metastasis targeting and antimetastatic therapy using polymeric, liposomal and micellar nanomedicines; L Rizzo; Session 2, Group C

724 Multiple Bioreducible Disulfide Linkage-Containing Poly(ethylene glycol)-b-Poly(e-caprolactone) Nanoparticles for Intracellular Doxorubicin Delivery; J Kim; Session 2, Group D 725 Multistage Stimuli-responsive and Sequential Size-alterable Nanovehicle for Systemic Nuclear-targeted Drug Delivery; L Li; Session 2, Group C 726 Nanobubbles Combined with Extracorporeal Shock Waves for Enhanced Targeted Intracellular Delivery of Doxorubicin; R Cavalli; Session 2, Group D 728 Nanomedicine in Obstetrics: Evaluation of a Novel Tocolytic Therapy Preventing Drug Passage to the Fetus; B Godin; Session 2, Group D 729 Nanoparticles Containing Lipopolysaccharide for Immunotherapeutic Inhibition of Tumour Cells Growth; M Abdel-Mottaleb; Session 2, Group C 730 Nanoparticles in cancer immunotherapy: towards a systemic application of resiquimod; C Thauvin; Session 2, Group D 731 Nanoparticles loading a natural anticancer agent tetrandrine for improving drug delivery; M Schneider; Session 2, Group C 732 Nanoparticulate Delivery of Growth Factors for Fracture Healing; O Udo-Chijioke; Session 2, Group D 734 New strategies based on gold nanorods to facilitate endosomal release; J Garcia; Session 2, Group D 735 Novel Polylysine PEG-Peptides Inhibit Scavenger Receptor Mediated Uptake of Nanoparticles by the Liver; K Rice; Session 2, Group C 736 On-demand Release of Entrapped Bioactive Nanoparticles from Alginate; C Kearney; Session 2, Group D 738 Optimization of the Formulation of Photoluminescent Semi Conducting Polymer Nanoparticles for Diagnostics and Bioimaging; L Urbano; Session 2, Group D 739 Oral Bile Salt Stabilised Vesicles for the Treatment of Parasitic Diseases; A Lalatsa; Session 2, Group C 740 Overcoming Multi-drug Resistance by Ultrasound Actuated Delivery to the Cytosol; W Pitt; Session 2, Group D 741 Oxidation-Responsive Polymers: Tailored Sensitivity to Reactive Oxygen Species for Drug Delivery Purposes; R d’Arcy; Session 2, Group C 742 Paclitaxel-Lapatinib loaded F127 Pluronic micelles; an in vitro- in vivo evaluation; F Dorkoosh; Session 2, Group D 743 PAMAM Dendrimer Interactions with Model Membranes; M Wilde; Session 2, Group C 744 Pegylated Docetaxel loaded Human serum albumin nanoparticles: Quality by design optimization, characterization, cytotoxicity and pharmacokinetics; S Pawar; Session 2, Group D 746 PEGylated Silk Nanoparticles for Drug Delivery Applications; T Wongpinyochit; Session 2, Group D 747 PEGylation and CPP-Bioconjugation of Diatomite Nanoparticles for Enhanced Stability,Biocompatibility and Cellular Internalization in Cancer Cells; M Terracciano; Session 2, Group C 748 pH responsive vesicles with controlled cell penetrating activity for intracellular anticancer drug delivery; S Salmaso; Session 2, Group D 750 pH-Controlled Morphology of Cationic Lipid Assemblies within Polyelectrolyte Gel Surface Layer Enclosing Superparamagnetic Core Particle for Co-Delivery of Theranostic Agents; H Chiu; Session 2, Group D 752 pH-sensitive fliposomes based on a conformational flip; W Viricel; Session 2, Group D 753 pH-sensitive liposomes for the delivery of therapeutic proteins: potential application for the treatment of bladder cancer; S Salmaso; Session 2, Group C 755 Polymeric Micelles with Endosomal Buffering Function Reverse Multidrug Resistant of Tumor; Q Yin; Session 2, Group C 756 Polymeric Nanomedicine for Tumor-Targeted Combination Therapy to Elicit Synergistic Genotoxicity against Prostate Cancer; Q Yang; Session 2, Group D 757 Polymeric Smart Nanoparticles for the treatment of EGFR overexpressing diseases:  preliminary in vitro characterization.; B Conti; Session 2, Group C 758 Post-insertion Technique effect on pH-responsiveness, Cytotoxicity and Long-circulation of PEGylated Liposomes; Z Wu; Session 2, Group D 759 Preclinical CT, BLI and PET imaging with 18F-FDG and 64Cu-liposomes for detection of metastatic lesions in mice; R De Souza; Session 2, Group C 760 Preparation and Characterization of Dexamethasone – PAMAM Dendrimer Complexes; B Yavuz; Session 2, Group D 762 Preparation and Characterization of Reactive Oxygen Species Sensitive Nanoconjugates as the Imaging Agent; E Lee; Session 2, Group D continued

41

Micro- and Nanoparticle Delivery continued \ 764 Preparation of polymer micelle-based fluorescent probe to image nitric oxide-producing macrophages; Y Tabata; Session 2, Group D 765 Preparation, Optimization, In-vitro and In-vivo Evaluation of a Liposomal Formulation for Co-Delivery of Paclitaxel and Lapatinib; F Dorkoosh; Session 2, Group C 766 Prevention of endotoxin-induced acute lung injury by intrapulmonary administration of platinum nanoparticles as reactive oxygen species scavengers; H Katsumi; Session 2, Group D 767 Probing the diffusive characteristics of silica nanoparticles functionalized with pharmaceutically relevant polymers through gastric mucus; E Mansfield; Session 2, Group C 768 Production of polyaspartamide based nanovectors by the method of solvent evaporation from ultrasound-made multiple emulsions; A Dalmoro; Session 2, Group D 769 Pullulan bioconjugate for selective targeting to the hepatocyte; A Balasso; Session 2, Group C 770 Pure Nanocrystals of a Poorly Water-Soluble Protease Inhibitor Sustain the Release by the Oral Route: A New Generation of Nanocarrier-less Nano-Delivery Systems; A Sosnik; Session 2, Group D 771 Quality by Design Approach for the formulation of Resveratrol lipid nanoparticles: Multivariate design for optimizing process and product parameters; C Houacine; Session 2, Group C 772 Raltegravir Prodrugs for Improved Nanoparticle Delivery; I Suydam; Session 2, Group D 773 Rapamycin liposomes functionalized with trastuzumab: development and characterization; J Eloy; Session 2, Group C 775 Redispersible microparticles composed of nanoparticles by spray drying with mannitol; A Torge; Session 2, Group C 776 Re-examining the EPR Effect to Improve Nanomedicine Translatability; J Hare; Session 2, Group D 777 Remote control hybrid nanoparticles as a thermoresponsive drug carrier for pancreatic cancer therapy; M Malekigorji; Session 2, Group C 779 ROS-induced Degradable Polymeric Nanoparticles for Intracellular Delivery of Paclitaxel; J Kim; Session 2, Group C 780 Rutin smartCrystals for Improvement of the Skin Appeal; R Mueller; Session 2, Group D 782 Self-Assembled Nanoconjugate of Amphotericin B and Water Soluble Chitosan; A R.; Session 2, Group D 784 Site-Specific Time and Sequential Nanoparticle Delivery of Chemotherapeutics for Synergy Enhancement; E Blanco; Session 2, Group D 785 Size exclusion chromatography: a useful method to determine peptide loading of nanoparticles; S Sladek; Session 2, Group C 786 Smart Chlorin e6 Tetraether Lipids Based Liposomes for Photodynamic Therapy; G Mahmoud; Session 2, Group D 787 Smart gold nanoparticles for enhanced tumour targeting; S Salmaso; Session 2, Group C 788 Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway in epithelial cells; R Shah; Session 2, Group D 789 SP-D loaded PLGA nanoparticles as drug delivery system for premature infant’s lung diseases; S Attias; Session 2, Group C 790 Squalenoylation of chitosan: a new platform for anti-infectives delivery?; E Lepeltier; Session 2, Group D 792 Stimuli Responsive Phospholipid-based Nanomaterials for On-demand Drug Delivery; J Du; Session 2, Group D 793 Styrene-maleic acid copolymer conjugated pirarubicin, an anticancer nanomedicine with good stability and tumor-targeting property; J Fang; Session 2, Group C 794 Super stealth liposomes for the delivery of anticancer drugs.; K Maso; Session 2, Group D 795 Suppression of Inflammatory Cytokines with “Eat-me” Signal Bearing Particles; Y Katayama; Session 2, Group C 797 Surfactant protein A-mediated targeting of alveolar macrophages using surface-modified biodegradable nanoparticles; E Fattal; Session 2, Group C 798 Synthesis of Redox-Sensitive Polymeric Nanoparticles with Potential Drug and Gene Delivery Applications; C Wang; Session 2, Group D 799 Synthesis of Triblock Co-Polymeric Micelles for Delivery of Anticancer Drugs; M MOHD AMIN; Session 2, Group C 800 Synthesis, characterization and in vitro release studies of doxorubicinloaded pH and thermal sensitive nanogels of N-isopropylacrylamide and carboxyalkyl methacrylates ; D Castro-Vidal; Session 2, Group D

42

801 Systemic Radionuclide Therapy Using Graphene Oxide Nanoplatelets and Mesoporous Carbon Nanoparticles; J Kim; Session 2, Group C 802 Systematically Optimized Lipidic Nanoparticles of Berberine with Enhanced Brain Targeting Potential for Alzheimer’s disease; S Lohan; Session 2, Group D 804 Targeted delivery of platinum-taxane combination therapy in ovarian cancer; T Bronich; Session 2, Group D 805 Targeted gold nanoparticles as sensitizers in ultrasound based cancer treatment; S Salmaso; Session 2, Group C 806 Targeted Imaging of Cyclooxygenase-2 in Inflammation and Cancer by Fluorocoxib A-Loaded ROS-Responsive Nanoparticles; T Werfel; Session 2, Group D 808 Targeting Cancer Stemness Phenotype Through Cell Membrane Receptors Using a Pegylated Lipid Platform; M Videira; Session 2, Group D 809 Targeting Drug Carriers Using Copper Free Click Chemistry and Metabolic Labelling; N Alcaraz; Session 2, Group C 810 The Development of Self-Sterilising Urinary Biomaterials Utilizing a pH-Responsive Surfactant System; J Trotter; Session 2, Group D 811 The NanoAssemblrTM Platform: Scalable, Microfluidics-based Manufacture of Polymeric Nanoparticles; C Walsh; Session 2, Group C 812 The Nanoparticle Corona in Pulmonary Surfactant is composed of Proteins AND Lipids; S Raesch; Session 2, Group D 813 The smartLipids® – 3rd Generation of Lipid Nanoparticles after SLN®  and NLC®; R Mueller; Session 2, Group C 814 The Vacuum SpinSwiper Device for Making PLGA Microparticles; B Lee; Session 2, Group D 815 Theranostic Barcoded Nanoparticles for Personalized Cancer Medicine; Z Ya’ari; Session 2, Group C 818 TMC-CSK modified Nanoparticles for Oral Delivery of Gemcitabine to Treat Breast Cancer; J Wen; Session 2, Group D 819 Transport Mechanism Of Coumarin 6 Nanocrystal In MDCK Monolayer and Larval Zebrafish; X Miao; Session 2, Group C 820 Transport Properties of Liposomes for Pulmonary Drug Delivery depend on the Surface Characteristics of  the Liposomes and the Atomization Technique used for Nebulization; R Prassl; Session 2, Group D 822 Trojan-Horse Nanocapsules – a Multistage Drug Delivery System for Deep Permeation in Tumor Tissue; Y Lai; Session 2, Group D 823 Tumor Targeting Efficiency of Hyaluronic acid Based Micelle Containing Paclitaxel; F Dorkoosh; Session 2, Group C 824 Tunable Encapsulation and Controlled Release of a Hydrophilic Drug by a New Modified Drop-wise Nanoprecipitation Method; J Xu; Session 2, Group D 825 Ultrahigh Drug Loading and Release from Biodegradable Porous Silicon Aerocrystals; C Kelly; Session 2, Group C 826 Ultrasonic assisted production of nanoliposomes as peptide delivery vectors; S Bochicchio; Session 2, Group D 827 Ultrasound-Responsive Nanobubbles for Enhanced Posterior Eye Drug Delivery; S Thakur; Session 2, Group C 828 Unintended Tissue Targeting: Is the Accumulation of Nano-DDS in Ovaries and Adrenals a Rather Common Phenomenon or an Artifact?; K Maeder; Session 2, Group D 830 Up-Regulating Autophagy in Attempt to Overcome Insulin Resistance Using Quaternized Starch as PI3P Carrier; N Marelly; Session 2, Group D 831 Upsalite®: A Novel Mesoporous Drug Delivery System; P Zhang; Session 2, Group C 832 Ursolic Acid Promotes Stabilization of pH-Sensitive and LongCirculating Liposomes under pH Decrease; D Ferreira; Session 2, Group D 833 Use of SBA-15 as biocompatible matrix for nanoconfinement and sustained-release of magnolol; A Stefanache; Session 2, Group C 834 Use of synthetic-sick screens to define improved combinations for cancer treatment: PAPSS1 silencing and lipid-based nanoparticulate formulations of DNA damaging agents; A Leung; Session 2, Group D 835 Virus Mimetic Nanocapsules with Sequential-Infected Multiple Drug Delivery for Tumor Therapy; S Hu; Session 2, Group C 836 Virus Mimetic: Bio-inspired Liposomes for Controlled Drug Release; S Chen; Session 2, Group D 838 Vitamin E-Conjugated Lipid Based Polymeric Micelles for Improved Delivery of Chemotherapeutics in Cancer; S BISWAS; Session 2, Group D 839 What’s the dose?  Accumulation of oligoarginine decorated nanoparticles on the surface of Caco-2 cells; I Tucker; Session 2, Group C

Oral Delivery for Food and Pharma 266 A bio-inspired delivery system for doxorubicin transport across intestinal epithelial cells; Q Zhu; Session 1, Group B 267 A Case Study - Formulation Development for Carcinogenicity Study; Z Nazir; Session 1, Group A 268 A cell penetrating peptide-medium chain fatty acid conjugate increases paracellular permeability across isolated rat intestinal mucosae; F McCartney; Session 1, Group B 270 A Novel Controlled-release Formulation of Carvedilol; L Tsung-Hsin; Session 1, Group B 271 A practical approach: A standardized method for investigation of supersaturation and determination of the effect of excipients on this; H Palmelund; Session 1, Group A 272 A Study of the Utilization of Starch Micro-Spheres as a Core Material for a Dry Powder Layering of an API to Facilitate High API Loading in Particles Below 250 microns; S Engels; Session 1, Group B 273 Application of sodium alginate for enteric coated lactoferrin tablets; C Takahashi; Session 1, Group A 274 Assessment of pH values, transit conditions and pressure events along the gastrointestinal tract in fasted and fed state using a wireless motility capsule (SmartPill®); F Schneider; Session 1, Group B 276 Automated screening approaches for solid dispersion approach of a poorly soluble compound.; G Verreck; Session 1, Group B 277 ß-Casein Based Nano-vehicles for Oral Delivery of Chemotherapeutic Combinations Overcoming Multidrug Resistance in Human Gastric Cancer; M Bar-Zeev; Session 1, Group A 278 Bioactive protein-based nanofibers promotes transepithelial permeation of intact therapeutic protein by interactions with biological components; K Stephansen; Session 1, Group B 279 Biphasic dissolution studies: Impact of concentration and particle size on partition rate; K Box; Session 1, Group A 280 Can judicious selection of polymer viscosity improve the GI robustness of HPMC hydrophilic matrices with low polymer contents?; L Mason; Session 1, Group B 281 Carrier Peptide-Mediated Transepithelial Permeation of Biopharmaceuticals:  Effect of Co-administration versus Covalent Conjugation; M Kristensen; Session 1, Group A 282 Casein nanocapsules: a new platform for oral drug delivery; D Torres; Session 1, Group B 284 Characterization of Orally Disintegrating Tablets Containing TasteMasked Mirtazapine Granules with Different Coating Ratio; E Aytekin; Session 1, Group B 285 Chewing Gum with a Built-in Trigger Mechanism for Drug Delivery; K Nielsen; Session 1, Group A 286 Chronocort® - a Modified Release Oral Hydrocortisone Formulation Customised to Mimic the Human Circadian Rhythm; D Margetson; Session 1, Group B 287 Circumvent p-glycoprotein-mediated efflux by Lipo- encapsulated pure nanodrug; D Xia; Session 1, Group A 288 Co-loading of Glucagon-like Peptide-1 and Dipeptidyl Peptidase 4 Inhibitor in pH Sensitive Polymer/Porous Silicon Nanomatrix for Type 2 Diabetes Mellitus; N Shrestha; Session 1, Group B 289 Combined use of Biofirm Penetration Enhancer and Sublingual Administration for Improving the Bioavailability of BBR; X Long; Session 1, Group A 290 Controlled Release Coatings of Ethylcellulose on Drug Loaded Multiparticulates:A Comparison of a Novel Rotor Dry Layering Process to a Traditional Wurster Bottom Spray Coating; B Jensen; Session 1, Group B 291 Controlled Release Formulations of Pelubiprofen Employing Kollidon® SR; B Chae; Session 1, Group A 292 Controlled Release Tablet Formulations: Effect of Hydrophilic Matrix and Fillers on Active Pharmaceutical Ingredient Release; J Conceição; Session 1, Group B 295 Design of a histology score card to standardize the assessment of intestinal toxicity of novel candidate pharmaceutical excipients; F McCartney; Session 1, Group A 297 Design of Modified Release Multi-Particulate Floating Drug Delivery System for Levodopa and Carbidopa Combination Based on a Multilayer Structure; S CHARDE; Session 1, Group A 298 Determining the azoreductase activity in bacteria residing the lower human gastrointestinal tract; G Glöckl; Session 1, Group B 299 Development of local controlled-release fenretinide as a chemopreventive therapy for oral squamous cell carcinoma (OSCC); K Nieto; Session 1, Group A 300 Development of MCC-free pellets with fast release for poorly soluble drugs; N Dudzinska; Session 1, Group B

301 Development of Pharmaceutical Abuse Deterrent Capsule Formulations; S Wengner; Session 1, Group A 302 Development of Rapid-acting Oral Insulin Formulation; Y Yang; Session 1, Group B 303 Development, characterisation and optimisation of PEG-chitosan based nanoparticle system for the oral delivery of insulin; R Rayasam; Session 1, Group A 304 Dissolution of niacin ER tablets under standard and biorelevant test conditions; B Milanowski; Session 1, Group B 305 Dissolution of Tacrolimus from Modified Release Formulations under Biorelevant Conditions; A Mercuri; Session 1, Group A 306 Effect of Bead Size and Counts per Unit in a Multi-Particulate System on Bioavailability.; Y Gattani; Session 1, Group B 307 Effect of Citrate Buffer on the Release Rate and Swelling Properties of Fluvastatin Matrix Tablet In Acid and Basic Media.; U Ubani-Ukoma; Session 1, Group A 308 Effect of pH combined with surfactant on solubility profile of weakly acidic HMG CoA  enzyme reductase  inhibitor- Atorvastatin Calcium; P DOSHI; Session 1, Group B 309 Effect of Talc Particle Size on Drug Release from Modified Release Dosage Forms; B Chickmath; Session 1, Group A 310 Enabling Controlled Release Formulations for Once Daily (QD) Dosing of a Poorly Water Soluble Compound; P Gupta; Session 1, Group B 311 Encapsulation by modification food protein to increase survival rate of probiotics in the stomach; R Tromp; Session 1, Group A 313 Enteric coated hard gelatin capsule development for pharmacokinetic studies; P Evans; Session 1, Group A 315 Enteric-coated tablets containing permeation enhancers improve oral bioavailability of Enoxaparin; M Goharzadeh; Session 1, Group A 316 Establishment of Virtual Bioequivalence Using Population-Based PBPK Modelling: Application to the Setting of Dissolution Limits; S Pathak; Session 1, Group B 317 Evaluation of Acetaminophen Particle Size and Crystal Morphology on Taste-Masking Performance from Coated Granules and Chewable Tablets; A Rajabi-Siahboomi; Session 1, Group A 319 Evaluation of HPMC as a Polymer Carrier in a Celecoxib Amorphous Solid Dispersion; T Brannigan; Session 1, Group A 321 Film Casting as a Screening Technique in the Selection of API-Polymer Compositions for Amorphous Solid Dispersion Production via Spray Drying; C Brennan; Session 1, Group A 322 Formulating a chewable tablet containing paracetamol and masking the taste of the active pharmaceutical ingredient; T Cech; Session 1, Group B 323 Formulating an orally disintegrating tablet carrying cetirizine HCl and evaluating advantages and disadvantages of different manufacturing procedures; T Cech; Session 1, Group A 324 Formulating Oils in the Zydis® Freeze Dried Orally Disintegrating Tablet; L Garrett; Session 1, Group B 326 Formulation Development and Preliminary Studies of Decitabine loaded PLGA Nanoparticles for Potential Oral Delivery; N Udupa; Session 1, Group B 328 Gastroretentive Dosage Form for Once Daily (QD) Dosing of a Compound with a Narrow Absorption Window; P Gupta; Session 1, Group B 329 High Shear Granulation to Leverage the Full Potential of Delta Polymorph Mannitol; F Bauer; Session 1, Group A 330 Hot Melt Extrusion to Improve Dissolution of Itraconazole; P Piccinni; Session 1, Group B 331 Human in vivo regional intestinal permeability: Quantitation using site-specific drug absorption data; D Dahlgren; Session 1, Group A 332 Hydrogels-Based Matrices Behavior: Experimental and Modeling Description; S Bochicchio; Session 1, Group B 333 Impact of monoacyl phosphatidylcholine on the nanoemulsification capacity of self-nanoemulsifying drug delivery systems; T Tran; Session 1, Group A 334 Improved loading of a poorly water soluble drug in Orally Dissolving Films through cyclodextrin inclusion complex.; T Pham; Session 1, Group B 335 In silico modeling of drug release from Eudragit® RL/RS coated drug beads using material properties and kinetic parameters of the free polymer films; X Wu; Session 1, Group A 336 In Vitro and In Silico Models in Pharmacokinetic Studies; S Bochicchio; Session 1, Group B 338 Increasing the complexity in epithelial cell culture to assess cytotoxicity of a permeability enhancer (CriticalSorbTM); R Cavanagh; Session 1, Group B continued

43

Oral Delivery for Food and Pharma continued 339 Infacort® - Development and Clinical Evaluation of a Taste Masked Multiparticulate Oral Hydrocortisone Formulation for Paediatric Use; D Margetson; Session 1, Group A 340 Intestinal permeation enhancers improve flux of food-derived tripeptides across rat intestinal mucosae in vitro; J Gleeson; Session 1, Group B 341 Investigating the barrier properties of an intestinal co-culture model of CCD-18co intestinal sub-epithelial myofibroblasts and Caco-2 intestinal epithelial cells; J Patient; Session 1, Group A 342 Investigating the impact of particle size and content of cross-linked PVP onto the resulting tablet characteristics; T Cech; Session 1, Group B 343 Investigation of dimethyl palmitoyl ammonio propanesulfonate as an intestinal permeation enhancer in isolated rat intestinal mucosae; F McCartney; Session 1, Group A 344 Investigation of the cytotoxicity of a sucrose laurate, a novel intestinal permeation enhancer; F McCartney; Session 1, Group B 345 Lipid co-administration that promotes incorporation into intestinal lipoproteins is critical for efficient lymphatic transport of a bio-mimetic triglyceride prodrug; S Han; Session 1 Group A 346 Lipophilic prodrugs design and in vitro characterization: towards oral chemotherapy; V Bala; Session 1, Group B 347 Liposomal encapsulation of anti-diabetic drugs; S Joshi; Session 1, Group A 348 Mass balance: an old concept for the new challenges proposed by personalized medicine; M Grassi; Session 1, Group B 349 Matrices containing Hydrophilic Excipients: Swelling and Dissolution Studies; K Hwang; Session 1, Group A 350 Melt extruded Sirolimus: Effect of TPGS on sirolimus dissolution and stability; P Kanaujia; Session 1, Group B 351 Micellar solubilization of fenofibrate by saponins and classical surfactants; Z Vinarov; Session 1, Group A 353  Modification of Eudragit® L 30 D-55 coated tablets to reduce the effect of residence time in acid on drug release; A Menge; Session 1, Group A 354 Mucoadhesive polymers and the application in the food industry: In vivo and in vitro assessments; S Smith; Session 1, Group B 355 Nanocarrier system for oral anticancer drug delivery using Styrene Maleic acid micelles.; N Parayath; Session 1, Group A 356 Nanoscale Phase Separations of immiscible Polymer Blends in Electrospun Nanofibres and their Potential Applications in Controlled Drug Delivery; P Tipduangta; Session 1, Group B 357 New Insights into the Stability of SR Lipid Matrix Tablets; Y Rosiaux; Session 1, Group A 358 New Insights into the Steric and Interactive Barrier of Intestinal Mucus: Impact on Particle Diffusion and Peptide Permeation; M García-Díaz; Session 1, Group B 360 Optimization of the Microencapsulation of Anthocyanins from Haskap Berries (Lonicera caerulea L.) in Ca-Alginate Beads for Oral Delivery; G Celli; Session 1, Group B 361 Optimization of Type I and II Lipid Based Drug Delivery System to limit inter-variability linked to the food effect, an in-vitro study; V Plassat; Session 1, Group A 362 Oral Absorption of Nanoparticles: Low Copy Number of a T7 Phage Display-derived Peptide Significantly Increases Translocation Across Caco-2 Cell Monolayers; D Myers; Session 1, Group B 363 Performance evaluation of Acryl-EZE® II enteric coated lansoprazole multiparticulates and esomeprazole tablets in low and intermediate pH media; A Rajabi-Siahboomi; Session 1, Group A 365 Phase separation in the gel layer of mixed HPMC/PEO hydrophilic matrices; A Hu; Session 1, Group A 366 Polymeric microcontainers improve oral bioavailability of a poorly soluble drug; L Hagner Nielsen; Session 1, Group B 367 Preliminary evaluation of hot melt extrusion for improving the oral bioavailability of substrates of P-glycoprotein (P-gp) efflux pump; A Melocchi; Session 1, Group A 368 Preparation and Evaluation of Fast Dissolving Oral Films Containing Lercanidipine HCl Nanoparticles; N Udupa; Session 1, Group B 369 Preparation and physiochemical characterisation of carvedilolpolyethylene glycol solid dispersions: potential for enhanced oral delivery; S Fallows; Session 1, Group A 370 Production of cocrystals in an amorphous matrix via spray drying; D Walsh; Session 1, Group B 372 Role of Salts in the Modulation of Drug Release From Carbopol Matrices; A Fazli; Session 1, Group B 373 SANS Analysis of Micellar Structures in the GI Tract during Food Digestion; O Rezhdo; Session 1, Group A

44

374 Self-assembled Nanobubbles as a Carrier for Oral Protein Drug Delivery; L Po-Yen; Session 1, Group B 375 Silica Encapsulated Lipid Based Drug Delivery Systems for Reducing the Food Effect of Ziprasidone; T Dening; Session 1, Group A 376 Studies on design, development, and stability of enteric coated HPMC capsules; B Kadri; Session 1, Group B 377 Supersaturation of Zafirlukast in simulated intestinal media, and the effect of precipitation inhibitors: Is it possible to predict a negative food effect in vitro?; C Madsen; Session 1, Group A 378 Supersaturation, phase separation and the measurement of drug precipitation rates; K Box; Session 1, Group B 379 Synthesis of hyaluronic acid-based nanoparticles for oral insulin delivery; P Rooney; Session 1, Group A 380 The Effect of Viscosity on the Swelling, Matrix Erosion, Dissolution and Compaction properties of Hypromellose Matrices; M Ghori; Session 1, Group B 381 The Role of Polyethylene Glycols on the Modulation of the Anionic ABCC2 Transporter; J Pollard; Session 1, Group A 382 The Serosal Layer’s Potential Impact On Rat Intestinal Tissue Viability And Permeability; C Roos; Session 1, Group B 383 The synergistic effect of silica and polymer in establishing improved lipid-based solid dosage forms for poorly water soluble drugs; C Prestidge; Session 1, Group A 385 Transport of apomorphine and its esters across Caco-2 cell monolayer; N Borkar; Session 1, Group A 389 Use of NMR and MRI to probe the in vitro dissolution of amorphous solid dispersions made with coPVP and Felodipine or Bicalutamide; S Wren; Session 1, Group A 390 Utilisation of RapidFACT strategies to evaluate and develop an In Vitro In/Vivo Correlation (IVIVC) for Modified Release Formulations of Lorcaserin HCl; Z Kane; Session 1, Group B

Parenteral Controlled Release 391 A Novel Fluorescent Assay to Determine the Influence of Oil Type and Surface Composition on Lipid Emulsion Lipoprotein Lipase Mediated Metabolism; P Dougall; Session 1, Group A 392 An injectable liquid crystal system for sustained delivery of entecavir; M Joo; Session 1, Group B 394 Controlled Release Kinetics of Vitamin Loaded Poly(glycerol sebacate); J Harris; Session 1, Group B 397 Development of an Extended-Release Leuprolide Formulation using the FormEZETM Technology; W Deng; Session 1, Group A 398 Development of Asiatic Acid Loaded Solid Lipid Nanoparticles for Anti-Cancer Therapy; T Garanti; Session 1, Group B 400 Development of electrospun sodium alginate/ethyl cellulose nanofiber scaffolds for urethral reconstruction; B Conti; Session 1, Group B 401 Direct injectable, solvent-free biodegradable polymers for parenteral controlled release; A Rodrigues; Session 1, Group A 403 Effect of Dobutamine on Pancreatic Cancer in 3D Tumour Spheroid Model; B Xie; Session 1, Group A 404 Glucosamine as a carrier for renal drug targeting; Y Li; Session 1, Group B 405 Improved Cisplatin Efficacy on HCT-116 Colorectal Cancer Cells and Decreased Toxicity in Rats from Tunable Biodegradable NanoComposite Hydrogel; h Abdel-Bar; Session 1, Group A 407 In Vivo Release of Celecoxib-loaded Acetyl-capped PCLA-PEGPCLA Thermogels in Rats; M Van Dijk; Session 1, Group A 410 N, N-dimethyl amino group based brain-targeting derivative of dopamine for the treatment of Parkinson’s disease; Z Zhang; Session 1, Group B 411 Novel Methods for the Evaluation of Drug Release from Drug Eluting Beads; T Swaine; Session 1, Group A 412 Oleogels as a New Alternative for Direct Injectable and Parenteral Controlled Release; K Maeder; Session 1, Group B 413 PEG-cholane can successfully enhance the solubility of poorly soluble drugs. A novel formulation for amphotericin B delivery; S Salmaso; Session 1, Group A 414 Polymer degradation induced nifedipine precipitation in PLGA implants; C Nitzschke; Session 1, Group B 415 Polymer Implants for Drug Delivery: The Relation between Structure and Release Kinetics; E DUFFAU; Session 1, Group A 416 Polyoxazoline coated poly(L-lysine) dendrimers as novel carriers intended for drug delivery; R England; Session 1, Group B 418 Questioning the rate-limiting drug release and absorption mechanisms from an intramuscular sustained-release nano-/

microsuspension: the effect of local macrophage depletion; N Darville; Session 1, Group B 420 Targeting ligand conjugated pH-sensitive Polymeric Drug based on Chitosan derivatives for Cancer Therapy; J Nah; Session 1, Group B 421 Thermosensitive Hydrogels for Bone Regeneration and Local Drug Delivery; M Roldo; Session 1, Group A

Regional Delivery 423 A Novel Transparent Cyclosporine Eye Drop; H Jeon; Session 1, Group A 424 A Novel ex vivo Assay to Evaluate the Role of Müller Cells in Retinal Drug Delivery; K Peynshaert; Session 1, Group B 425 A Physically-Associative, Shear-Responsive Ophthalmic Hydrogel for Anterior and Posterior Segment Drug Delivery; T Hoare; Session 1, Group A 426 Absorption Kinetics of Dendrimers across the Pulmonary Epithelium: Comparing Degree of PEGylation; J Reineke; Session 1, Group B 430 Anti-Angiogenic Strategies for Chemoembolization of Liver Tumors; K Fuchs; Session 1, Group B 431 Antioxidant Activity and Real-Time Imaging of HPMC–coated Cerium Oxide Nanoparticles: New Modality for Age-Related Cataract; A Al-Kinani; Session 1, Group A 432 Application of PBBP Modeling to Liver Targeted Drug Delivery Systems; I Dubbelboer; Session 1, Group B 434 Clinical and Preclinical Demonstration of Continuous and Adjustable Methotrexate Delivery from a Novel Refillable “Port Delivery System” Implant; S Erickson; Session 1, Group B 435 Controlled Release of levofloxacin from Vitamin E loaded Silicone Hydrogel Contact Lenses; P Paradiso; Session 1, Group A 437 Corneal ulcer amelioration in response to in situ gelling naltrexone hydrochloride (NTX) films: pharmaceutical formulation and clinical evaluation; H Abdelkader; Session 1, Group A 438 Cytotoxicity, Pro-Inflammatory Potential and Drug Permeability Profile of Dapivirine-Loaded Poly(Lactic-co-Glycolic Acid) Nanoparticles; J das Neves; Session 1, Group B 439 Delivery of Brain-Penetrating Nanoparticles Across the Blood-Brain Barrier with Focused Ultrasound: Brain Tumor and Neurodegenerative Disease Applications; R Price; Session 1, Group A 440 Design of multifunctional liposomes having target specificity, temperature-sensitivity and imaging for efficient and personalized chemotherapy; K Kono; Session 1, Group B 441 Development and Assessment of Thermosetting Ketoconazole (KZ) Vaginal Gel Formulations; R Walker; Session 1, Group A 442 Development and Characterization of Dexamethasone-Loaded Crosslinked Hyaluronic Acid Films for Ocular Therapy; J Calles; Session 1, Group B 443 Development and evaluation of brain targeting RVG peptide-modified protein nanocarrier; N Hamano; Session 1, Group A 445 Development of a mucoadhesive system for release of dexamethasone in oral cavity; A Vea-Barragan; Session 1, Group A 446 Development of Mucoadhesive Gels Containing Moxifloxacin for the Treatment of Periodontal Diseases; S S¸enel; Session 1, Group B 447 Drug Eluting Beads vs. Lipiodol-based Emulsion regarding Local Drug Release and Effect in Patients with Hepatocellular Carcinoma; E Lilienberg; Session 1, Group A 448 Effective Fabrication of Tumor-bearing Animal Models by Cancer Cell Sheet Transplantation; M Nakayama; Session 1, Group B 450 Enhanced pulsatile on-demand drug release from injectable, magnetic ‘plum pudding’ hydrogels with embedded microgels.; S Campbell; Session 1, Group B 451 Estrone-1-sulfate (E1S) has impact on the kinetic parameters of transporter mediated taurine glutamate influx to Caco-2 cells; B Steffansen; Session 1, Group A 453 Development of hydrogels for drug and cell delivery to the distal airways; C Payne; Session 1, Group A 454 Extended Release of Inhaled Treprostinil-Prodrug Formulation for Prolonged Pharmacokinetics; K Chen; Session 1, Group B 455 Fabrication of characteristically enhanced moldable electrospun scaffolds; W Choi; Session 1, Group A 456 Gelatin-based Nanogels in Intravesical Gene Delivery; L Chang; Session 1, Group B 457 Gellan gum fluid gels as a mucoadhesive nasal delivery system; M Mahdi; Session 1, Group A 458 Highly ironic acid: divergent properties of high and low molecular weight hyaluronic acid on macrophage polarization and angiogenic function; J Rayahin; Session 1, Group B

459 Image-guided Drug Delivery across the Blood-Brain Barrier using Theranostic Microbubbles; T Lammers; Session 1, Group A 460 Implications of Polymer Properties on the Manufacture of Soft Contact Lens as a Tool for Ocular Drug Delivery; S Mustafa; Session 1, Group B 463 In vitro drug release from intra-ocular lenses using a microfluidic device; A Pimenta; Session 1, Group A 464 In vivo predictive ability of two selected in vitro methods applied on DC Beads; E Ahnfelt; Session 1, Group B 465 Inhalable nano-embedded microparticles for sustained delivery of cationic antimicrobial peptides: overcoming lung barriers; I d’Angelo; Session 1, Group A 466 Inhalable particles containing Nitazoxanide alone and in combination with Isoniazid and Rifabutin for the treatment of Tuberculosis; A Gupta; Session 1, Group B 467 In-Situ Forming Implant for Local Delivery of Superparamagnetic Iron Oxide Nanoparticles for Application of Induced Hyperthermia; S Ehrenberger; Session 1, Group A 469 Layered Nanoemulsion-based Mucoadhesive Buccal Systems for Controlled Delivery of Oral Cancer Therapeutics; T Elbayoumi; Session 1, Group A 470 Locally-Controlled Release of Chemotherapeutic Drugs via Palladium-Functionalized Implants; B Rubio-Ruiz; Session 1, Group B 471 Mechanical Characterization of ECM Hydrogels for CNS Regeneration with Rheometer and Texture Analyzer; i kadiyala; Session 1, Group A 472 Microparticle-based Delivery of Clindamycin for Prevention of Mandibular Infection; S Shah; Session 1, Group B 473 Minimizing the Non-specific Binding of Nanoparticles in the Brain Enables Active Targeting of Fn14-positive Brain Tumors; A Kim; Session 1, Group A 474 Modifying Drug Release Kinetics of Enteric Coated Tablets Targeted to the Duodenum by CO2 Laser Irradiation; V Titapiwatanakun; Session 1, Group B 476 Nanomedicine for prevention of corneal allograft rejection; Q Xu; Session 1, Group B 477 Omentum ECM-based hydrogel as a platform for cardiac cell delivery; M Shevach; Session 1, Group A 478 Patterned Nanoporous Polypyrrole for Tunable Ocular Drug Delivery; A Seyfoddin; Session 1, Group B 479 PEG-Polyacetal-Curcumin Conjugate in the Rescue of Acute Rat Spinal Cord Injury; M Vicent; Session 1, Group A 480 Penetration enhancers in transcorneal delivery of riboflavin; V Khutoryanskiy; Session 1, Group B 481 Perivascular administration of atorvastatin needs to be sustained in order to decrease neointimal hyperplasia in mice carotid artery ligature model.; I Mylonaki; Session 1, Group A 482 PLGA nanoparticles incorporated into a light-responsive gel as novel ocular injectable implant; R Bisht; Session 1, Group B 483 Porous Conducting Polymer Prepared Through Liquid Crystal for Stimuli Responsive Drug Delivery; D Uppalapati; Session 1, Group A 484 Porous PEDOT Honeycomb Structures for Stimuli Responsive Ocular Drug Delivery; M Yasin; Session 1, Group B 485 Preformulation Studies of Silicone Elastomer Type Combination Vaginal Ring of Dapivirine and Levonorgestrel; S Kumar; Session 1, Group A 488 Scaffolds optimized for the regional release of TGF-ß3 and BMP7 induce cartilage formation; M Garcia-Fuentes; Session 1, Group B 489 Selective Accumulation of PEG-liposomes in Brain after Traumatic Brain Injury; B Boyd; Session 1, Group A 490 Self-assembling benzothiazole prodrugs for targeted cancer therapy; F Citossi; Session 1, Group B 491 Site-specific simultaneous delivery of metronidazole and clarithromycin in treatment of H. pylori infections; A Adebisi; Session 1, Group A 492 Spray dried vesicular delivery system targeting pulmonary tuberculosis; A Hamed; Session 1, Group B 493 Stability of Docetaxel in polyurethane matrix and implications on release behavior- A SAXS account; M Shaikh; Session 1, Group A 494 Sustained Delivery of Local Anesthetic to Address Post-surgical Complications; M Sharma; Session 1, Group B 495 Sustained Intra-Articular Release of Celecoxib from In Situ Forming Gels Made of Acetyl-capped PCLA-PEG-PCLA Triblock Copolymers in Horses; M De Leeuw; Session 1, Group A 496 Synthesis and Evaluation of Hyaluronic Acid Hydrogel as a Biodegradable Polymer; H Obata; Session 1, Group B continued

45

Regional Delivery continued 497 Systematic investigation of the role of extracellular calcium in enhancing stratification of buccal cell cultures to enhance in vitro assessment of transmucosal drug delivery; A Iyire; Session 1, Group A 498 Targeted pulmonary montelukast sodium loaded lecithin based soft agglomerates for treatment of asthma; R Osman; Session 1, Group B 500 The Development of All-Trans Retinoic Acid-Loaded CollagenHyaluronic Acid Films for Respiratory Tissue Regeneration; C O’Leary; Session 1, Group B 501 The improvement of Solid Lipid Microparticle breathability for an anti-TB inhalation therapy; V Iannuccelli; Session 1, Group A 503 Trojan starch-based nanoparticles for the deep lung delivery of IgG1; S Barthold; Session 1, Group A 504 Tying up the giant: the influence of cross-linked networks of hyaluronic acid on macrophage function; R Gemeinhart; Session 1, Group B

RNA and DNA Delivery 843 A Lipid Nanoparticle siRNA Delivery System for Non-Hodgkin Lymphoma; K Whitehead; Session 2, Group C 844 Albumin-mediated protection, reduced immunogenicity and extended circulatory half-life of cholesterol modified small interfering RNA; K Bienk; Session 2, Group D 845 anti-IL8 siRNA Nanoparticles Induce Knockdown in Epithelial Cells-in vitro and in vivo; J Ramsey; Session 2, Group C 848 Attachment of Hydrophobic Tails to Polyamino Alcohols Enhances DNA and siRNA Delivery; Y Wu; Session 2, Group D 849 Autophagy-related Gene Expression Analysis Of Mouse Embryonic Fibroblast Cells Treated With Polyethylenimine; J Kuo; Session 2, Group C 850 Branched modified R9 cell-penetrating peptide for efficient gene delivery into mammalian cells; J Yoo; Session 2, Group D 851 Carrier exchange between the core and shell of PLL- and PEI-DNA nanoparticles; E Vuorimaa-Laukkanen; Session 2, Group C 852 Catechol-conjugated Polymeric Films for the Adeno-associated Virus-mediated Transfection; S Lee; Session 2, Group D 853 Cell Derived Nano-Ghosts: A Novel Targeted Gene Delivery System For Cancer Therapy; L Kaneti; Session 2, Group C 854 Cell-Penetrating Peptide Mediated Gene Delivery via Polymeric Microneedles; A Platform for DNA Vaccination; J McCaffrey; Session 2, Group D 856 Chitosan coated PLGA Nanoparticles for Pulmonary Delivery of mRNA encoding a Zinc Finger Nuclease: An in-vivo proof of concept study for somatic genome editing; B Loretz; Session 2, Group D 857 Chitosan-pDNA Nanoparticles Facilitate Controlled Gene Delivery on Collagen Scaffolds for Orthopaedic Tissue Engineering Applications; R Raftery; Session 2, Group C 859 Co-delivery with other nucleic acids affects the efficiency of mRNA translation; J Devoldere; Session 2, Group C 860 Colloidal stability of polymeric nanocapsules in an ex-vivo model of vitreous humor; S Reimóndez-Troitiño; Session 2, Group D 861 Combinatorial Library of Ternary Polyplexes Enables Identification of Improved siRNA Nanocarriers for Rapid In Vivo Translation; T Werfel; Session 2, Group C 862 Comprehensive study of DC-Chol/DOPE liposome for the delivery of siRNA in lung cancer; A Alshehri; Session 2, Group D 863 Construction of Structural Viral-Mimicry by Peptide/DNA Coassembly; R Ni; Session 2, Group C 865 Cyclodextrin-based co-formulations for targeted delivery of siRNA to prostate cancer; C O’ Driscoll; Session 2, Group C 867 Design Of A Multifunctional Vector For Delivery Of miRNA-34a For Metastatic Prostate Cancer; S Loughran; Session 2, Group C 870 Development of Adipocyte-Targeted Oligopeptide Gene Delivery System; H Kim; Session 2, Group D 871 Development of Functional Viral-Mimicry by Optimization of Peptide/ DNA Co-assembly; R Ni; Session 2, Group C 872 Development of PGA Based Systems for pDNA Delivery; A Niño; Session 2, Group D 873 Development of Star Shaped Polypeptides As Non-Viral Gene Delivery Vectors to Produce Gene Activated Matrices for Bone Tissue Engineering; D Walsh; Session 2, Group C 874 Distribution of PEI-PEG-based polyplexes in tumor tissue and possible approach to improve gene delivery; M Durymanov; Session 2, Group D

46

875 Efficient Expression of mRNA PEG-Peptide Polyplexes in Liver; K Rice; Session 2, Group C 876 Efficient One-step Preparation of siRNA-encapsulated Non-cationic Liposomes; M Somiya; Session 2, Group D 877 Efficient siRNA delivery system mediated with dendritic gold nanocrystals; M Lee; Session 2, Group C 878 Elucidation of the Mechanism of Increased Activity of Immunostimulatory DNA by Formation of Polypod-like Structure; K Mohri; Session 2, Group D 879 Exosomes underperform compared to liposomes for functional, in vitro siRNA delivery; S Stremersch; Session 2, Group C 880 Formulation Development and Evaluation of Ultradeformable cationic Liposomes for Delivery of Oligonucleotides; G Asthana; Session 2, Group D 881 Gene Delivery to the Brain Using Brain Penetrating DNA Nanoparticles; P Mastorakos; Session 2, Group C 882 Heme Oxygenase-1 Gene Delivery using a Polymeric Carrier for the Treatment of Ischemic Stroke; J Oh; Session 2, Group D 883 Hyaluronic acid-incorporated calcium phosphate nanoparticles for specific tumor-targeted siRNA delivery; M Lee; Session 2, Group C 884 Intracellular redox potential-responsive micelles for enhanced miR-34a delivery; l hanmei; Session 2, Group D 885 Intraperitoneal liposomal-based siRNA delivery: A Systematic Evaluation in the Ascites Fluid; G Dakwar; Session 2, Group C 886 Life prolongation in rats with malignant glioma by intranasal siRNA/ drug co-delivery to the brain with cell-penetrating peptide-modified polymer micelles; T Kanazawa; Session 2, Group D 887 Lipidoid siRNA Nanoparticles for Intestinal Disease Therapeutics; R Ball; Session 2, Group C 888 Lipoplexes Containing Bipolar Tetraether Lipids for Transfection of Cancer Cell Lines; K Engelhardt; Session 2, Group D 889 LNA/2’OMe Delivery to Helicobacter pylori within Gastric Mucus; R Santos; Session 2, Group C 891 Mannosylated Polyion Complexes for In Vivo Gene Delivery into CD11c+ Dendritic Cells ; A David; Session 2, Group C 893 Peptide Nanofiber Vectors of siRNA for Glioblastoma Treatment; M Mazza; Session 2, Group C 895 poly(2-dimethylaminoethyl methacrylate)-functionalized graphene oxide nanoflakes for efficient cellular delivery of siRNA; J Lee; Session 2, Group C 896 Polymeric and lipidic nanoparticles for targeted siRNA delivery; G Golomb; Session 2, Group D 897 Polymeric Nanoparticles For The Pulmonary Delivery Of miRNA To Treat Chronic Obstructive Pulmonary Disease (COPD); A Mohamed; Session 2, Group C 899 Reciprocal dormancy-promoting nanomedicine altering EGFR and TSP-1 for the management of glioblastoma; R Satchi-Fainaro; Session 2, Group C 900 Regression of prostate tumors following intravenous administration of tumor-targeted dendriplexes; C Dufes; Session 2, Group D 901 Regulation of Osteogenic Genes using microRNA-Activated Scaffolds to Enhance Mesenchymal Stem Cell Osteogenesis; F O’Brien; Session 2, Group C 902 RNAi and gene delivery mediated via novel Lipopolyplexes; S Pinnapireddy; Session 2, Group D 904 Self-destroying Bioreducible Polymer with Agmatine Moiety for Efficient Gene Delivery Systems; T Kim; Session 2, Group D 905 Simple Method for Preparation of 20-50 nm Lipid Nanoparticles Encapsulating siRNA Using a Y Connector; T Schrøder; Session 2, Group C 906 Span based nanoparticles as efficient non-viral vectors for in vivo PRPF31 gene delivery to treat inherited retinal dystrophy; A Pensado; Session 2, Group D 908 Tailoring the Surface of a Gene Delivery Vector with Carboxymethylated Dextran: a Systematic Analysis; C Fortier; Session 2, Group D 910 Targeted Gene Delivery into Peripheral Nervous System Mediated by Trimethyl Chitosan Nanoparticles; A Pego; Session 2, Group D 911 Targeted mitochondrial delivery of functional nucleic acids using MITO-Porter; E Kawamura; Session 2, Group C 912 Targeting chitosan oligosaccharide nanoplexes to lung cancer cells for enhanced internalization and improved siRNA delivery; U KOLI; Session 2, Group D 913 The NanoAssemblr™ Platform: Scalable, Microfluidics-based Manufacture of RNA Lipid Nanoparticles; C Walsh; Session 2, Group C 915 Ultrasound-mediated gene transfer to the brain; S Pun; Session 2, Group C

Topical and Transdermal Delivery 917 A microfludic system using a hollow microneedle for targeted drug delivery of phenyephrine for treatment of fecal incontinence; M Han; Session 2, Group C 918 A novel spraying method for preparing Eudragit® E PO-Soluplus®Perphenazine thin matrix films; K Korhonen; Session 2, Group D 919 Acute Dermal Irritancy and Anti-Arthritic Efficacious study of Alginate Bilayer Film containing Hydroxytyrosol in Freud’s Adjuvant inducedArthritic Rat Model; S Ng; Session 2, Group C 920 Allergen-coated microneedles as a novel way for asthma preventive immunotherapy; A Shakya; Session 2, Group D 921 Antimicrobial hydrogels based on poly(vinyl alcohol)- poly(methyl vinyl ether-alt-maleic anhydride) combinations for wound care applications; E Calo’; Session 2, Group C 922 Bacterial Nanocellulose as Wound Dressing for Controlled Fast and Prolonged Release of Octenidine; D Fischer; Session 2, Group D 923 Challenging the Topical Antimicrobial Paradigm: Application of Transdermal Permeation Enhancer Technologies to the Treatment of Skin and Soft Tissue Infections.; J McArthur; Session 2, Group C 924 Chlorhexidine digluconate nanoemulsions for topical antisepsis; P Kakadia; Session 2, Group D 925 Colocalization of Two Fluorphores with Polymeric Micelles by FRET Confocal Microscopy; J Liaw; Session 2, Group C 927 Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-dose Combination of Cardiovascular Drugs; H Quinn; Session 2, Group C 928 Development and Characterization of Mucoadhesive In Situ Nasal Gelling Systems.; H Parekh; Session 2, Group D 929 Development and Evaluation of Tocotrienol-based Nanoemulsion Platforms for Dermal Chemoprevention Applications; T Elbayoumi; Session 2, Group C 930 Development of a Novel Transdermal Drug Delivery System using an Atmospheric-pressure Low-temperature Plasma Jet; K Kusamori; Session 2, Group D 933 Development of Thermostable Oxytocin-Coated Microneedle Patch for Treatment of Postpartum Hemorrhage; M Prausnitz; Session 2, Group C 934 Effect of Photoinitiator Concentration on the Properties of Unmedicated Hydrogels.; R Wong; Session 2, Group D 935 Encapsulation Of Diterpene Parvifloron D In Hybrid Nanoparticles For Cancer Targeted Therapy; C Silva; Session 2, Group C 936 Enhanced Release and Solubilization of Paclitaxel by Buccal Delivery System based on DMßCD and Pluronic F127; C Ng; Session 2, Group D 937 Evaluating the impact of various additives upon the gel-point temperature of aqueous poloxamer-based formulations; T Cech; Session 2, Group C 938 Evaluation of In Vitro Skin Permeability of Succinylated Type I Atelocollagen; S Park; Session 2, Group D 939 Formulation and development of a novel dermal system for the local delivery of the anti-cancer agent MTL-004; M Marwah; Session 2, Group C 940 Formulation and evaluation of topical formulation of a local anaesthetic drug for pain management; S Sawarkar; Session 2, Group D 941 Formulation and Evulation of Loxoprofen Sodium Containing Topical Gel; C ASIK; Session 2, Group C 942 Human Growth Hormone Coated Microneedles for the Treatment of Wrinkles; I Choi; Session 2, Group D 943 Hyaluronan-based Dissolving Microneedles for Intradermal Protein Delivery: Protein Stability and Microneedle Dissolution in Skin; J Mönkäre; Session 2, Group C 944 Imiquimod Permeation into the Skin to Treat Basal Cell Carcinoma; M AL-Mayahy; Session 2, Group D 945 Improve of tyrosinase inhibitor activity by trans-resveratrol-loaded solid lipid nanoparticles; R Rigon; Session 2, Group C 946 In vitro biocompatibility studies of microneedle arrays for use in the transdermal delivery of ibuprofen sodium.; M McCrudden; Session 2, Group D

947 In vivo Monitoring of Compound Permeation and Age Related Effects in Human Stratum Corneum; N Starr; Session 2, Group C 948 In Vivo Theophylline, Caffeine and Glucose Monitoring Using Hydrogel-Forming Microneedles; E Caffarel-Salvador; Session 2, Group D 949 Influence of fresh or defrosted pig ear tissue upon tape stripping results; C Keck; Session 2, Group C 951 Isotretionin colloidal carriers for topical acne treatment: ATR-FTIR and in vitro cytotoxicity studies; M ERDAL; Session 2, Group C 953 Microemulsion Improves Oral and Topical Absorption of Acycovior; J Tsai; Session 2, Group C 954 Microemulsions for topical Fluconazole delivery; T Gratieri; Session 2, Group D 955 Microneedle-mediated delivery of donepezil: potential for improved treatment options in Alzheimer’s disease.; M Kearney; Session 2, Group C 956 Micropore Closure Kinetics are Delayed Following Microneedle Insertion in Elderly Subjects; N Brogden; Session 2, Group D 958 Nanofibers Based On Chondroitin Sulfate Intended For Wound Healing; C Caramella; Session 2, Group D 959 Nanotechnological approaches for skin regeneration: The topical administration of rhEGF loaded Nanostrucutred lipid carriers enhances healing in a swine wound model; R Hernandez; Session 2, Group C 960 Novel Bioadhesives Based on Gelatin and Alginate with Controlled Release of Antibiotic Drug; M Foox; Session 2, Group D 961 Optimization of Electrospun Nanofiber Mats for Transdermal Delivery; E Kahraman; Session 2, Group C 962 P.L.E.A.S.E.® Fractional Laser Ablation for the Cutaneous Deposition of Triamcinolone Acetonide Loaded PLGA Microparticles; M Singhal; Session 2, Group D 963 Pharmacokinetic profile of donepezil hydrochloride microneedle encapsulation for the treatment of Alzheimer’s disease; J Kim; Session 2, Group C 964 PLGA/PEI/pH1N1 Polyplex coated Microneedle as an Efficient Transdermal DNA Vaccine Delivery System; H Seok; Session 2, Group D 965 Polymer-microneedles coated with a hydrophilic solution; H LEE; Session 2, Group C 966 Preliminary Studies on the Design of a Temperature Regulated Patch; K Dodou; Session 2, Group D 967 Propranolol and Timolol-Loaded Nanoparticles for Topical Treatment of Infantile Hemangiomas; N Brogden; Session 2, Group C 969 smartPearls for the Dermal Delivery of Physically Stable Amorphous Cyclosporine; C Keck; Session 2, Group C 970 smartPearls-Dermal Delivery System for Cosmetics and Consumer Care based on Amorphous Actives; C Keck; Session 2, Group D 971 smartPearlsTM for the Dermal Delivery of Azithromycin against Borreliosis Infection; R Mueller; Session 2, Group C 973 Sterilisation Considerations in the Preparation of Polymeric Microneedle Arrays: Enhancing Controlled Delivery of the Model Protein Ovalbumin; A Courtenay; Session 2, Group C 974 Studies on a semisolid emulsion of doxycycline for transdermal drug delivery; K Dodou; Session 2, Group D 975 Sustained Delivery of Peptides and Proteins by High Content Phospholipids-based Phase Separation Gel; T Gong; Session 2, Group C 976 Targeting of skin resident dendritic cells via laser microporation; Y Machado; Session 2, Group D 978 The hen’s egg chorioallantoic membrane (HET-CAM) test to predict the ophthalmic irritation potential of  cysteamine-containing gels: Quantification using Photoshop® and ImageJ; B McKenzie; Session 2, Group D 979 Thermosensitive Dendritic Polyglycerol-Based Nanogels for Cutaneous Delivery of Biomacromolecules; K Obst; Session 2, Group C 980 Transdermal and Dermal Drug Delivery by means of Polyglycerol-based Nanogels; F Rancan; Session 2, Group D 982 Transdermal Photodynamic Therapy Using Carbon Dot Chlorin e6 - Hyaluronate Conjugate; S Beack; Session 2, Group D

47

Experience the CRS Exposition! Join your colleagues in the Exposition Hall (Lennox Suite) to discuss profitable collaboration for discovery, solutions, and opportunities.

Exposition Hours Sunday, July 26 5:30 – 7:30 p.m.

Welcome Reception/Networking

Monday, July 27 9:30 – 10:30 a.m. 12:00 – 1:00 p.m. 4:30 – 5:30 p.m.

Meet with Exhibitors Meet with Exhibitors (lunch available for purchase) Happy Hour and Networking

Tuesday, July 28 9:30 – 10:30 a.m. 12:00 – 1:30 p.m. 3:00 – 4:30 p.m.

Meet with Exhibitors Meet with Exhibitors (lunch available for purchase) Meet with Exhibitors

Exhibitors The following descriptions, supplied by the exhibiting companies as of June 10, 2015, provide product, service, and contact information. Please see the program addendum for additional exhibitor information.

S 304

– Sponsor Adhesives Research/ARx, LLC, U.S.A., Tel: +1.717.235.7979, www.adhesivesresearch.com. Adhesives Research is a leading developer and ISO 9001 & 13485 certified manufacturer of specialty adhesives and films for transdermal, oral delivery and body-worn devices. ARx, LLC, is an FDA registered, fully GMP compliant, DEA licensed developer and manufacturer of specialty drug delivery systems including transdermal/topical patches and oral/mucosal thin films.

1101 Advanced Polymer Materials Inc., Canada, Tel:

100



48

+1.514.683.8488, www.apmpolymers.com. Advanced Polymer Materials Inc. is a Canada based manufacturing company with R&D capability. We produce innovative and unique biodegradable and biocompatible polymer materials to fill the need for scientific advancement in pharmacy and medicine. We also provide custom synthesized polymers upon demand and according to our customers’ specifications.

Agilent Technologies, Inc., United Kingdom, Tel: + 0845 712 5292, www.agilent.com. Agilent is a leader in the pharma, life sciences, diagnostics, and applied markets. The company provides laboratories worldwide with end-to-end solutions: instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent also ensures that your instruments and processes conform to the highest compliance.

704

Akina, Inc., PolySciTech Division, U.S.A., Tel: +1.765.464.0390, www.polyscitech.com. Research products available include biodegradable block and specialty copolymers (Polyvivo), fluorescent dyes (FlammaFluor), specialty chitosan variations (Kitopure), and release media (polyvitro). Custom synthesis to match your specification and contract analysis services are also available. Also available is 3DCellMaker media modifier to promote growth of cells into spheroids and 3D structures.

203

Ashland Specialty Ingredients, Switzerland, Tel: +41 52 560 5500, www.ashland.com.

902

Avanti Polar Lipids, Inc., U.S.A., Tel: +1.205.663.2494, www.avantilipids.com. Avanti Polar Lipids, with an unparalleled reputation for purity, is clearly established as world leader in the production of phospholipids, sphingolipids, and sterols. Exciting new products for the research chemist and cGMP lipids for pharmaceutical production. Recent developments include adjuvants, glycosylated sphingolipids, new fluorescent and deuterated lipids; plus analytical services.

701/ 801

BASF SE, Germany, Tel: +49 621 60 20173, www.pharma-ingredients.basf.de. BASF offers comprehensive solutions to the pharmaceutical industry, ranging from a broad, high-quality excipients portfolio to APIs. With its expertise in polymer chemistry, its worldwide R&D capabilities and the company’s commitment to developing value-adding excipients, BASF continuously creates solutions to challenges related to instant and modified release, solubilization, soft gels, and skin delivery.



S

103



303

101



601

901

400

S

BioNavis Ltd., Finland, Tel: +358 102715030, www.bionavis.com. BioNavis is a Finnish manufacturer of MP-SPR Navi™ research instruments, which is a powerful label-free method for drug delivery and targeting studies. Our instruments are based on MultiParametric Surface Plasmon Resonance (MP-SPR) that allows to: optimize targeting from small molecule weight drugs up to nanoparticles and viruses; evaluate affinity and kinetics of the molecular binding events; quantify drug-target, drug-lipid membranes and even drug-living cell monolayer interactions; distinguish paracellular and transcellular drug uptake; monitor drug release from polymer film in real time; reduce bulk effect by in-line measurements; and understand better your molecules with kinetics and dynamic conformation change information from MP-SPR.

604

Celanese EVA Polymers, U.S.A., Tel:

+1.972.443.4000, www.vitaldose.com. Celanese EVA Polymers combines the unique properties of VitalDose® excipients with high-touch service, indepth technical expertise, and comprehensive regulatory knowledge to help customers meet their product objectives. VitalDose® EVA polymers are used for controlled release drugs and medical applications through many routes of administration. Learn more at www.VitalDose.com.

200 Colorcon, United Kingdom, Tel: +44 1322 29 30 00,

www.colorcon.com. Colorcon is a world leader in the development, supply, and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our valueadded services, which support all phases of solid oral dose design and development.

BUCHI Labortechnik AG, Switzerland, Tel: +41 71 3946363, www.buchi.com/en/content/spray-dryingencapsulation-solutions. For more than 35 years BUCHI spray drying and encapsulation solutions have been appreciated by scientists worldwide. BUCHI encapsulation devices combined with a variety of glassware, nozzles and accessories allow you to achieve encapsulated particles from nano- to millimeter scale. Visit us at our booth to discuss your tailored solution.

804

Caleva Process Solutions, United Kingdom, Tel: +44 1258 47 11 22, www.caleva.com. Caleva Process Solutions Ltd. is a British-based designer and manufacturer of extruders and spheronizers for the pharmaceutical industry with more than 40 years’ experience. We specialize in design, build, and supply of equipment for production and laboratory development of pharmaceutical pellets (spheroids). Call us on +44 (0) 1258 471122.

903 CordenPharma, Switzerland, Tel: 1.800.868.8208,



S

Capsugel Dosage Form Solutions/Bend Research,

U.S.A., Tel: +1.541.382.4100, www.capsugel.com. Capsugel’s Dosage Form Solutions, including Bend Research and Encap, solves customers’ product development challenges, including bioavailability enhancement, modified release, and inhalation formulation. High-quality science and engineering is core to our offering at each stage of the product development cycle and has enabled the successful advancement of hundreds of compounds.

104



Captisol, a Ligand Technology, U.S.A., Tel:

+1.877.575.5593, www.captisol.com. Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This unique technology has enabled seven FDA-approved products, including Onyx Pharmaceuticals’ Kyprolis®, Baxter International’s Nexterone®, and Merck’s NOXAFIL IV.

Catalent Pharma Solutions, U.S.A., Tel:

+1.877.587.1835, www.catalent.com.

Corbion Purac Biomaterials, Netherlands, Tel: +31 183 695 529, www.corbion.com/biomedical. Corbion Purac Biomaterials has more than 40 years of experience as a leading global supplier of lactide/ glycolide resorbable homopolymers and copolymers. We offer a broad range of standard PURASORB® polymers and monomers as well as provide custom synthesis capabilities for specific formulation requirements.

www.cordenpharma.com/apis/derivitizedphospholipids. CordenPharma is your full-service CDMO partner in the contract development and manufacturing of APIs, drug products, and associated packaging services from R&D to commercialization. With multiple cGMP facilities across Europe and the United States, CordenPharma specializes in supplying custom synthesized materials such as lipids, peptides, carbohydrates, and conjugates.

Delta ModTech, U.S.A., Tel: +1.763.755.7744, www.deltamodtech.com. Delta ModTech® is dedicated to providing precise, flexible, and innovative manufacturing and packaging systems worldwide. Delta ModTech offers solutions for a variety of complex medical, pharmaceutical, label, and cosmetic products. Delta ModTech systems are designed and engineered to meet your application requirements, improve your profitability, and reduce your risk.

1200 Dissolution Technologies, U.S.A., Tel:

S

+1.302.235.0621, www.dissolutiontech.com. Dissolution Technologies is an international peer-reviewed, indexed quarterly journal reporting dissolution-related current information and scientific articles. The website, www. dissolutiontech.com, is searchable and contains the current and all back issues with articles available for free as a PDF download. Dissolution Technologies is celebrating twenty years of publishing this open-access journal. 49

1201 Drug Development & Delivery, U.S.A., Tel:

S

500

S

+1.973.299.1200, www.drug-dev.com. Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals working in research and development, pre-formulation, formulation development, bioavailability enhancement, particle design, APIs, and analytical methods. DURECT Corp./LACTEL® Absorbable Polymers,

U.S.A., Tel: +1.408.777.4927, www.absorbables.com. Visit LACTEL at booth #500 to inquire about our biodegradable polymers and their use in nano- and micro-based sustained release delivery systems. LACTEL polymers are also used in tissue engineering, electrospinning, 3D printing, drug-eluting stents, and more. We offer an extensive stock inventory and have substantial expertise in custom synthesis.

504 Elsevier, United Kingdom, +1.212.989.5800,



S

201



401

Evonik Industries AG, Germany, Tel: +40 6151 18 4019, www.evonik.com/healthcare. Evonik, a global leader in specialty chemicals, provides drug delivery technologies, API manufacturing, intermediates, and amino acids. Delivery technologies include development services, solubility enhancement, functional excipients, and GMP manufacturing for oral and parenteral formulations. Advanced delivery technologies provided for small molecules, peptides, proteins, antibodies, and nucleic acids used in extended-release parenterals. Freund-Vector Corporation, U.S.A., Tel: +1.319.377.8263, www.freund-vector.com. FreundVector Corporation is a world leader in the design, manufacturing, and marketing of solid dosage processing equipment for the coating, granulating, and drying of powders, granules, beads, and tablets for the pharmaceutical and healthcare industries. Product lines include tablet pan coaters, roll compactors, fluid bed granulators/coaters/dryers, and high-shear granulators and automated process control systems.

50

www.gattefosse.com. Gattefossé functional lipid excipients provide re-innovation opportunities in oral, topical, vaginal, and rectal drug delivery. Visit our stand to learn how lipid excipients modulate drug release, increase solubility and bioavailability in oral delivery; or how to improve skin penetration, texture, stability, and sensorial properties of topical medicines.

Gaylord Chemical Company, U.S.A., Tel: +1.985.649.5464, www.gaylordchemical.com. Gaylord Chemical produces Procipient® (dimethyl sulfoxide USP, PhEur) a high-purity DMSO manufactured according to ICH Q7 guidelines. It is supported by a Health Canada DMF, a Type II Drug Master File, and CEP granted by EDQM. Procipient is effectively utilized worldwide in numerous registered pharmaceutical dosages and medical devices.

1104 GRIFOLS, Spain, Tel: +34 935 71 01 65,



www.grifols.com. Grifols is a global healthcare company with a 75-year legacy of improving people’s health and well-being through the development of life-saving plasma medicines (i.e., albumin), hospital pharmacy products, and diagnostic technology for clinical use.

302

Hanson Research Corp., U.S.A., Tel: +1.818.882.7266, www.hansonresearch.com. Hanson Research Corp. is the longest-running engineering firm to specialize in dissolution and diffusion test technology. Founded in 1951 by the innovator of the world’s first dissolution tester, Hanson provides over half a century of research, service, and expertise in designing premium test equipment for QC and R&D labs worldwide.

905

Izon Science, United Kingdom, Tel: +44 1865 784 630, www.izon.com. Izon Science provides instrumentation for accurate nanoparticle characterisation in areas of nanomedicine, virus quantification, and extracellular vesicles. Unlike light scattering techniques, Izon Science’s Tunable Resistive Pulse Sensing (TRPS) technology provides real measurements for accurate and reliable measurement of size distribution, concentration, and surface charge of nano and microparticles.

www.elsevier.com. Elsevier publishes the Journal of Controlled Release, an official journal of the Controlled Release Society and the Japanese Society of Drug Delivery System. Elsevier is the leading publisher dedicated to providing authors the latest articles, tools, and resources within pharmaceutical sciences.

402 Gattefossé, France, Tel: +0033472229800,



803

703 MedPharm, United Kingdom, Tel: +44 483457580,

www.medpharm.co.uk. MedPharm is the market leader in the development, testing, and manufacture of products and technologies for topical (skin, nail, mucosal membranes, eye, nose, lung) and transdermal use. MedPharm has developed over 20 products in 15 years and develops proprietary topical and transdermal drug delivery systems to advance in collaboration with its partners.

403

Merck Millipore, Germany, Tel: +49 6151 72 00, www.merckmillipore.com. Merck Millipore is the life science business of Merck KGaA. We provide excipients, ODT technology, drug delivery compounds, and chemicals to support all stages of drug manufacturing from research to industrial-scale production and quality control. Our products meet the highest purity standards with EMPROVE® documentation and services ensuring regulatory compliance.

705

Mott Corporation, U.S.A., Tel: +1.860.747.6333, www.mottcorp.com. Mott provides porous metal membranes that are an enabling technology for sustained release devices by achieving accurate, repeatable diffusion or ultra-low flow control for a variety of molecules and formulations. The technology is adaptable for powered and non-powered devices and can also be configured to provide bacterial and nonbacterial filtration.

1102 NOF Corporation, Japan, Tel: +81 3 5424 6741,



www.dds-drug.com. NOF produce GMP-grade activated PEGs, phospholipids, ultra-pure polysorbate 20 and 80, ultra-pure poloxamer 188, and excipients for controlled release technology research and development, like SS-cleavable and pH-responsive lipid series for nucleic acid delivery. We continue to provide cutting-edge products for siRNA formulation, antibody drug conjugation, hydrogel medical devices, and targeted delivery of oncology drugs.

OctoPlus NV, Netherlands, Tel: +720 318 2339, www.octoplus.nl.

300

1204 OnDrug Delivery, United Kingdom, Tel: +44 1273

S

605



320279, www.ondrugdelivery.com. Celebrating its tenth anniversary in 2015, ONdrugDelivery Magazine is a series of themed drug delivery features magazines available in print and electronic versions. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 30,000, and with contributions and loyal support the most important companies in the drug delivery business—from among the largest to the smallest—ONdrugDelivery Magazine is a must for those in the industry who need to know what’s going on in drug delivery worldwide.

Pantec Biosolutions AG, Liechtenstein, Tel: +423 377 7800, www.pantec-biosolutions.com. Pantec Biosolutions is the leader in controlled transdermal drug and immunogen delivery utilizing advanced laser-based EPIMMUN™ technology. Together with research partners, Pantec Biosolutions carries out studies for oncology and allergy applications in the field of immunotherapy to enhance the value of existing immunogens and investigate novel forms of treatment.

1003 Patheon, U.S.A., Tel: +1.866.728.4366, www.patheon.

com. Patheon is a leading provider of contract development and commercial manufacturing services to the pharmaceutical and biotechnology sectors. The company offers one of the broadest sets of solutions to customers including commercial manufacturing, drug product services, biologics, pharmaceutical product development services and active pharmaceutical ingredients.

1203 Pharmaceutical Technology, U.S.A, Tel:

S

+1.732.346.3027, www.pharmtech.com. Pharmaceutical Technology is the authoritative source of peer-reviewed research and expert analysis for scientists, engineers, and managers engaged in process development, manufacturing, formulation and drug delivery, API synthesis, analytical technology and testing, packaging, IT, outsourcing, and regulatory compliance in the pharmaceutical and biotechnology industries.

1202 PharmaCircle LLC, U.S.A., Tel: +1.760.436.1199,

S

501





404





301



www.pharmacircle.com. PharmaCircle is a leading provider of global data and analysis on the pharmaceutical, biotechnology and drug delivery industries. PharmaCircle’s premier database connects product and pipeline information for drugs and biologics with formulation and component details, and provides due diligence level data on nearly 6,000 drug delivery technologies and devices. Pierre Fabre Medicament–Supercritical Fluids Division, France, Tel: +33563812450,

www.supercritical-solutions.com. Pierre Fabre Medicament, a French independent pharmaceutical laboratory, has developed a division using supercritical fluids. It proposes its expertise in supercritical fluids to external pharmaceutical laboratories for innovative pre-formulation of API (taste masking, enhancement of solubility and bioavailability), in extraction and purification, and in cleaning of medical devices. GMP supercritical CO2 unit. Polymun Scientific Immunbiologische Forschung GmbH, Austria, Tel: +43 2243 25060 300,

www.polymun.com. Polymun is a privately held CMO near Vienna, Austria. Core activities are contract development and manufacturing of biopharmaceuticals as well as liposomal formulations. Polymun operates in accordance with GMP guidelines and holds an Austrian production license, thus meeting all EU requirements for drug manufacturing, and is also inspected by FDA. Polysciences Inc., U.S.A., Tel: +1.215.488.7498, www.polysciences.com. Polysciences Inc. provides custom manufacturing and development of biodegradable materials for drug discovery and delivery, medical devices, biotechnology, electronics, and analytical chemistry industries, as well as high-purity optical monomers, UV absorbing materials, and specialty polymer additives to the ocular lens industry. To learn more, please visit www.polysciences.com or call +1.215.343.6484.

51

502

Powder Systems Limited (PSL), United Kingdom, Tel: +44 1514 487700, www.powdersystems.com. PSL is an international manufacturer of quality innovative technology and process solutions for the pharmaceutical and biopharmaceutical industries since 1989. PSL process experts developed the Microsphere Refiner technology for the sterile formulation of polymeric microspheres used as parenteral drugs for controlled release delivery. The technology allows filtration, classification, washing, and recovery.

805

Sirius Analytical, United Kingdom, Tel: + 44 1342 820 720, www.sirius-analytical.com. Established in 1989, Sirius Analytical specializes in the provision of instruments and CRO services, primarily to the pharmaceutical, biotechnology, academic, and agrochemical sectors. Sirius’s products and services focus on measurement. Properties include pKa, log P, log D, solubility, dissolution, particle size and shape analysis, and various other solid state properties.

Precision NanoSystems, Canada, Tel:

702

503



SOTAX AG, Switzerland, Tel: +41 61 487 54 54, www.sotax.com. SOTAX is a global leader in providing innovative solutions for pharmaceutical testing. The company offers high-quality dissolution testing systems, physical tablet testing instruments, automated sample preparation workstations for composite assay and content uniformity testing, as well as associated technical and application services. Since 2013, the Dr. Schleuniger® Pharmatron brand completes the SOTAX product portfolio and expertise in the physical testing segment.

904

Southwest Research Institute, U.S.A., Tel: +1.210.522.2913, www.swri.org. SwRI® provides extensive contract R&D capabilities, including the development of custom encapsulation and controlled release formulations for applications ranging from pharmaceuticals to consumer and diversified products. Capsules and particles can be prepared in sizes from nanometers to several millimeters. Biomaterials, materials development, synthesis, and modeling capabilities are also available.

603

+1.888.618.0031, www.precisionnanosystems.com. Precision NanoSystems’ proprietary microfluidic-based nanoparticle manufacturing platform enables the development and seamless scale-up of novel nanomedicines. The automated NanoAssemblr™ Benchtop Instrument is designed for rapid prototyping of nucleic acid-lipid nanoparticles, liposomes, and polymer nanoparticles. The NanoAssemblr™ Scale-Up System uses parallelized microfluidic mixers to produce clinical-scale batches using identical process conditions. ProMed Pharma LLC, U.S.A., Tel: +1.763.331.3817,

www.promedpharmallc.com. ProMed Pharma develops processes and platforms for controlled release of drugs utilizing a variety of molded polymer dosage forms. Device applications include drug eluting pacing leads, stents, catheters, and orthopedic implants. As a CMO/ CRO, ProMed also develops extended release formulations utilizing subcutaneous and ophthalmic implants, intrauterine devices, and intravaginal rings.

102 Shin-Etsu, Germany, Tel: +49 611 962 6199, www.se-pfmd.com. Shin-Etsu began producing pharmaceutical excipients in 1962. Shin-Etsu’s cellulose excipients can make a valuable contribution in various areas of pharmaceutical technology: for example, as film coatings (Pharmacoat), solid dispersion (Shin-Etsu Aqoat HPMCAS), matrix tablets (Metolose SR), enteric coating (HPMCP and HPMCAS), and ODT (L-HPC and SmartEx). 1001 Simcyp (A Certara Company), United Kingdom,





602





52

Tel: +44 1142922321, www.simcyp.com. Simcyp (a Certara company) scientists will be available to present the latest developments and advancements in the Simcyp Simulators. The simulator is widely used in the pharmaceutical industry to predict the impact of various factors including physiological and formulation parameters on drug absorption and bioavailability. The mechanistic physiologically based-IVIVC and Simcyp. Simulations Plus, U.S.A., Tel: +1.661.723.7723,

www.simulations-plus.com. GastroPlus sets the standard for PBPK/PD modeling for different administration routes in humans and animals plus population simulations and DDI capabilities. DDDPlus and MembranePlus offer simulations of in vitro dissolution and permeability experiments. The ADMET Design Suite mines compound libraries, designs new molecules, and virtually screens structures for >150 ADMET properties.

1002 Springer, Germany, Tel: +49 6221 487 0,



S

802

www.springer.com. Springer is the proud publishing partner of CRS, with the journal Drug Delivery and Translational Research and the flagship book series Advances in Delivery Science and Technology. Please stop by our booth to browse new products and order books at the conference discount. Stable Micro Systems Ltd., United Kingdom, Tel: +44 1483 427345, www.stablemicrosystems.com. Stable Micro Systems will be exhibiting the TA. XTplus, which can be used for many controlled release applications. It is ideal at measuring the fracture force of micro spheres, tablet swelling properties, and disintegration rates. Special devices are used for simulating and measuring muco and bio-adhesion together with tablet fracture properties.

1103 Wyatt Technology Corporation, U.S.A., Tel:

+1.805.681.9009, www.wyatt.com. Wyatt Technology is the recognized leader in instrumentation for determining the absolute molar mass, size, charge, and interactions of macromolecules and nanoparticles in solution. These tools include in-line multi-angle static light scattering, high-throughput dynamic light scattering, differential refractometry, electrophoretic mobility, differential viscosity, field flow fractionation, and automated composition gradient.

Sponsors of the 42nd Annual Meeting & Exposition of CRS Sponsors Make It Happen Many of the meeting events are possible only through the generosity of sponsors. Please join CRS in thanking our 2015 sponsors* who support delivery science and add substantial value to the CRS Annual Meeting & Exposition. *Sponsors as of June 10, 2015. Please see Program Addendum for additional sponsors.

BASF offers comprehensive solutions to the pharmaceutical industry, ranging from a broad portfolio of excipients to active ingredients. With its expertise in polymer chemistry, its research and development capabilities around the globe and the company’s clear commitment to developing pharmaceutical excipients, BASF continuously creates solutions that contribute to its customers’ success. BASFs high-quality ingredients and services can help with challenges related to instant and modified release, solubilization, soft gels, and skin delivery. www.pharma-ingredients.basf.com/Excipients/ Home.aspx Caisson Biotech has developed a biosuperior, biodegradable drug delivery system, HEPtune®. The heparosan polymer delivery vehicle overcomes challenges including immunogenicity, safety, solubility, half-life extension, and efficacy. Heparosan is degraded via natural pathways and is applicable to proteins, peptides, aptamers, fragmented antibodies, small molecules, coordination complexes, and liposomal and micellular delivery systems. www.caissonbiotech.com The Catalent Applied Drug Delivery Institute is passionate about improving outcomes for patients, providers, and innovators through expanded application of drug delivery technologies. We drive technology adoption by connecting leading academic and industry experts with educational symposia, resource development, and publications. We encourage dialogue, research, and innovation of drug delivery technologies. www.drugdeliveryinstitute.com Celator Pharmaceuticals is transforming combination therapy in oncology by creating a more effective way of studying, optimizing, and delivering a new generation of combination products to enhance outcomes for patients and providers. www.celatorpharma.com

Coating Place is a contract manufacturer specializing in Wurster fluid bed coating and related services for pharmaceutical, consumer, and diversified product areas since 1976. Services include formulation development, feasibility trials, scale-up, process validation, technical transfer, and contract processing. Technologies include extrusion/spheronization, ion resin complexes, tableting, capsule filling, pan coating, and a GLP support laboratory. www. coatingplace.com CordenPharma is your full-service partner in the contract development and manufacturing (CDMO) of APIs, drug products, and associated packaging services. Through a network of fully inspected cGMP facilities across Europe and the United States and legacy of platform technologies, CordenPharma experts translate complex ideas at any stage of development into highvalue products. www.cordenpharma.com Dissolution Technologies is an international peerreviewed, indexed quarterly journal reporting dissolution-related current information and scientific articles. The website, www. dissolutiontech.com, is searchable and contains the current and all back issues with articles available for free as a PDF download. Dissolution Technologies is celebrating twenty years of publishing this open access journal. www.dissolutiontech.com Diurnal Limited is a specialty pharmaceutical company based in the United Kingdom, and its mission is to address the major unmet patient needs in endocrinology by creating highquality products for lifelong treatment of chronic conditions. Diurnal’s lead products Infacort® and Chronocort® are in phase 3 testing to treat the rare disease congenital adrenal insufficiency. www.diurnal.co.uk

53

Sponsors The Dow Chemical Company provides unique and diverse solutions that enable consumer brands around the world to deliver exceptional product performance and process enhancements, such as controlled release of active ingredients. As a leader in material science, Dow’s portfolio of technologies and scientific knowledge can address the complex challenges associated with controlled release. www.dow.com

Microtek Labs Inc., Microtek leads the way in microencapsulation technologies. As a privately held company founded in 1985, we specialize in custom microencapsulation and product development services. From product conception, to process development, to full production, we strive to leverage our more than 100 years combined microencapsulation experience for the benefit of our clients. www.microteklabs.com

Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals working in research and development, drug delivery, preformulation, formulation development, bioavailability enhancement, particle design, APIs, and analytical methods. www.drug-dev.com

The Nagai Foundation Tokyo was founded in 1986 in commemoration of Prof. Tsuneji Nagai receiving the 1986 Hoest-Madsen Medal from FIP as the first for the Japanese. Then it was officially approved as governmentlicensed in 1994 for the purpose of promoting international exchange in pharmacy and pharmaceutical sciences, being specially approved as a public interest incorporated association in April 2012. www.nagai-found.or.jp

Envisia Therapeutics is committed to the discovery and development of novel therapies that address significant unmet medical needs in ophthalmology. Using the PRINT® technology, Envisia is rationally designing therapeutics that are precisely engineered to overcome the biologic, chemical, or other barriers that limit existing ocular therapies. www.envisiatherapeutics.com GrayBug is a preclinical-stage pharmaceutical company focused on developing breakthrough products for serious ocular diseases. The company is developing a continuum of therapeutic products for major ocular disease indications utilizing proprietary micro- and nanoparticle controlled-release technologies. The broad platform has applicability for potential strategic partnerships. www.graybug.com Visit LACTEL at booth #500 to inquire about our biodegradable polymers and their use in nano- and micro-based sustained release delivery systems. LACTEL polymers are also used in tissue engineering, electrospinning, 3D printing, drug eluting stents, and more. We offer an extensive stock inventory and have substantial expertise in custom synthesis. www.absorbables.com

54

Novaliq GmbH, based in Heidelberg, Germany, is a drug delivery company developing a superior generation of innovative ocular formulations for poorly soluble drugs based on its unique drug carrier platform and proprietary EyeSol® technology. The patented ocular formulations are based on highly biocompatible and non-aqueous liquids, which can be easily applied in the form of topical eye drops. A new generation of both prescription and consumer products is possible through the unique properties of the delivery vehicle. www.novaliq.de Celebrating its Tenth Anniversary in 2015, ONdrugDelivery Magazine is a series of themed drug delivery features magazines available in print and electronic versions. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 30,000, and with contributions and loyal support the most important companies in the drug delivery business - from among the largest to the smallest - ONdrugDelivery Magazine is a must for those in the industry who need to know what’s going on in drug delivery worldwide. www.ondrugdelivery.com

Sponsors ORA, Inc., is a global, full-service ophthalmic clinical research and product development firm. Over the past 30 years, it has helped clients earn 39 FDA approvals. ORA supports a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently and successfully bring their new products from concept to market. ORAa’s pre-clinical and clinical models, unique methodologies, and regulatory strategies have been refined and proven across thousands of projects both in the United States and internationally. ORA brings together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals in order to maximize the value of new product initiatives. For additional information, please visit http://oraclinical.com. At Pfizer, we strive to set the standard for quality, safety, and value in the discovery, development, and manufacturing of medicines for people. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. www.pfizer.com Pharmaceutical Technology offers news, analysis, and peer-reviewed PharmTech.com research in formulation development (including excipients) and drug manufacturing to more than 38,000 decision makers in the top pharmaceutical, specialty pharmaceutical, and biotechnology companies via the Pharmaceutical Technology print magazine, PharmTech.com, and three newsletters: ePT, Sourcing and Management, and the Equipment and Processing Report. www.pharmtech.com Advancing Development & Manufacturing

Founded in 2003, PharmaCircle is a leading provider of global data and analysis on the pharmaceutical, biotechnology, and drug delivery industries. PharmaCircle’s premier database connects product and pipeline information for drugs and biologics with formulation and component details, and provides due diligence level data on nearly 6,000 drug delivery technologies and devices. www.pharmacircle.com

Phoenix Research Labs’ Micron IV Retinal Imaging System is designed specifically for in vivo use with lab animals to advance eye and eye-brain research. Using the Micron IV you can capture stunning retinal images in bright field, angiography, or fluorescent modalities. Scale and extend your research capabilities by adding modules for true image-guided OCT, focal ERG, anterior segment imaging, and image-guided laser delivery. For more information, visit www.phoenixreslabs.com. pSivida Corp. products deliver drugs and biologics at controlled, steady rates for weeks, months, or years. pSivida developed three of four FDAapproved sustained release drugs for ophthalmology (Vitrasert®, Retisert®, and ILUVIEN®). pSivida’s Medidur™ is in phase III clinical trials for posterior uveitis. Preclinical research focuses on ocular and systemic delivery of biologics and drugs for ophthalmic and non-ophthalmic diseases. www.psivida.com Ronald T. Dodge Company has extensive capabilities and technology in the complex field of microencapsulation. We serve clients around the world with applications know-how using technology platforms from fluid bed coating to parylene coating. Capsule sizes range from the nanoparticle level to 2.55 mm. www.rtdodge.com Springer is the proud publishing partner of CRS, with the journal Drug Delivery and Translational Research and the flagship book series Advances in Delivery Science and Technology. Please stop by our booth to browse new products and order books at the conference discount. www.springer.com Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions that measurably improve individuals’ lives. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.

CRS thanks Marketing Edinburgh and VisitScotland for their support of the 2015 CRS Annual Meeting & Exposition.

55

2015 CRS Awards & Recognition Join Us in Celebrating Our Esteemed Colleagues The Controlled Release Society is proud to honor this year’s awardees for their dedication and contributions to delivery science and CRS. Join us in honoring all stages of what it means to be a delivery scientist, from recognizing tomorrow’s leaders with the Postdoctoral Achievement Award of the Foundation’s prestigious fellowship to celebrating the lifelong dedication of our newest inductees into the College of Fellows. Awards will be given at the opening session and the three plenary sessions. See individual award times on the following pages. Congratulations, 2015 CRS awardees!

2015 Annual Meeting Program Committee

Thank You Outgoing Board Members

Thank you to this year’s Annual Meeting Program Committee for their time and talents in planning this scientifically outstanding meeting.

With immense appreciation and sincere gratitude, we honor the following members of the Board of Directors for their leadership and service to CRS over the past years:

Chair Justin Hanes Johns Hopkins University, U.S.A. Deputy Chair Kinam Park Purdue University, U.S.A. Team Members Adah Almutairi University of California, U.S.A. You Han Bae University of Utah, U.S.A. Igor Bodnár Firmenich, Switzerland David Brayden University College Dublin, Ireland Doug Dale DuPont Industrial Biosciences, U.S.A. Bill Lambert Omeros Corp., U.S.A. Yvonne Perrie Aston University, United Kingdom Suzie Pun University of Washington, U.S.A. Ilva Rupenthal University of Auckland, New Zealand Ron Smith Merck & Company, Inc., U.S.A.

56

Yvonne Perrie Director-at-Large Aston University, United Kingdom

Ian Tucker Immediate Past President University of Otago, New Zealand

Special thanks and appreciation to the following members of the Board of Scientific Advisors who will be rotating off the committee for their service to CRS over the past three years. • Edith Mathiowitz, Brown University, U.S.A. • Terry Allen, University of Alberta, Canada • Jake Barralet, McGill University, Canada • Charles Frey, Coating Place Inc., U.S.A. • Justin Hanes, Johns Hopkins University, U.S.A. • Leaf Huang, University of North Carolina, U.S.A. • Gert Storm, Utrecht University, The Netherlands • Ernst Wagner, Ludwig Maximillians University, Germany

Distinguished Service Award The Distinguished Service Award is presented to a CRS member who has exhibited exceptional commitment and service to the society and is selected by the Board of Directors. Presentation: Opening Session, Monday, July 27 8:00 – 9:30 a.m. Kinam Park received his Ph.D. in pharmaceutics from the University of Wisconsin in 1983. After postdoctoral training in the Department of Chemical Engineering at the same university, he joined the faculty of Purdue University in 1986. Since 1998, he has held a joint appointment in the Department of Biomedical Engineering, and he became the Showalter Distinguished Professor of Biomedical Engineering in 2006. His research focuses on oral delivery, drug-device combination products, and long-term microparticle formulations. He is the founder of Akina, Inc., specializing in polymers for drug delivery. He is currently the editor-in-chief of the Journal of Controlled Release.

College of Fellows The College of Fellows recognizes those members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years. Contributions may have been technical, scientific, and/or managerial in one or more fields of research, commercial development, education, and/or leadership within the areas of interest to CRS. Fellowship is the most prestigious level of membership in CRS. Presentation: Opening Session, Monday, July 27 8:00 – 9:30 a.m. Hamid Ghandehari is a professor of pharmaceutics and bioengineering at the University of Utah. His laboratory pioneered the use of recombinant polymers for controlled gene delivery, designed watersoluble polymers for targeted delivery of bioactives to sites of tumor angiogenesis, and investigated transepithelial transport of poly(amido amine) dendrimers for oral drug delivery and the influence of shape, size, and surface properties of inorganic nanoconstructs on cellular uptake and toxicity. Dr. Ghandehari has authored nearly 150 peer-reviewed articles and given 200 invited talks. He joined CRS in 1992 and currently serves as a member of the CRS Board of Scientific Advisors.

Edith Mathiowitz is a full professor of medical science and engineering at Brown University in the Department of Molecular Pharmacology, Physiology, and Biotechnology. Her extensive experience includes development of polymers that are used in drug and gene delivery systems and tissue engineering applications, including stem cell recruitment. Dr. Mathiowitz trained as a postdoctoral associate with Prof. Robert Langer at the Massachusetts Institute of Technology. Dr. Mathiowitz’s work not only resulted in major publications but also translated into two startup companies, Spherics, Inc., and Perosphere, Inc., which focus their efforts on developments to improve patient compliance. Samir Mitragotri is a professor of chemical engineering at the University of California, Santa Barbara. His research interests are in the field of transdermal drug delivery, oral drug delivery, and nanoparticle-based drug delivery systems. He has published around 200 papers and is an inventor of around 100 pending or issued patents. He is a member of the National Academy of Engineering and an elected fellow of the National Academy of Inventors, the American Institute for Medical and Biological Engineering, and the American Association for the Advancement of Science. He is an associate editor of the Journal of Controlled Release. Yvonne Perrie is the head of pharmacy and chair in drug delivery within Aston Pharmacy School, Aston University, Birmingham, United Kingdom. She has a B.Sc. (first-class honors) in pharmacy from Strathclyde University. Yvonne attained her Ph.D. from the University of London under the supervision of Prof. Gregoriadis. Yvonne’s research is multidisciplinary and is focused on the development of drug carrier systems to facilitate the delivery of drugs and vaccines, providing practical solutions for current healthcare problems. Yvonne has published approximately 100 peer-reviewed papers, 5 patents, and 4 textbooks. Thomas Rades is the research chair in pharmaceutical design and drug delivery in the Department of Pharmacy, University of Copenhagen, Denmark. His research interests include the solid state of drugs and dosage forms, and nanoparticles as delivery systems for drugs and vaccines. Research in both areas aims to improve drug therapy through appropriate formulation and characterization of medicines and to increase understanding of the physicochemical properties of drugs and medicines. Prof. Rades is an editor of the Journal of Pharmaceutical Sciences and the European Journal of Pharmaceutics. He holds an honorary doctorate from Åbo Akademi University, Finland.

continued 57

Founders Award

Outstanding Pharmaceutical Paper Award

The society grants this honor to a current CRS member who is internationally recognized for outstanding contributions in the science and technology of controlled release.

Cosponsored by PharmaCircle

Presentation: Opening Session, Monday, July 27 8:00 – 9:30 a.m. Award Lecture: Starting up a New Life Science Company Gary W. Cleary is an internationally recognized scientist in the field of drug delivery systems and polymer technologies as well as founder and cofounder of Cygnus and Corium, Inc., both drug delivery companies where he has served as chairman, president, and chief technology officer. He holds 50 patents in this area. He has received several entrepreneur of the year awards from Life Sciences for Northern California, New Jersey Center for Biomaterials, AAPS Rainer Hoffman Award, and the UCSF Distinguished Alumnus Award. During his career he has held research and management positions at the U.S. Public Health Service, FDA, Alza, Key Pharmaceuticals, Genentech, Cygnus, and Corium. Cleary has a Pharm.D. (University of California, San Francisco), Ph.D. (Rutgers), and MBA (University of Miami).

CRS/T. Nagai Postdoctoral Research Achievement Award Cosponsored by The Nagai Foundation Tokyo This award recognizes an individual postdoc who has recently completed postdoctoral research in controlled release science and technology and the postdoc’s advisor, who played an integral role in the achievements. Presentation: Opening Session, Monday, July 27 8:00 – 9:30 a.m.

This award recognizes a CRS member whose wining abstract relates specifically to pharmaceutical research. A New Structural Design of a Closed-Loop Insulin Delivery Implant Extends the Duration of Insulin Efficacy in a Type 1 Diabetic Rat Model by Impeding Immune Cell Infiltration Author present: Monday, July 27, during Poster Session I at poster #61 from 9:30 – 10:30 a.m. Tuesday, July 28, during Research Highlight Talk in the Delivery of Peptides and Proteins Session, 2:10 – 2:15 p.m. Jason Li received a master’s degree in mechanical and biomedical engineering in 2011 from the University of Toronto, Canada, and is currently a Ph.D. candidate in the Department of Pharmaceutical Sciences at the University of Toronto. His research experience spans the development of nanomaterials-based diagnostic biosensors, implantable closed-loop drug delivery systems, nano-medicines for drug delivery and imaging applications, and the application of these technologies to both in vitro and whole animal models of bone remodeling, diabetes, and cancer.

Jorge Heller Journal of Controlled Release Outstanding Paper Award Cosponsored by Elsevier This award recognizes an outstanding regular paper related to the science of controlled release (not an invited, review, or special meeting paper) that was published during 2014 in the Journal of Controlled Release.

Award Lecture: Endosomal Escape: Elusive or Illusive

Presentation: Plenary Session, Tuesday, July 28 8:00 – 9:30 a.m.

Gaurav Sahay is an assistant professor in the College of Pharmacy at Oregon State/ Oregon Health Science University. Profs. Robert Langer and Daniel Anderson served as his mentors for postdoctoral training at the Massachusetts Institute of Technology. Dr. Sahay received his Ph.D. under Prof. Alexander Kabanov at the University of Nebraska. Currently, Sahay Lab is dissecting the molecular mechanisms involved in intracellular trafficking of nanomedicines and engineering methods to trigger their endosomal escape for cytosolic delivery of RNA therapeutics. Advisors: Prof. Robert Langer and Prof. Dan Anderson, MIT, U.S.A.

Richard J. Price, Ph.D., is a professor of biomedical engineering at the University of Virginia (UVA). Early in his career, he performed seminal studies demonstrating that microbubble activation with ultrasound could be used to deliver nanoparticles across endothelial barriers. His current research centers on the use of MRI-guided focused ultrasound for targeting the delivery of drugs and genes across the blood-brain barrier for the treatment of brain tumors and the prevention of Parkinson’s neurodegeneration. He is also the research director of the UVA Focused Ultrasound Center. In this capacity, he leads an institution-wide effort to identify, investigate, and translate new focused ultrasound applications.

Outstanding Annual Meeting Abstract Paper Awards

Non-invasive Delivery of Stealth, Brain-Penetrating Nanoparticles Across the Blood−Brain Barrier Using MRIGuided Focused Ultrasound Journal of Controlled Release 189: 123-132 (2014) Richard J. Price, Elizabeth Nance, Kelsie Timbie, G. Wilson Miller, Ji Song, Cameron Louttit, Alexander L. Klibanov, Ting-Yu Shih, Ganesh Swaminathan, Rafael J. Tamargo, Graeme F.Woodworth, Justin Hanes, and Richard J. Price

Presentation: Opening Session, Monday, July 27 8:00 – 9:30 a.m.

58

Drug Delivery and Translational Research Outstanding Paper Award Cosponsored by Springer This award recognizes outstanding research in the field of drug delivery and translational research that was published during 2014 in Drug Delivery and Translational Research.

Your Membership: Your Access to the Future of Delivery Science and Technology

Presentation: Plenary Session, Tuesday, July 28 8:00 – 9:30 a.m. Kanjiro Miyata received his Ph.D. under the supervision of Kazunori Kataoka in the Department of Materials Engineering, University of Tokyo, in 2006. From 2006 to 2009, he worked as an assistant professor in the Department of Bioengineering. In 2009, he moved to the Center for Disease Biology and Integrative Medicine, University of Tokyo. Since 2013, he has been an associate professor in the center. His main research interest is smart polymeric nanocarriers for nucleic acid delivery. Kazunori Kataoka, Ph.D., is a professor of biomaterials at the Graduate School of Engineering, University of Tokyo, Japan. He has been appointed to a joint position since 2004 at the Graduate School of Medicine, University of Tokyo, as a professor of clinical biotechnology at the Center for Disease Biology and Integrative Medicine. He served as a president of the Society of Polymer Science, Japan (2010–2012) and as a president of the Controlled Release Society (2012–2013). He is a founding fellow of the CRS College of Fellows (2010). He is on the editorial and advisory boards of 14 international journals, and he has been the editor of Journal of Biomaterials Science, Polymer Edition since 2004. His current major research interest is supramolecular materials for nanobiotechnology, particularly focusing on drug and gene targeting, and he has published more than 500 papers with an h-index of 113 (Google Scholar). Multifunctional Polyion Complex Micelle Featuring Enhancedstability, Targetability, and Endosome Escapability for Systemic siRNA Delivery to Subcutaneous Model of Lung Cancer Drug Delivery and Translational Research 4: 50-60 (2014) Hyun Jin Kim, Takehiko Ishii, Meng Zheng, Sumiyo Watanabe, Kazuko Toh, Yu Matsumoto, Nobuhiro Nishiyama, Kanjiro Miyata, and Kazunori Kataoka

Exclusive Benefits in Research •  Online subscription to Drug Delivery and Translational Research (DDTR) •  Subscription to the CRS Newsletter •  Journal of Controlled Release discounted subscription • Discounts on registration fees for the CRS Annual Meeting & Exposition •  Peer-reviewed webinars, including recorded presentations from annual meetings

Make Connections •  Join a national, regional, or student chapter •  Utilize the membership directory • Access communities of experts in specialized areas • Participate in Young Scientist activities • Attend CRS meetings

Ensure Your Future •  Volunteer •  Participate in the Mentor Event at the Annual Meeting • Gain recognition through CRS awards • Utilize the online career center

Take advantage of all your membership has to offer. Access it online now.

controlledreleasesociety.org Syringe and white capsule images courtesy of istock.com. Hygiene products image courtesy of shutterstock.com.

59

Acknowledgements Volunteers Make It Happen From annual meeting program planning to specialized committees providing leadership and oversight on everything from awards to satellite meetings, CRS volunteers are the engines that drive our society forward. In return, they gain valuable experiences, professional connections, and the knowledge that they have made a real difference in their careers and in their profession. Thank you to the many volunteers listed here who have served CRS during the past year.

CRS Board of Directors

Board of Scientific Advisors

President: Arthur J. Tipton Southern Research Institute, U.S.A.

Secretary: Christine J. Allen University of Toronto, Canada

Chair: Edith Mathiowitz

President-Elect: Debra J. Bingham Valeo Partners, U.S.A.

Director-at-Large: Maria Jose Alonso University Santiago de Compostela, Spain

Members: Theresa M. Allen, Marcel B. Bally, Jake E. Barralet, Charles R. Frey, Hamid Ghandehari, Justin S. Hanes, Leaf Huang, Akihiko Kikuchi, Richard W. Korsmeyer, Glen S. Kwon, Claus-Michael Lehr, Barbara Lueckel, Suzie Pun, Gert Storm, Ernst Wagner.

Immediate Past President: Ian G. Tucker University of Otago, New Zealand

Director-at-Large: Ben J. Boyd Monash University, Australia

Treasurer: Ruth B. Schmid SINTEF, Norway

Director-at-Large: Andrew L. Lewis Ipsen, France

Treasurer-Elect: Christopher W. McDaniel White Creek Pharma Advisors, U.S.A.

Director-at-Large: James D. Oxley Southwest Research Institute, U.S.A.

2015 Annual Meeting Program Committee Chair: Justin S. Hanes. Deputy Chair: Kinam Park. Members: Adah Almutairi, You Han Bae, Igor Bodnar, David J. Brayden, Douglas A. Dale, William Lambert, Suzie Pun, Ilva D. Rupenthal, Ronald L. Smith. Board Liaison: Yvonne Perrie. Annual Meeting Committee Chair: Christian Seiler. Members: Steven A. Giannos, Sandra Klein, Richard W. Korsmeyer, Ron Ortiz, Nicole Papen-Botterhuis, Mark R. Prausnitz, Ruth B. Schmid. Board Liaison: Debra J. Bingham. Audit Committee Chair: Ruth B. Schmid. Deputy Chair: Christopher W. McDaniel. Members: Miriam Girones, Julius F. Remenar, Patrick A. Walters.

60

Deputy Chair: Thomas Rades

Board Liaison: Christine J. Allen.

Director-at-Large: Yvonne Perrie Aston University, United Kingdom

College of Fellows Selection Committee Chair: Ronald J. Versic. Deputy Chair: Ronald A. Siegel. Members: Theresa M. Allen, Lisa Brannon-Peppas, Susan M. Cady, Joseph Kost, Jean-Christophe Leroux. Board Liaison: Ian G. Tucker.

Consumer and Diversified Products Division Committee Chair: Christopher W. McDaniel. Deputy Chair: Fanwen Zeng. Past Chair: Nicole Papen-Botterhuis. Secretary: Kenneth H. Carson. Members: Igor Bodnar, John C. Brahms, Craig R. Bunt, Douglas A. Dale, Jiten O. Dihora, Charles R. Frey, Irwin C. Jacobs, Jei C. McKinney, Joke Meeus, JeanAntoine Meiners, Claudio Ortiz, James D. Oxley, Ruth B. Schmid, Tapashi Sengupta, Ronald J. Versic, Teresa Virgallito. Board Liaison: James D. Oxley.

CRS Foundation Chair: Randall J. Mrsny. Members: Susan M. Cady, Richard H. Guy, Kinam Park. Board Liaison: Ian G. Tucker.

CRS Founders Award Chair: Richard H. Guy. Deputy Chair: Paolo Colombo. Members: Tamara Minko, Francis C. Szoka, Jr.

CRS Journal of Controlled Release Best Paper Award Chair: Thomas Rades. Deputy Chair: Veronique Preat. Members: Abdul W. Basit, Elias Fattal, JeanChristophe Leroux, Anette Mullertz, Yvonne Perrie, Steven P. Schwendeman.

CRS Outstanding Pharmaceutical Paper Award Chair: Hamid Ghandehari. Members: Laura Marie Ensign, Arash Hatefi, Seulki Lee.

CRS T. Nagai Postdoctoral Research Achievement Award Chair: Ernst Wagner. Members: Mansoor M. Amiji, Elias Fattal, Leaf Huang, Glen S. Kwon.

CRS Young Investigator Award Chair: W. Mark Saltzman. Members: Ali Khademhosseini, Joachim Kohn, Claus-Michael Lehr.

Drug Delivery and Translational Research Outstanding Research Paper Selection Committee Chair: Elka Touitou. Deputy Chair: Padma V. Devarajan. Members: Franco Alhaique, Sing Yian Chew, David R. Friend, Kenneth A. Howard, Vinod D. Labhasetwar, Natalie Medlicott, V. Prasad R. Shastri.

Drug Delivery and Translational Research Editorial Board Editor-in-Chief: Vinod D. Labhasetwar. Associate Editors: Martyn C. Davies, Kensuke Egashira, Justin S. Hanes. Editors: Rinti Banerjee, Raymond T. Bartus, Jayesh Bellare, Ben J. Boyd, Diane J. Burgess, Perry Calias, Sing Yian Chew, Mark Davis, Kenneth A. Dawson, Farid A. Dorkoosh, Elazer R. Edelman, Pierandrea Esposito, David R. Friend, Rogerio S. Gaspar, Kenneth A. Howard, Jeffrey A. Hubbell, Lisbeth Illum, Mansoor A. Khan, Robert Levy, Weiyue Lu, David M. Lynn, Natalie Medlicott, Tamara Minko, Samir Mitragotri, Kinam Park, Mark R. Prausnitz, Suzie Pun, Michael J. Rathbone, V. Prasad R. Shastri, Lonnie D. Shea, Patrick J. Sinko, Thomas R. Tice, Elka Touitou, Ijeoma Uchegbu, Xiao Yu Wu, Qiang Zhang.

Finance Committee Chair: Ruth B. Schmid. Deputy Chair: Christopher W. McDaniel. Members: Weiguo Dai, Bastiaan J. DeLeeuw, Don Enns, Miriam Girones, Julius F. Remenar, Patrick A. Walters.

International Committee Chair: Ronit Satchi-Fainaro. Deputy Chair: Michael Doschak. Past Chair: Claudio Ortiz. Members: Christophe J. Barbe, Shiow Fern Ng. Board Liaison: Maria Jose Alonso.

Newsletter Committee Chair: Yvonne Perrie. Deputy Chair: Roderick B. Walker. Members: Charles R. Frey, Steven A. Giannos, Arlene McDowell, Bozena B. Michniak-Kohn.

Nominating Committee

CRS Local Chapters

Chair: Ian G. Tucker. Members: Debra J. Bingham, Diane J. Burgess, Charles R. Frey, Sevda Senel, Istvan Toth, Mark A. Tracy.

Australian Local Chapter President: Ben J. Boyd Canadian Local Chapter President: Todd R. Hoare China Local Chapter President: Wei-San Pan Germany Local Chapter President: Regina Scherliess Greece Local Chapter President: Panos Macheras India Local Chapter President: Amarjit Singh Israeli Local Chapter President: Dan Peer Italy Local Chapter President: Bice A. Conti Malaysia Local Chapter President: Mohd Cairul Iqbal Mohd Amin New Zealand Local Chapter President: Arlene McDowell Nordic Local Chapter Chair: Ingunn Tho Spain-Portuguese Local Chapter President: Adolfina Ruiz Martinez Taiwan Local Chapter President: Ming-Thau Sheu Turkey Local Chapter President: Yildiz Ozsoy-Erginer United Kingdom-Ireland Local Chapter President: Gavin Andrews

Preclinical Sciences and Animal Health Division Chair: Peter Cheifetz. Deputy Chair: Terry L. Bowersock. Past Chair: Marilyn N. Martinez. Members: David J. Brayden, Raquel De Souza, Praveen S. Hiremath, Michail Kastellorizios, Tim McCaffery, Sevda Senel, Thierry Vandamme. Board Liaison: Andrew L. Lewis.

Satellite Meeting Committee Chair: Khaled Greish. Deputy Chair: Chi-Hwa Wang. Members: JeanAntoine Meiners, James D. Oxley, Teresa Virgallito, James B. West. Board Liaison: Christopher W. McDaniel.

Volunteer Recruitment Committee Chair: Louise RosenmayrTempleton. Deputy Chair: Biana Godin Vilentchouk. Past Chair: Arlene McDowell. Members: David Chen, Prajakta DandekarJain, Medha D. Joshi, Defang Ouyang, Jennifer Wong. Board Liaison: Ben J. Boyd.

Young Scientist Committee Chair: Patrick Lim Soo. Deputy Chair: David Chen. Past Chair: Joshua J. Reineke. Members:Patrick Baumhof, Adam Bohr, Kaushalkumar Dave, Raquel De Souza, Emmanuel Ho, Joke Meeus, Shiow Fern Ng, Yewande I. Oni, Jill M. Steinbach, Jorrit Water, Jennifer Wong, Jinzi Zheng. Board Liaison: Maria Jose Alonso.

CRS Student Chapters Student Chapter Connecticut President: Michail Kastellorizios Student Chapter Illinois President: Yu Zhang Student Chapter NJ/NY/PA President: Tannaz Ramezanli Student Chapter The Hebrew University of Jerusalem Chair: Aniv Mann Student Chapter University of Missouri Kansas City President: Vivek Agrahari

61

2015 CRS Presenting Author Index Abstract authors named as the presenting author for a particular abstract can be found in the index below. To search all authors of an abstract, please use the CRS Annual Meeting App or CRS website. A. Santos, H..........................524 Abdel-Bar, H. M...................405 Abdelkader, H................ 125, 437 Abdel-Mottaleb, M. M..........729 Abelha, T. F............................181 Abu Ammar, A......................544 Adebisi, A..............................491 Aguirre, T. A..........................115 Ahmad Khanbeigi, R.............691 Ahnfelt, E..............................464 Alcaraz, N. A.........................809 Algahtani, M. S......................230 Algul, D.................................625 Alhijjaj, M..............................260 Al-Jamal, K. T................ 103, 574 Al-Kassas, R..........................643 Al-kinani, A. A.............. 431, 506 Almansour, K.........................128 AL-Mayahy, M. H.................944 Alpar, H.................................110 Alsaadi, M. M........................601 Alsaddique, J..........................119 Alshamsan, A.........................718 Alshehri, A............................862 Alyami, H..............................214 Amini, M. A..........................674 Ando, D...................................81 Appold, L..............................235 Araœjo, F.................................60 Arya, J....................................145 Asare-Addo, K.......................250 Asik, C...................................941 Asthana, G. S.........................880 Attias, S.................................789 Aytekin, E..............................284 Azagury, A.............................184 Bae, Y. H..................................22 Baker, C.................................512 Baker, C. M............................517 Bala, V....................................346 Balasso, A...............................769 Ball, R. L................................887 Barlow, J.................................518 Barrett, S. E.............................41 Barthold, S.............................503 Bar-Zeev, M..........................277 Bauer, F..................................329 Beack, S.................................982 Behar-Cohen, F. F....................27 Beloqui, A..............................589 Berthier, D. L.........................508 Bhattacharjee, S.......................59 Bhusal, P................................189 Bienk, K.................................844 Bikiaris, D..............................582 Bisht, R..................................482 Biswas, S................................838 Blanco, E...............................784 Blanco-Prieto, M. J................137 Bochicchio, S..........332, 336, 826 Bolkestein, M.........................616 Borkar, N...............................385

62

Box, K. J.......... 130, 265, 279, 378 Boyd, B. J...............................489 Brannigan, T. I.......................319 Brennan, C.............................321 Brogden, N. K................ 956, 967 Bronich, T. K..........................804 Buanz, A................................180 Bunker, A...............................721 Caban, S.................................647 Caffarel-Salvador, E...............948 Calixto, G...................... 228, 239 Calles, J. A.............................442 Caló, E...................................921 Campbell, S. B.......................450 Cano-Sarabia, M...................564 Caramella, C..........................958 Cascante, A............................543 Castoldi, A.............................612 Castro-Vidal, D. A.................800 Cavalli, R...............................726 Cavanagh, R..........................338 Cech, T............ 322, 323, 342, 937 Celli, G. B..............................360 Chae, B..................................291 Chang, L. C...........................456 Chang, R. S............................112 Charde, S. Y...........................297 Chen, K. J..............................454 Chen, K. Y.............................142 Chen, S. Y..............................705 Chen, S..................................836 Chen, W.................................640 Chereddy, K. K.......................587 Chickmath, B.........................309 Chiu, H. C.............................750 Choi, I. J.................................942 Choi, W.................................455 Christensen, D.........................13 Chung, T. W...........................664 Citossi, F................................490 Conceição, J...........................292 Conti, B..................400, 532, 757 Courtenay, A. J.......................973 Crecente-Campo, J................584 Crofts, F. J..............................580 Csaba, N..................................75 Dahlgren, D...........................331 Dahmash, E. Z......................257 Dakwar, G. R.........................885 Dall, O. M.............................156 Dalmoro, A.............523, 645, 768 Dandekar, P............................912 d’Angelo, I.............................465 d’Arcy, R................................741 Darville, N.............................418 Das, M. K..............................572 das Neves, J............................438 Dave, R..................................519 David, A................................891 Davidson, S............................570 de Juan, E.................................28 de la Fuente, M......................702

De Leeuw, M.........................495 De Souza, R................... 537, 759 Deng, W.................................397 Dening, T. J............................375 Desai, D...................................30 Devoldere, J............................859 di Cagno, M. P.......................177 Díaz-Herráez, P.....................553 Dixon, J. E.............................104 Dodou, K....................... 966, 974 Donaghey, R..........................202 Dorkoosh, F............742, 765, 823 Doshi, P.................................308 Dougall, P. W.........................391 DSouza, B................................89 Du, J. D..................................792 Dubbelboer, I. R....................432 Dudzinska, N.........................300 Dufes, C................................900 Duffau, E...............................415 Durymanov, M. O.................874 Ehrenberger, S. S....................467 Eilleia, S. Y.............................135 Elbayoumi, T. A............. 469, 929 Eliasof, S..................................21 Eloy, J. O................................773 Engelhardt, K........................888 Engels, S. M...........................272 England, R. M.......................416 Erdal, M. S.............................951 Erickson, S. R........................434 Evans, P..................................313 Faham, A.................................15 Fahier, J. L..............................209 Faivre, J..................................594 Fallows, S. J............................369 Fan, W.....................................67 Fang, J....................................793 Fattal, E.................................797 Fazli, A. A..............................372 Fernández Piñeiro, I...............256 Ferreira, D. S.................. 624, 832 Fichtner, M............................694 Fischer, D...............................922 Fong, W. K.............................650 Fonte, P..................................108 Foox, M.................................960 Fortier, C...............................908 Frank, J...................................685 Fritz, T...................................716 Fu, Y......................................539 Fuchs, K.................................430 Fuhrmann, G.........................651 Gadgil, P................................623 Gaillard, P. J...............................2 Gallagher, K. H......................220 Gander, B.................................93 Garanti, T...............................398 Garbayo, E.............................131 Garcia, J.................................734 Garc’a-D’az, M......................358 Garcia-Fuentes, M.................488

Garrett, L. M.........................324 Gasco, P...................................44 Gattani, Y. S...........................306 Gelfuso, G. M........................656 Gemeinhart, R. A..................504 Ghori, M. U...........................380 Giles, M. B...............................69 Gleeson, J. P...........................340 Glöckl, G...............................298 Godin, B................................728 Goharzadeh, M......................315 Golomb, G........ 72, 560, 657, 896 Golombek, S. K......................231 Gong, T..................................975 Gordon, S..............................690 Gräf, F....................................186 Grassi, M...............................348 Gratieri, T..............................954 Greish, K...............................710 Grigoletto, A..........................107 Grizic, D................................622 Guillot, A...............................172 Gupta, A................................466 Gupta, P......................... 310, 328 Haber, T.................................600 Hafner, A...............................706 Hagner Nielsen, L.................366 Hahn, S. K.............................126 Hamano, N............................443 Hamed, A..............................492 Han, H. S...............................571 Han, J.....................................696 Han, M. R..............................917 Han, S....................................345 Hanmei, l...............................884 Hare, J. I.................................776 Harris, J. J...............................394 Hassan, H. F............................68 Hathout, R. M............... 182, 665 He, Q.............. 541, 588, 633, 719 Heider, M..............................678 Heinrich, A. K.......................676 Hernandez, R. M...................959 Hernandez, R. M...................583 Herranz Blanco, B..................713 Hibbitts, A.............................655 Hoare, T..................425, 540, 715 Holmes, M. C..........................24 Hoppel, M.............................514 Horiguchi, M.........................687 Houacine, C...........................771 Hu, A.....................................365 Hu, S. H.................................835 Huang, Q.................................16 Huang, W. C..........................635 Hwang, K. M................. 245, 349 Iannuccelli, V................. 123, 501 Iavicoli, P................................237 Igartua, M...................... 154, 569 Ikem, T...................................106 Irwin, N. J..............................581 Ivory, M. O............................158

Iyire, A. R..............................497 Jain, R....................................649 Jena, S. S................................526 Jensen, B................................290 Jeon, H. S...............................423 Jeong, S..................................644 Jokinen, A..............................722 Joo, M. K................................392 Joshi, S. V...............................347 Joyce, J. C...............................122 Jung, H. S...............................567 Jung, Y. J................................162 Kaasalainen, M......................639 Kadiyala, I..............................471 Kadri, B. V.............................376 Kahraman, E..........................961 Kakadia, P. G.........................924 Kamei, N........................... 34, 74 Kaminskas, L. M............ 133, 535 Kanaujia, P.............................350 Kanazawa, T...........................886 Kandil, B..................................94 Kane, Z..................................390 Kaneti, L................................853 Kang, S...................................152 Kanu, L. N.............................240 Kastner, E..............................222 Katayama, Y...........................795 Katsumi, H............................766 Kawakami, K................... 64, 707 Kawamura, E.........................911 Kazlauske, J............................175 Kearney, C. J..........................736 Kearney, M. C........................955 Keck, C. M..... 577, 949, 969, 970 Kelly, A. L..............................212 Kelly, C..................................825 Kemp, O................................221 Kent, R......................................4 Khadke, S. K..........................614 Khoury, L. R..........................701 Khutoryanskiy, V. V................480 Kim, A. J................................473 Kim, D...................................617 Kim, H. J................................870 Kim, H...................................618 Kim, H...................................148 Kim, J. S.................................779 Kim, J. Y.................................661 Kim, J. Y.................................963 Kim, J. O........................ 563, 693 Kim, J. H................................724 Kim, J.....................................801 Kim, M. J...............................114 Kim, T. i.................................904 Kim, Y. J.................................529 Ko, H.....................................634 Koner, J. S..............................170 Kono, K..................................440 Korhonen, K..........................918 Koss, K. M.............................149 Kost, J........................................6 Kristensen, M........................281 Kumar, S................................485 Kumar, S. P.............................697 Kunschke, N..........................207 Kuo, J. H................................849 Kusamori, K...........................930

Kwon, G. S...............................50 Laaksonen, T..........................261 Lai, K. K................................596 Lai, Y. H................................822 Lalatsa, A...............................739 Lammers, T............................459 Larra–eta, E...........................223 Laurent, F..............................144 Lavelle, E. C............................12 Léandre, V...................... 139, 224 Lee, B. K................................814 Lee, E. S.................................762 Lee, H....................................965 Lee, J. Y..................................668 Lee, J. E.................................895 Lee, M. S....................... 877, 883 Lee, M. W..............................178 Lee, S.....................................852 Lehto, V. P.............................675 Lei, Y.......................................37 Leite-Silva, V. R....................511 Lepeltier, E............................790 Leung, A................................834 Li, D......................................146 Li, J..........................................61 Li, L.......................................725 Li, M......................................116 Li, R.......................................138 Li, Y.......................................404 Liau, J. J....................................57 Liaw, J....................................925 Lilienberg, E..........................447 Lim, S. M...............................134 Lima, E. M............................660 Lin, W. J.................................562 Lin, Y. J. J...............................573 Listro, T.................................195 Liu, D....................................200 Liu, G....................................565 Lohan, S................................802 Loira Pastoriza, C..................120 Lollo, G.................................680 Long, X..................................289 Lopes, P. S..............................509 Loretz, B................................856 Loughran, S. P........................867 Lovric, J.................................578 Lukowski, G. T......................516 Machado, Y. J.........................976 Madi, A. M............................171 Madsen, C. M........................377 Maeda, H...............................554 Maeder, K...................... 412, 828 Mahajan, N.................... 188, 234 Mahdi, M. H.........................457 Mahmoud, G. F.....................786 Malekigorji, M.......................777 Malhaire, H.............................86 Mansfield, E..........................767 Marelly, N..............................830 Margetson, D. N............ 286, 339 Marizza, P..............................136 Marsh, P...................................33 Marwah, M............................939 Maso, K.................................794 Mason, L. M..........................280 Mastorakos, P.........................881 Mateescu, M. A.....................147

Mathes, C..............................263 Mayer, L. D..............................20 Mazza, M....................... 605, 893 McAllister, M..........................10 McArthur, J. D.......................923 McCaffrey, J...........................854 McCartney, F.................268, 295, 343, 344 McConville, J. T.....................118 McCrudden, M. T..................946 McIntosh, I............................173 McKenzie, B..........................978 McLaughlin, A. W.................169 McLaughlin, R. T.................. 531 Meenach, S. A........................555 Melocchi, A................... 258, 367 Mendelsohn, A. D...................39 Menge, A. K..........................353 Mercuri, A.............................305 Mi, F. L..................................602 Miao, X..................................819 Milanowski, B........................304 Minko, T..................................25 Miriyala, N............................575 Mistilis, M. J..........................255 Mohamed, A. A.....................897 Mohd Amin, M. C................799 Mohri, K................................878 Mönkäre, J.............................943 Montenegro-Nicolini, M.......160 MorellÓ-Bolumar, D..............510 Müller, R. H...........780, 813, 971 Mustafa, S..............................460 Myers, D. R...........................362 Mylonaki, I............................481 Nagano, K................................87 Nah, J. W...............................420 Nakai, T.................................673 Nakase, I................................551 Nakayama, M.........................448 Narita, Y.................................610 Nazir, Z..................................267 Neal, G..................................210 Needham, D............................38 Nehoff, H. L..........................709 Neufeld, R. J...............................3 Ng, C. L......................... 241, 936 Ng, S. F. F...............................919 Ni, R.............................. 863, 871 Nielsen, K. A..........................285 Nieto, K. J..............................299 Niño, A..................................872 Nitzschke, C..........................414 Niven, R...................................19 Niwa, T....................................91 Novikova, A...........................236 O’ Driscoll, C. M...................865 Obara, S.................................197 Obata, H................................496 Obermeyer, J. M.....................121 O’Brien, F. J..................... 46, 901 Obst, K..................................979 Ochiuz, L...............................620 O’Connor, G..........................683 Oh, J......................................882 O’Leary, C.............................500 Osman, R...............................498 Page, S......................................48

Palmelund, H.........................271 Palmer, D.................................43 Papen-Botterhuis, N. E.........522 Paradiso, P..............................435 Parayath, N. N.......................355 Parekh, H. S...........................928 Park, H. J................................527 Park, S. N......................... 90, 938 Pascual-Gil, S........................638 Pathak, S................................316 Patient, J. D............................341 Pawar, S. B.............................744 Payne, C. M...........................453 Pego, A. P...............................910 Pensado, A.............................906 Pereira, M..............................714 Petrilli, R................................533 Peynshaert, K.........................424 Pham, Q...................................79 Pham, T..................................334 Piccinni, P..............................330 Pimenta, A.............................463 Pinnapireddy, S. R..................902 Pitt, W. G..............................740 Plassat, V........................ 251, 361 Pollard, J.................................381 Poncelet, D..............................36 Po-Yen, L...............................374 Prassl, R.................................820 Prausnitz, M. R......................933 Prestidge, C. A.......................383 Price, R..................................439 Pun, S. H....................... 140, 915 Quadir, A...............................174 Quinn, H. L...........................927 R., A. K..................................782 Raavé, R.................................534 Rades, T...................................47 Raemdonck, K.......................598 Raesch, S. S............................812 Raftery, R. M.........................857 Rahbek, U. L............................35 Rajabi-Siahboomi, A. R..317, 363 Ramsey, J................................845 Rancan, F...............................980 Rao, D. A...............................609 Rayahin, J. E..........................458 Rayasam, R............................303 Rege, S...................................648 Reimóndez-Troitiño, S...........860 Reineke, J....................... 426, 585 Rezhdo, O..............................373 Rice, K........................... 735, 875 Riehl, M.................................215 Rigon, R. B............................945 Rizzo, L. Y.............................723 Rodrigues, A. G.....................401 Rodrigues, F...........................507 Roldo, M................................421 Rooney, P...............................379 Roos, C..................................382 Rosales Morgan, Y. G............855 Rosenbaum, S........................157 Rosiaux, Y..............................357 Roy, K.............................. 82, 161 Rubio-Ruiz, B........................470 Saari, H..................................629 Sabo, P...................................264

63

Sakr, O.....................................78 Salem, A................................194 Salmaso, S...... 413, 748, 753, 787, 805 Saltzman, W. M.........................1 Santos, R. S............................889 Sarmento, B...........................611 Satchi-Fainaro, R...................899 Sawarkar, S. P.........................940 Schneider, F...........................274 Schneider, M..........................731 Schrøder, T. D........................905 Scomparin, A.........................590 Scurr, D. J...............................515 Sediq, A. S..................... 176, 244 Sekerdag, E............................603 Senel, S............................ 18, 446 Seo, B. B......................... 155, 165 Seok, H. H.............................964 Serrano, D. R.........................225 Seyfoddin, A..........................478 Shah, R. M..............196, 233, 788 Shah, S. R..............................472 Shahbazi, M. A......................636 Shaikh, M..............................493 Shakya, A. K..........................920 Sharma, M.............................494 Sharma, S...............................102 Shen, H..................................141 Shevach, M............................477 Shimizu, K.............................613 Shrestha, N............................288 Silva, C. O...................... 615, 935 Simon-Yarza, T......................717 Singh, B.....................................8 Singh, K. K............................192 Singhal, M.............................962 Sivert, A.................................127 Sladek, S................................785 Smith, S. L.............................354

64

Somani, S...............................692 Somiya, M.............................876 Son, S.....................................576 Song, Y...................................254 Sosnik, A....................... 641, 770 Starr, N. J...............................947 Stefanache, A.........................833 Steffansen, B..........................451 Stelzner, J. J............................216 Stephansen, K........................278 Stevens, M...............................45 Stone, P..................................669 Storm, G..................................52 Stremersch, S.........................879 Su, C. y...................................684 Su, Y. R..................................586 Suleiman, E...........................670 Sung, H. W............................557 Suter, F.....................................53 Suydam, I. T...........................772 Swaine, T. S............................411 Tabata, Y................................764 Takahashi, C..........................273 Tang, H....................................88 Taverner, A..............................97 Tchuenbou-Magaia, F. L.......525 Teixido, M...............................70 Terracciano, M.......................747 Thakur, S. S............................827 Thauvin, C.............................730 Tietjen, G. T..........................558 Tipduangta, P.........................356 Titapiwatanakun, V........ 211, 474 Tomlinson, I. A........................55 Torge, A.................................775 Torres, D................................282 Tran, T...................................333 Tres, F....................................227 Tromp, R. H..........................311 Trotter, J. L.............................810

Tsai, J. C.................................953 Tseng, H................................179 Tsung-Hsin, L.......................270 Tucker, I. G............................839 Ubani-Ukoma, U...................307 Uchida, T...............................199 Udo-Chijioke, O. C...............732 Udupa, N................326, 368, 681 Uppalapati, D.........................483 Urbano, L...............................738 Van Dijk, M...........................407 Vanterpool, F. A.....................185 Vea-Barragan, A. C................445 Veiseh, O..................................96 Verreck, G...................... 276, 631 Vicent, M. J............................479 Videira, M..................... 698, 808 Viitala, T................................677 Vinarov, Z..............................351 Viricel, W...............................752 Vueba, M. L................... 167, 246 Vuorimaa-Laukkanen, E.......851 Walker, R. B................... 198, 441 Walsh, C.................262, 811, 913 Walsh, D. G...........................370 Walsh, D. P............................873 Wang, C. H.................... 101, 798 Wang, D...................................51 Wang, H. Y..............................77 Wang, J....................................40 Wang, T. W............................658 Wehbe, M..............................699 Wei, W.....................................73 Weissbrodt, J............................54 Wen, J.............................. 98, 818 Wengner, S.............................301 Werfel, T.................124, 806, 861 Whitehead, K. A....................843 Wilde, M...............................743 Witzigmann, D.............. 201, 552

Wong, R. S.............................934 Wongpinyochit, T..................746 Wren, S..................................389 Wu, H. C...............................672 Wu, X. Y........................ 335, 548 Wu, Y.....................................848 Wu, Z............................ 632, 758 Xia, D....................................287 Xie, B.....................................403 Xie, L.....................................168 Xu, J.......................................824 Xu, Q.....................................476 Ya’ari, Z..................................815 Yamada, Y..............................682 Yang, J....................................530 Yang, M. M............................662 Yang, Q..................................756 Yang, Y...................................129 Yang, Y. T...............................302 Yasin, M. N............................484 Yavuz, B.................................760 Yazeji, T..................................704 Yeo, Y.......................................49 Yin, Q....................................755 Yoo, J......................................850 Yu, J.......................................105 Yu, R......................................252 Yuba, E..................................151 Zakhvatayeva, A....................249 Zhang, H...............................630 Zhang, P.................................831 Zhang, Q...............................547 Zhang, T................................546 Zhang, Z................................410 Zhang, Z................................654 Zhong, Z...................................5 Zhou, L....................................83 Zhu, Q...................................266 Zinger, A................................100 Zuwala, K..............................703

2016 CRS ANNUAL MEETING & EXPOSITION

SEATTLE WA S H I N G T O N , U S A July 17–20 Washington State Convention Center

©JPL Designs/Shutterstock.com

Abstract submission opens November 2015 controlledreleasesociety.org/meetings

MODIFIED RELEASE EXPERTISE. FOR WHEN YOU NEED

THE RIGHT SOLUTION. Thanks to the integration of Capsugel, Bend Research and Encap Drug Delivery, we have you covered across the entire spectrum of drug release profiles. Our dosage form solutions can be coupled with a premier capability in bioavailability enhancement, and are tailored for single or fixed dose combinations in capsule, multiparticulate and tablet presentations. And by offering the world’s first intrinsically enteric capsule drug delivery technology, we can enable rapid evaluation of acid labile candidates and the oral delivery of vaccines and complex biologics. To find your solution visit www.Capsugel.com/DFS or call +1.541.312.CAPS. Scan to learn more

Better medicines through science and engineering. Visit us in Booth #601 | Presenting four technical posters